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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic 
cancer, and the 5th most common cause of cancer death in the UK. One of the 
peculiarities of this malignancy is its ability to invade nerves, a process called 
perineural invasion (PNI). PNI is found in almost 100% of PDAC, and is associated 
with poor prognosis, tumour recurrence and generation of pain. However, the 
molecular bases of PNI remain largely unknown. 
We investigated the molecular alterations underlying the neuro-epithelial interactions 
in PNI using one and two dimensional liquid chromatography – mass spectrometry 
(1D and 2D LC-MS) of laser microdissected PNI and non-PNI cancer from formalin 
fixed, paraffin embedded PDAC tissues. We also performed 1D LC-MS analysis of 
invaded and non-invaded nerves from the same cases. In addition, we developed an 
in vitro model of PNI using a co-culture system comprising PC12 cells, a rat 
pheochromocytoma cell line, as the neuronal element and PDAC cell lines.  
The overall proteomic profiles of PNI and non-PNI cancer appeared largely similar; 
of very few deregulated proteins, we have validated the up-regulation of 
antiapoptotic protein Olfactomedin 4 in PNI cancer using immunohistochemistry.  
In contrast, nerve samples demonstrated widespread molecular alterations 
characteristic of neuronal plasticity upon invasion by cancer cells. 
Immunohistochemistry confirmed the up-regulation of VGF in nerves from PDAC 
and chronic pancreatitis (CP) specimens compared to normal pancreas, as well as 
in invaded compared to non-invaded nerves in PDAC tissues. Furthermore, VGF 
expression strongly correlated with pain in CP; similar analysis in PDAC cases is still 
pending. Using the in vitro co-culture model, several PDAC cell lines were able to 
induce PC12 cells neuronal plasticity including survival, neurite extension as well as 
VGF expression, recapitulating thus the changes observed in human tissues. 
PDAC-induced PC12 plasticity was not mediated via NGF, a neurotrophin acting 
upstream of VGF and thought to be involved in the neuro-epithelial interactions. The 
induction of VGF expression was shown not to be necessary for PC12 cell survival, 
however, it contributed to the neurite extension induced by PDAC cell lines. 
In summary, based on proteomics analysis and in vitro modelling, we show the 
complex and intricate involvement and crosstalk of both tumoral and neural 
elements that are activated during perineural invasion in pancreatic cancer.  
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1D One Dimensional 
2D Two Dimensional 
ACCHN Adenoid Cystic carcinoma of the Head and Neck 
BSA Bovine Serum Albumin 
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Nex Intrapancreatic Extratumoural PNI 
NGF Nerve Growth Factor 
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1. Introduction 
 
1.1. Pancreatic cancer 
Pancreatic cancer is the 10th most common cancer and the 4th most common cause 
of cancer death in the USA. In 2010, there were an estimated 43,000 cases and 
37,000 deaths [1]. Mortality rates have closely followed incidence emphasizing the 
deadly nature of this disease. Pancreatic ductal adenocarcinoma (PDAC) is the 
most common type of pancreatic cancer comprising around 90% of cases [2] and it 
is also the most lethal one [2, 3].  
Pancreatic cancer patients present with predominantly nonspecific symptoms 
including abdominal/back pain, indigestion, jaundice and weight loss [4, 5]. 
Therefore, late diagnosis is common and most patients have either locally advanced 
or metastatic disease at presentation [1, 6]. Currently, surgery is the only potentially 
curative treatment available [7, 8], however due to advanced stage at presentation, 
only 10-20% of patients have a potentially resectable disease [9, 10]. PDAC has the 
worst prognosis of all cancers with an overall 5-year survival of less than 5% and a 
median survival of less than 6 months [11]. Even in the small proportion of patients 
who receive potentially curative surgery, the median survival is 11-20 months and 
the 5-year survival is only 7-25% [11], with most series reporting  around 10% or 
less actual 5-year survival rates [12, 13]. Furthermore, long-term survival in 
pancreatic cancer is rare; 5-year survival in PDAC is not equivalent to cure as most 
of the 5-year survivors ultimately die of recurrent disease [11, 14, 15]. The 
improvement in surgical techniques and perioperative care over the last three 
decades has significantly reduced perioperative mortality and morbidity; however, 
the disease specific mortality remains largely unchanged [5, 16] (Figure 1). 
PDAC is characterised by extensive local invasion and early metastases. Even in 
patients with small tumours (≤2cm), only 1/3 will have stage I disease and at least 
50% will have locally advanced (stage III) or metastatic (stage IV) disease [17-19]. 
The biologically aggressive behaviour of PDAC is clearly evident by the much 
favourable prognosis of other malignancies within the same region of the pancreas 
(periampullary cancers) including bile duct, duodenal and ampullary cancers and 
pancreatic cancers other than PDAC [20, 21]. In view of this invasive behaviour and 
the favourable prognostic significance of resection margins that are microscopically 
free of tumour (R0) [22-24], extensive radical surgeries have been performed to 
17 
 
achieve locoregional control of the tumour. However, evidence suggest that more 
radical procedures do not improve survival [25]. In fact, even with radical surgeries, 
20-80% of patients still have positive resection margins [26, 27]. It is thus widely 
accepted now that the biology of PDAC and not the exact type of surgical resection 
is the most important determinant of outcome [7, 19, 28]. 
    
 
 
 
 
 
 
          
Figure 1. Postoperative mortality and median survival of PDAC patients following tumour 
resection over the last three decades.  Adapted from  [29]. 
 
The prognostic significance of several biological features of PDAC has been 
investigated. This is becoming more important as surgery has a limited role and new 
adjuvant and neoadjuvant approaches will benefit strongly from patient stratification 
based on pathological prognostic parameters and/or molecular biomarkers. Overall, 
tumour stage [14], degree of differentiation [24, 30-32], tumour size [30, 33] and 
lymph node (LN) metastases [23, 24, 28] appear to be strong prognostic factors.  
The ability to invade nerves, perineural invasion (PNI), is another adverse biological 
feature of PDAC. It is a common and characteristic pathological finding in pancreatic 
cancer patients that has been associated with poor outcome. In the following 
sections, I will review the relevant neural anatomy and histological structure of 
nerves before discussing, in details, the published literature addressing PNI with 
specific focus on PDAC. 
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1.2. Perineural invasion 
1.2.1. Pancreatic innervations and structure of peripheral nerves 
Innervation of the pancreas 
The pancreas is a retroperitoneal organ that lies in close proximity to the major 
abdominal vessels and neural ganglia, namely the superior mesenteric vessels, 
celiac axis, portal vein and the celiac and superior mesenteric ganglia and plexi. 
Extrinsic sympathetic and parasympathetic nerves primarily from both celiac and 
superior mesenteric plexi richly innervate the pancreas via two pancreatic nerve 
plexi. Plexus pancreaticus capitalis I originates from the celiac plexus and arrives to 
the dorsal aspect of the head of the pancreas via the posterior hepatic plexus, 
whereas plexus pancreaticus capitalis II that is derived from the superior mesenteric 
plexus enters the lower part of the uncinate process of the pancreas along the 
inferior pancreaticodoudenal artery [34, 35] (Figure 2). In addition, the body and tail 
of the pancreas are innervated by the celiac plexus directly and via the splenic 
plexus [35].  Furthermore, the pancreas receives direct innervation from the enteric 
nervous system of the gut, mainly from the stomach and duodenum [36].  
 
 
 
 
 
Figure 2. Schematic representation of the nerve supply to the head and neck of pancreas as 
depicted from a posterior view. CG: celiac ganglia; MG: mesenteric ganglion; PLX 1: plexus 
pancreaticus capitalis I; PLX 2: plexus pancreaticus capitalis II. Adapted from [34]. 
 
Within the pancreas, large number of ganglia is present, particularly in the head and 
neck region. These, along with the vast network of neural plexi around the ducts, 
acini, blood vessels and the islets, represent the intrinsic enteric nervous system of 
the pancreas [37, 38]. Complex interaction between the intrinsic and extrinsic 
systems as well as hormonal modulation control various physiological functions of 
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exocrine and endocrine pancreas, including secretion of enzymes and pancreatic 
juice, islet cell secretions and pancreatic blood flow [39]. These functions are 
mediated by an array of neurotransmitters such as acetylcholine (ACTH), 
norepinephrine (NE), nitric oxide (NO) and serotonin as well as neuropeptides, 
including gastrin releasing peptide (GRP), vasoactive intestinal polypeptide (VIP), 
calcitonin gene-related peptide (CGRP) and neuropeptide Y (NPY) [40]. In addition 
to their normal physiological functions, pancreatic nerves have been implicated in 
the regulation of regeneration and apoptosis in several pathological conditions such 
as pancreatitis and pancreatic cancer [37, 41]. Lastly, afferent nerves from the 
pancreas convey nociceptive and mechanoceptive pain signals either directly to the 
central nervous system via the vagus nerve or along the sympathetic nerves to the 
dorsal root ganglia of the spinal cord [39].  
 
Structure of peripheral nerves 
Peripheral nerves are composed of axons and Schwann cells surrounded by 
endoneurium and enclosed by the perineurium to form nerve fascicles. Groups of 
fascicles are enveloped in a fibrous sheath called the epineurium [42] (Figure 3). 
 
          
 
 
       
         
 
Figure 3. Structure of peripheral nerves, Adapted from Human Anatomy and Physiology, 7th 
ed., by Elaine N. Marieb and Katja Hoehn. 
 
The epineurium is composed of an outer layer of areolar connective tissue 
containing vascular networks and an inner dense layer made of collagen 
(particularly type I and III), elastic fibres, fibronectin as well as fibroblasts [43-45].  
20 
 
The inner layer is closely associated with the perineurium. The epineurium is 
densely vascularised and blood vessels cross nerve sheaths to reach inner parts of 
the nerve [46]. 
The perineurium is a dense fibrous sheath comprising up to 15 concentric layers or 
laminae, each lamina is composed of flattened perineural cells with basement 
membrane on either side [42] (Figure 4). Collagen fibres, primarily type III and IV, in 
addition to laminin and fibronectin as well as fibroblasts are disposed between 
laminae [45, 47]. Within each lamina, tight junctions between perineural cells keep 
them firmly opposed and “dove-tailed” together [48]. The innermost layer of the 
epineurium is formed by tightly bound perineural cells separated from the 
endoneurium by the perineural space [47]. This is a potential space, the appearance 
of which in histological sections is a processing artefact [49, 50]. The perineurium, 
however, is defective at nerve endings, sites of entrance/exit of blood vessels as 
well as where it is penetrated by reticular fibres [47]. The primary functions of the 
perineurium are to provide mechanical support [42], maintain intrafascicular 
pressure [42] and provide, along with endoneural blood vessels, a diffusion barrier, 
the blood-nerve barrier, that maintains the endoneural hemostasis [47]. 
 
 
 
 
 
 
Figure 4. Histological structure of a pancreatic nerve using hematoxylin and eosin ( H&E) 
staining showing nerve bundle (NB), perineurium (wide arrow) with perineural cells (narrow 
arrows) and the perineural space (*). 
 
The endoneurium is made of collagen fibres (mainly type I and III, and to less extent 
IV) in addition to fibronectin and laminin as well as capillary endothelial cells, 
pericytes and small number of fibroblasts [45, 48]. Embedded within the 
endoneurium are the individual nerve fibres and associated Schwann cells. 
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1.2.2. Definition of PNI 
The phenomenon of nerve invasion by cancer cells has been most commonly 
referred to as perineural invasion, less often as neural invasion and rarely 
perineurial invasion. A review of PNI in cutaneous malignancies advocated the 
diagnosis of PNI when cancer cells are observed in the perineural space whereas 
intraneural involvement and the circumferential presence of cancer cells around 
nerves are only supportive of the diagnosis of PNI in equivocal cases [50]. Another 
recent review suggested, however, that a widely accepted definition of perineural 
invasion is the invasion in, around,  or through the nerves and proposed a definition 
that includes invasion of any of the three layers of the nerve sheaths or the 
presence of cancer cells around the nerve involving at least one third of its 
circumference [51]. However, the majority of studies that investigated PNI did not 
actually provide a definition to what they considered as PNI [17, 18, 26-28, 31, 52-
64]. Moreover, in the studies that did provide a definition, the majority considered 
PNI only when cancer cells invaded the perineural space or the nerve bundle [65-
78], and only few adhered to the wider definition as suggested above [33, 79] 
(Figure 5).  
 
 
 
 
   
Figure 5. Histological patterns of perineural invasion. A: invasion of the perineural space; B: 
Invasion of the perineural space and nerve bundle; C: Nerve involvement where the nerve is 
surrounded by cancer but not invaded. 
 
Further variation arises from the use of various classifications and grading systems 
for PNI. Whereas some groups used the term PNI without further specification, 
others differentiated between intrapancreatic perineural invasion (IPNI) and 
extrapancreatic neural plexus invasion (Plx) [27, 28, 33, 64]. Yet others 
subclassified IPNI into intratumoural and extratumoural PNI (Nex) [57]. Some 
authors also described the degree of PNI, usually on a scale of 0-3 according to the 
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frequency of PNI lesions in histological sections [28, 54, 57-59, 66] . However, the 
number of invaded nerves defining each grade varied between different studies. 
Furthermore, some studies considered nerve bundle invasion [69, 70] or PNI 
extending beyond the main tumour [75] as grade 3 regardless of the number of 
occurrences whereas others used the same grading (0-3) to denote the depth of 
invasion (nil, neurium, perineural, nerve bundle) rather than the frequency of PNI 
[63]. Other studies defined the degree of PNI by the number of invaded nerves 
relative to the total number of nerves observed [80]. In one study, the degree of PNI 
was calculated by multiplying the scores of the severity of PNI (the depth of invasion 
into the nerve) by the frequency of PNI lesions [81]. The assignment of higher grade 
of PNI to nerve bundle invasion suggests it is a more severe form of PNI that may 
have more impact on outcome, a finding that has been reported in rectal cancer 
[82]. However, one study that looked at the depth of PNI in pancreatic cancer found 
that nerve bundle invasion was not predictive of prognosis compared to perineural 
invasion or neural involvement [33]. Even after using the same scoring system (on a 
scale of 0-4) for PNI, some studies grouped grades 0 and 1 together and compared 
them with grades 2 & 3 [28, 33, 58, 64] while others compared grade 0 with the rest 
of the grades [54, 59].  
While there are some arguments supporting each of these definitions and grading 
systems, none of them has been validated, making it difficult to standardize PNI 
parameters and subsequently compare outcomes from different studies. It is clear 
that while there is no consensus as to the definition of PNI, the most common 
definition used appears to be invasion of the perineurium and/or nerve bundles.  
 
1.2.3. Pathology of PNI 
Several studies examined the histological and ultrastructural features of PNI. Using 
electron microscopy analysis of oesophageal cancer sections, Takubo et al reported 
marked degeneration of perineurium in PNI along with loss of perineural cells and 
irregularities of basal laminae resulting in cancer cells lying in direct contact with the 
endoneurial elements [52]. Importantly, the authors also noticed the presence of 
cytoplasmic projections and lysosome-like structure at the invading front of cancer 
cells suggesting an active role of cancer cells in the degeneration of perineurium 
and gaining access into the perineural space. Similar findings were also reported in 
pancreatic cancer [83, 84].  
23 
 
Histologically, perineurally invasive cancer cells appeared well to moderately 
differentiated, forming glandular structures in most cases [33] and cancer cells in 
direct contact with the nerve appeared more flattened than those that are part of the 
same gland but not in direct contact  with the nerve [83]. 
In a detailed histological analysis of serial sections of PDAC tissues, Kayahara et al 
concluded that PNI occurs through direct invasion and destruction of the 
perineurium and/or through perforating blood vessels. They also found that 
perineurally invasive cancer cells form an advancing tip and grow in continuous 
fashion, branching where the nerve branches [65] (Figure 6). Similar continuous 
pattern of growth as well as extensive branching of PNI following the neural 
branching was also noted in 3D reconstruction of serial PNI sections [85]. Although 
rarely, discontinuous growth along the perineural space has also been observed 
[59]. A varying degree of nerve damage is common in PNI and proximal and distal 
extension of the cancer for few centimetres could sometimes be seen [53].  
 
 
 
 
 
 
 
Figure 6. The pattern of invasion and spread of cancer cells along nerves in PNI. N: nerve; 
PN: perineurium; LN: lymph node; 1: direct invasion of perineurium; 2: continuous growth of 
cancer along the perineural space; 3: branching of cancer cells as the nerve branches; 4: 
advancing tip of cancer, 5: possible extension into LN via nerves. Adapted from [65]. 
 
From the primary tumour, PNI develops continuously along nerves to reach the 
superior mesenteric and celiac plexi and as the invasion advances, PDAC cells may 
spill out of the perineurium into adjacent fatty tissue [59, 86]. Significant association 
was found between intrapancreatic tumour invasion and extrapancreatic plexus 
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invasion lending support to the direct and continuous extension of cancer cells from 
the primary tumour along the nerve to reach the main neural plexi [54, 64, 66, 68]. 
The most commonly involved plexus in pancreatic cancer of the head and neck 
region is the plexus pancreaticus II, less frequently the plexus pancreaticus I, the 
nerve plexus of the hepatopancreatic ligament and the plexus around the 
mesenteric vessels [19, 66, 87]. In pancreatic body and tail tumours, the splenic 
plexus is the most commonly invaded, but the celiac or superior mesenteric plexi are 
also occasionally involved [27]. 
 
1.2.4. Incidence and clinical significance of PNI in PDAC 
As alluded to previously, PNI is a characteristic feature that is frequently observed in 
PDAC. Most studies reported intrapancreatic PNI in 50-100% of cases while neural 
plexus invasion occurred in 35-70% (Table 1). The estimates vary widely secondary 
to differing definitions of PNI, the extent of surgical resection (in the case of plexus 
invasion), the extent to which tumour samples are evaluated [88] as well as the 
accuracy of reporting [79]. In addition, routine H&E staining may underestimate the 
incidence of PNI. In oral cavity squamous cell carcinoma, Kurtz et al showed that 
the incidence of PNI increased by 100% upon re-reviewing the original H&E slides 
and by almost 200% by IHC using antibodies against the neuronal marker S100B 
protein [78]. In this study, the mean number of PNI lesions identified using 
immunohistochemistry (IHC) was largest in the cases where PNI was identified in 
original reports and least in the cases in which PNI was only identified by IHC, 
suggesting that PNI can be missed when it is not frequent [78]. 
The enhanced detection of PNI using IHC has also been reported in other tumours 
including ampullary [89] and colorectal [90] cancer, suggesting that the rate of PNI 
could be much higher than currently thought. In pancreatic cancer, it has been 
suggested that PNI is present in 100% of cases if carefully looked for [91]. 
Furthermore, KRAS mutation analysis of nerve plexus revealed PNI that was not 
evident on routine histological sections suggesting widespread perineural 
microinvasion [88]. While the clinical significance of such finding is currently 
unknown, the high recurrence rate following apparently curative resection may 
suggest that these microinvasive lesions could be a source of recurrent disease. 
Finally, PNI has been commonly observed even in small tumours ≤20mm [17, 23]. 
25 
 
This, along with the observation of PNI in minute tumours <2mm found at one 
autopsy study indicates that PNI is an early event in pancreatic cancer invasion [92]. 
 
Table 1. Incidence of PNI and its correlation with survival in PDAC. NA: not assessed; IPNI: 
intrapancreatic PNI; Plx: neural plexus invasion; Nex: intrapancreatic extra-tumoural PNI.  
Study Incidence of PNI 
yes/total (%) 
Correlation with 
survival 
Notes 
Nagai H 1985 [60] 6/8 (75%) NA T1/T2 autopsy cases (≤2cm) 
Nagakawa T 1991 [66] 
     IPNI 
     Plx 
 
33/34 (97%) 
21/34 (62%) 
 
NA 
NA 
 
Nagakawa T 1993 [26] 
     IPNI 
     Plx 
 
21/21 (100%) 
17/21 (81%) 
 
NA 
No 
 
Nakao A 1996 [54] 
     IPNI 
     Plx 
 
116/129 (90%) 
80/116 (69%) 
 
Yes 
Yes 
 
Sperti C 1996 [56] 71/113 (63%) Yes (univariate)  
Furukawa H 1996 [17] 19/31 (61%) NA Small PDACs ≤2cm 
Kayahara M 1996 [27] 
     Plx 
14/20 (70%)  NA  
Takahashi T 1997 [57] 
     IPNI 
     Nex 
     Plx 
 
88/90 (98%) 
47/90 (52%) 
47/90 (52%) 
 
Yes 
Yes 
No 
 
Dang C 1998 [84] 
     IPNI 
     Plx 
 
22/30 (73%) 
20/30 (67%) 
NA 
NA 
 
Hermanek P 1998 [18] 187/219 (85%) NA  
Ozaki H 1999 [55] 90/126 (76%) Yes (for stage I & 
II) 
 
Meyer W 2000 [30] 42/93 (45%) Yes (univariate)  
Okusaka T 2001 [62]. 87/95 (92%) NA  
Hirai I 2002 [59] 17/24 (71%) Yes (multivariate)  
Cleary SP 2004 [31] 34/123 (28%) No  
Tezel E 2004 [93] 
     Plx 
 
18/64 (28%) 
 
Yes 
 
Shimada K 2006 [28] 
     IPNI 
     Plx 
 
82/88 (93%) 
30/88 (34%) 
 
Yes (univariate) 
No 
 
Shimada et al 2006 [23] 
     IPNI 
 
8/10 (80%) 
 
NA 
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Study Incidence of PNI 
yes/total (%) 
Correlation with 
survival 
Notes 
     Plx 47/173 (27%) Yes (univariate) 
Mitsunaga S 2005 [58] 
     IPNI 
     Plx 
 
95/101 (94%) 
35/101 (35%) 
 
Yes (univariate) 
Yes (multivariate) 
 
Dang C 2006 [70]  /56 (30%) Yes
 
(multivariate)  
Mitsunga S 2007 [33] 
     Plx  
 
49/75 (65%) 
 
Yes (univariate) 
 
Garcea G 2007 [94]  19/27 (70%) Yes  
Ma J 2008 [72] 34/51 (68%) Yes  
Morris-stiff G 2009 [21] 134/144 (93%) NA  
Wang W 2009 [69] 137/137 (100%) NA  
Chen JWC 2009 [67] 31/60 (52%) Yes
 
(multivariate)  
Ceyhan GC 2009 [81] 115/149 (79%) No  
Shimada K 2011 [64] 
     IPNI 
     Plx 
 
146/153 (95%) 
94/153 (61%) 
 
Yes (multivariate) 
Yes (univariate) 
 
 
The anatomical location of the pancreas in close proximity to the major abdominal 
neural plexuses and the rich innervation of the pancreas have been suggested as 
an explanation for the high incidence of PNI in PDAC. Evidence, however, suggests 
that this common occurrence of PNI is strongly related to the biology of PDAC. For 
instance,  Kayahara et al found that the incidence of plexus invasion in pancreatic 
cancer (61%) was significantly higher than in bile duct (21%) and papilla of Vater 
(3%) tumours, all of which lie within the same anatomical position [87]. Several other 
studies corroborated these findings [19-21]. 
PNI has been associated with incomplete resection of PDAC [54, 95], tumour 
recurrence [58, 64, 96-98], generation of pain [99] as well as poor prognosis (Table 
1). Nakao et al reported that PNI, particularly extrapancreatic plexus invasion, 
significantly correlated with survival; all patients who survived more than three years 
in their study showed no plexus invasion [54]. Similarly, in the study of Tezel et al, 
none of the patients with plexus invasion survived for three years compared to 18% 
3-year survival in patients without plexus invasion [93]. Furthermore, Ozaki et al 
reported significant influence of intrapancreatic PNI on survival, particularly in early 
stage PDAC. They found that stage I and II (no LN metastases) patients without 
IPNI had significantly better 5-year survival (75%) compared to those with IPNI 
(29%) but there was no difference in survival in stage III and IV patients [55]. This 
may suggests a role of PNI in driving the local tumour spread, but once the tumour 
Table1 continued… 
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is advanced PNI loses its prognostic significance. Mitsunaga et al found that plexus 
invasion distance of ≥2.5mm from pancreatic capsule correlated with poor prognosis 
on both univariate and multivariate analysis [33]. Furthermore, in a review of the 
Japanese experience of pancreatic cancer resections, Matsuno et al found that 
involvement of the neural plexi conferred poor prognosis whether it was resected or 
not, suggesting that the invasion of neural plexus reflects the malignant phenotype 
of PDAC [7]. It is generally accepted that periampullary cancers have better 
prognosis than PDAC [20, 21, 67]; a recent study suggested that this difference 
could be due to the more frequent occurrence of PNI in PDAC compared to the 
other cancers and that PNI was a stronger prognostic factor than the location of the 
tumour [100]. While most studies showed significant influence of PNI on survival, 
few failed to show such prognostic significance (Table 1). In a systematic review of 
prognostic factors in pancreatic cancer, Garcea et al found that PNI significantly 
correlated with median survival but not with overall 5-year survival [29]. It is worth 
mentioning however, that the review did not include some of the studies in Table 1 
and the heterogeneity of these studies in terms of patients’ characteristics, definition 
of PNI and the anatomical location (IPNI vs plexus invasion) makes meta-analysis of 
such disparate studies difficult. 
 
1.2.5. Pain and PNI in pancreatic cancer 
In addition to recurrence and poor survival, PNI correlates closely with pain in 
pancreatic cancer patients [70, 81]. Abdominal pain is a common presenting feature 
and the degree of pain has been associated with advanced tumours, unresectability 
[98] and poor survival [62, 81, 101]. 
The mechanisms of pain in PDAC are not well understood. There is accumulating 
evidence which suggest that in pancreatic cancer, as well as in chronic pancreatitis, 
pain is of neuropathic origin as a result of direct damage to the nerves [81]. 
Pancreatic neuropathy could also be mediated through neuro-immune interactions 
as a result of perineural immune cells infiltrate, and/or from direct invasion of nerves 
by cancer cells [102]. In a recent study, Demir et al showed that pain in pancreatic 
cancer is associated with increased perineural mast cells infiltration [103]. 
Alterations in the pattern of autonomic innervations of the pancreas have also been 
demonstrated, whereby CP and PDAC patients with pancreatic neuritis, PNI or 
abdominal pain had decreased cholinergic and sympathetic innervations of the 
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pancreas [104]. In another study, an increase in sympathetic and CGRP expressing 
sensory neurons was demonstrated in a transgenic mouse model of pancreatic 
cancer [101]. 
Several neurotrophic factors, chemokines and neuropeptides have been associated 
with pain in pancreatic cancer, but experimental evidence for most of them is 
generally lacking. NGF and its receptor TrkA remain one of the best studied in this 
regard.  In a transgenic mouse model of pancreatic cancer, it has been suggested 
that initial sprouting and sensitisation of nerve fibres induced by NGF from 
macrophages and subsequent damage to those nerves as the tumour advances 
may contribute to pain generation [101]. The vanilloid receptor TRPV1, a non-
selective cation channel expressed in sensory nerve fibres has been shown to be 
over-expressed in pancreatic cancer and correlated with the intensity of pain [105]. 
Interestingly, NGF has been shown to modulate both the level and activity of TRPV1 
in pancreatic sensory neurons in chronic pancreatitis [106]. Therefore, NGF 
signalling pathway has been tested as a potential therapeutic strategy for skeletal, 
inflammatory and neuropathic pain using monoclonal antibodies targeting NGF or its 
receptor TrkA [107-109]. 
 
1.2.6. PNI in other cancers  
Although PNI has been most commonly seen in pancreatic cancer, it has also been 
described in several other cancers including cutaneous and non-cutaneous head 
and neck cancers [110, 111], prostate [112], colorectal [79] and gastric cancers 
[113]. 
In prostate cancer, the wide-spread use of Prostate Specific Antigen (PSA) as a 
screening tool resulted in increased detection rate. While many of these cancers are 
indolent and can be managed with a wait and watch approach, the greatest 
challenge is to identify the subset of patients who require more aggressive treatment 
including surgery and radiotherapy [114]. Radical prostatectomy, the standard 
surgical treatment for prostate cancer is not without risks, particularly in relation to 
nerve damage with resulting urinary incontinence and erectile dysfunction, and a 
nerve sparing variant could be performed in selected patients [115]. In this context 
of complex management options, PNI has been investigated as a possible indicator 
of a more malignant cancer phenotype that requires more immediate and 
aggressive treatments. 
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PNI has been reported in 19-34% of prostate biopsies [116-118] and in 42-79% in 
prostatectomy specimens [112, 119, 120]. PNI is associated with recognised 
aggressive features of prostate cancer such as advanced Gleason score, stage, 
positive resection margins as well as extraprostatic extension [112, 116, 119, 121]. 
The presence of PNI in prostate biopsies can also be a predictor of the final 
pathological stage following prostatectomy [122].  
Several studies also showed that PNI is associated with biochemical recurrence, 
and reduced biochemical failure-free survival and overall survival in prostate cancer 
patients following both radiotherapy and surgery [116, 117, 121, 123]. Some studies, 
however, have failed to demonstrate prognostic significance for PNI [112, 119]. 
A recent systematic review by Cozzi et al found that patients with PNI on prostate 
biopsy specimens had a significantly higher risk of extraprostatic extension of 
tumour [124].  A separate systematic review of the prognostic significance of PNI in 
prostate cancer biopsies concluded that whilst the significance of PNI remains 
controversial, the weight of evidence suggests that the presence of PNI is a 
significant prognostic indicator and such patients should be offered treatment rather 
than watchful waiting [125].  
More recently, the implications of PNI in colorectal cancer have been investigated. 
PNI has been reported in 18-34% of rectal cancers [82, 126, 127] and in 13-31% of 
colon cancers [126, 128]. PNI is also associated with advanced disease, incomplete 
resection, local recurrence as well as higher likelihood of metastasis [79, 82, 126, 
129]. In addition, PNI is a strong and independent predictor of 5-year overall survival 
and disease-free survival [79, 82, 126, 130]. 
In their detailed study of PNI in rectal cancer, Ceyhan et al found that preoperative 
chemoradiotherapy significantly reduced PNI prevalence and severity compared to 
primary resection only and these patients had lower recurrence rate but no 
difference in survival [82]. In another study, stage II patients with PNI who received 
adjuvant chemotherapy had a significantly better disease-free survival compared to 
those not receiving chemotherapy whereas stage II patients without PNI showed no 
benefit, suggesting a role for PNI in stratification of colorectal cancer patients for 
adjuvant therapy [130]. This is particularly important in patients with stage II disease 
and those with node negative disease where there is no consensus on the role of 
adjuvant therapy. Santos et al found that PNI is a significant prognostic factor in 
stage II colon cancer patients [131] whereas Desolneux et al demonstrated the 
prognostic significance of PNI in node negative colorectal cancer [132].  
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Indeed, Liebig et al showed that the survival of patients with node negative 
colorectal cancer who have PNI is significantly worse than patients with nodal 
involvement and suggested PNI should be used for stratification for adjuvant therapy 
[79]. 
In gastric cancer, PNI occurs in 31-75% of cases [113, 133, 134]. Tianhang et al 
reported that PNI is associated with stage, poor differentiation and peritoneal 
metastasis and was an independent prognostic factor for overall 5-year survival 
[134]. Similar results were also reported by others [113, 135]. PNI was also shown 
to be a significant prognostic factor, along with tumour diameter and lymphatic/blood 
vessel invasion, that defines a high-risk subset of T2N0 gastric cancer patients who 
could potentially benefit from adjuvant therapy [136].   
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1.2.7. Mechanisms underlying PNI  
Interactions between nerves and target tissues are part of normal physiology. In 
addition to functional control, the nervous system regulates structural development, 
maintenance and regeneration of various tissues and organs [37, 137-139].  
In cancer, neuro-neoplastic interaction is a mutual relationship in which not only 
nerves can modify the biology of tumour cells but also, as recent studies suggest, 
and akin to neoangiogenesis and lymphangiogenesis, tumours are able to promote 
neoneurogenesis. This view has been supported by increased neurite growth in 
dorsal root ganglia (DRGs) co-cultured with several cancer cell lines [140-142], 
increased neural density in a mouse model of pancreatic cancer [101] as well as by 
the demonstration of neurogenesis and its negative impact on disease progression 
and prognosis in several human cancers such as colorectal [141] and prostate 
cancer [142]. 
PNI represents an environment in which the cancer cells and nerves are physically 
and functionally intertwined. By virtue of the obvious spatial proximity, PNI has been 
recognised since the 19th century but our understanding of its significance and exact 
nature has only started to evolve over the past three decades [51]. Initially, PNI was 
thought to be a form of lymphatic space invasion, however, later studies confirmed 
that the perineural space is not a lymphatic space, it does not connect with 
lymphatic channels and there are no lymphatic channels within nerves [49, 143]. 
Subsequently, two theories attempted to explain this specific route of cancer spread. 
The first theory suggested a physical explanation of PNI and proposed that cancer 
cells are spreading across a path of least resistance [49, 143]. Whilst the perineural 
space may be considered as a low resistance and accommodating path for cancer 
cells, arriving into that space is far from least resistance considering the structure of 
nerves and their sheaths. In addition, electron microscopy studies suggested active 
destruction of the perineurium by cancer cells during the process of PNI as 
discussed earlier. Furthermore, several recent studies have shown that neuro-
neoplastic interaction appears to be more than just histological proximity and nerves 
seem to provide more than a defined anatomical path for cancer spread, supporting 
the second theory, neurotropism, as an explanation for PNI.  The microenvironment 
created by this interaction appears to provide a suitable milieu for tumour growth 
resulting in enhanced proliferation and inhibition of apoptosis of cancer cells as well 
as increased neurite outgrowth [140, 144-147]. Moreover, in an in vitro co-culture 
model of DRGs and prostate cancer, the presence of stromal cells appears to 
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further increase the cancer cell and neurite growth [148].  Interestingly, a similar in 
vitro model of PNI using PDAC cells and DRGs or myenteric plexus cells 
demonstrated that morphological changes in cancer cells including flattening and 
elongation occurred at the migration front of cancer cells before direct contact with 
the neural element was established [149]. This mutual interaction was explored in 
several studies that investigated the role of various proteins in the process of PNI, 
mostly focusing on neurotrophins and neurotrophic factors, neural adhesion 
molecules as well as other neuronal proteins that have previously been implicated in 
cancer (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of the various signalling molecules thought to be 
involved in perineural invasion. Adapted from [150]. 
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Neurotrophins 
Neurotrophins are a group of structurally related growth factors including nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3) and neurotrophin-4 (NT-4). These factors bind to two types of unrelated 
receptors: Trk receptor tyrosine kinases A, B and C and the low affinity p75NTR 
receptor, a member of the tumour necrosis factor superfamily. All these 
neurotrophins bind to the p75NTR receptor but individual neurotrophins bind 
preferentially to one or more Trk receptors [151, 152]. The interaction between 
neurotrophins and their receptors is vital for neuronal development, maintenance 
and survival. In addition, neurotrophins have been shown to play important role in 
neuronal and non-neuronal cancer progression [151]. The biological actions 
however, are complex and may be paradoxical depending on the exact neurotrophin 
and receptors involved. The binding of neurotrophins to Trk receptors, which is 
modulated by the presence of p75NTR induces survival, whereas binding to p75NTR on 
its own induces apoptosis. To add to the complexity, pro-forms of neurotrophins can 
bind with higher affinity to the p75NTR receptor inducing apoptosis [153].   
NGF and Trk receptors, particularly TrkA, have been shown to correlate with PNI, 
pain and poor prognosis in pancreatic cancer [70, 71, 154], while the expression of 
p75NTR negatively correlated with PNI and conferred better prognosis [70]. Other 
studies, however, showed positive correlation between p75NTR and PNI [69] and 
failed to show any correlation between NGF and TrkA and prognosis [72].  
NGF has also been shown to increase proliferation and invasiveness of PDAC cell 
lines [155] and the invasion of prostate cancer cell lines [156]. For example, NGF 
appears to increase invasion of Panc1 PDAC cell line via stimulation of MMP-2 
expression and activity through TrkA and subsequent activation of MAPK signalling 
pathway [157]. Yet in other studies, NGF has stimulatory, inhibitory or no effect on 
growth and invasion of various PDAC cell lines [158-160]. The actions of 
neurotrophins on cancer cells has been shown to be dose dependent and varies 
with cell types, and it has been suggested that the ratio of TrkA and p75NTR 
determines the outcome of NGF action on these cells [70, 159, 160]. Furthermore, 
studies that dissected the spatial distribution of neurotrophins and their receptors in 
tissue samples reported inconsistent results. While NGF was found to be highly 
expressed in both cancer and nerves in some studies [71, 72, 161], others  reported 
low levels of expression in cancer but high levels in nerves within tumours [158] or 
absence of NGF in normal and cancer tissue [159]. On the other hand, Trk receptors 
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were reported to have higher expression in cancer compared to normal pancreas in 
one study [159], another found that Trk A was absent in cancer and highly 
expressed in the perineurium [71], whilst a third study reported that Trk A expression 
was weak in cancer and almost absent in the perineurium ([72]. A separate study 
described the absence of Trk B expression in PDAC [161]. p75NTR was probably the 
least controversial, as several studies reported high levels of expression in nerves 
but low or no expression in both normal and PDAC tissue, with lower levels of 
expression in PDAC  [69, 159, 161]. 
The opposing actions of neurotrophins and the conflicting expression patterns 
reported by many authors has suggested that the biological actions of neurotrophins 
binding to their receptors do not rely only on expression levels but also the context, 
including cell type and ratio of expression of the two types of receptors, Trk and 
p75NTR. However, despite their role in cancer invasion, the expression patterns of 
the mentioned neurotrophins and their receptors in pancreatic cancer do not point to 
particular mechanism in the development of PNI. These observations have 
prompted the suggestion of two different ways in which neurotrophins and their 
receptors could contribute to PNI, firstly, by promoting survival of neurons and 
axonal growth towards cancer cells and thus facilitating PNI and secondly, by 
promoting cancer growth and invasion and inhibiting apoptosis of cancer cells [71, 
72]. 
Pleiotrophin (PTN) is another neurotrophic factor that has been linked to PNI in 
pancreatic cancer. It has been shown to be expressed in pancreatic cancer cells 
while its receptor N-syndecan was strongly expressed on the perineurium of nerves 
within the tumour mass and both correlated with PNI suggesting that this axis may 
promote neural growth into the cancer [77]. 
GDNF family     
The glial-derived neurotrophic factor (GDNF) family is another family of neurotrophic 
factors that has been implicated in PNI. This family includes in addition to GDNF, 
artemin (ARTN), neurturin (NRTN) and persephin (PSPN). These neurotrophic 
factors exert their action by binding to a multicomponent receptor composed of 
GDNF family receptor-α (GFR-α1-4) as binding sites and the RET receptor tyrosine 
kinase as the signalling part of the receptor [162, 163]. These factors are involved in 
neuronal survival and differentiation, as well as neuronal and non-neuronal 
malignancies [163]. GDNF is the best studied factor in relation to pancreatic cancer 
and PNI. GDNF is expressed in intrapancreatic nerves as well as pancreatic cancer 
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and its expression is correlated to PNI [164-166], whereas RET is over-expressed in 
pancreatic cancer and its expression correlated with survival [165, 166]. In bile duct 
cancer, GDNF expression correlated with PNI but RET was not present in cancer 
cells [167]. Functionally, GDNF has been shown to increase the expression and 
activation of MMP-9 via MEK/ERK and PI3K pathways [168] and stimulate migration 
and invasion of PDAC cell lines via the same pathways [169]. In a recent study, Gil 
et al demonstrated that GDNF produced by DRGs induced directional migration of 
MiaPaca2 cells towards nerves in a dose dependent manner via the 
GDNF/GFRα1/RET signalling pathway [170]. Another study showed that 
endoneurial macrophages secret GDNF that increases the perineural invasive 
behaviour of PDAC cells in both in vitro and in vivo models again via activation of 
ERK [171]. 
 ARTN as well as its receptor GFRα3/RET were reported to be highly expressed in 
both pancreatic cancer and nerves within cancer specimens and this protein also 
appears to increase invasiveness of PDAC cell lines [172], however, a direct link to 
PNI has not been established yet. 
 
Cell adhesion molecules   
Several studies suggested a role for the neural cell adhesion molecule (NCAM) in 
PNI as it was found to be associated with the extent of PNI in pancreatic cancer 
[173] and with the presence of PNI in squamous cell carcinoma of the head and 
neck (SCCHN) [174]. Furthermore, NCAM was found to be expressed in nerves in 
prostate cancer with significantly higher levels in nerve invaded by cancer compared 
to non-invaded nerves [175]. On the other hand, NCAM immunoreactivity was 
reported in nerve cells but not on the perineurium and endoneurium suggesting that 
NCAM may not be involved directly in the process of PNI [173]. Several other 
studies, however, failed to show any correlation between NCAM expression and PNI 
in PDAC [176], SCCHN [177] and adenoid cystic carcinoma of the head and neck 
(ACCHN) [178]. In a gene expression profiling study comparing matched laser 
capture microdissected perineurally invasive and non-perineurally invasive salivary 
adenoid cystic carcinoma cells (ACC) from human tissues, Melanoma Cell Adhesion 
Molecule (MCAM) was found to be over-expressed in perineurally invasive cancer 
[74]. Subsequently, the same group showed that silencing MCAM reduced 
proliferation and invasion of ACC cells in vitro [179].  
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Another adhesion molecule, L1-CAM reportedly correlated with the degree of PNI, 
pain and survival in PDAC patients [73]. 
Chemokines 
The chemokine CXCL12 that is expressed in prostate cancer cells and nerves has 
also been suggested to act in a paracrine/autocrine manner to promote PNI in 
prostate cancer via its receptor CXCR4 that is expressed in cancer cells [180]. A 
recent study by Marchesi et al implicated another chemokine receptor, CX3CR1, in 
PNI [80]. In this study, PDAC cell lines expressing CX3CR1 had increased 
adhesiveness and chemotaxis towards CX3CL1 chemokine that is present in 
nerves. This was mediated via G protein-dependent signalling with activation of β1 
integrin and FAK.  The study also reported that CX3CR1 was expressed in most 
PDAC cases, correlated with PNI and independently predicted tumour recurrence 
[80].  
 
Neurotransmitters 
The role of neurotrasmitters in tumourogenesis and cancer progression is being 
increasingly investigated as epidemiological studies into the relationship of stress 
and cancer suggested a role for the autonomic nervous system in cancer [181]. A 
recent observational study has also shown that the use of β2-adrenergic blockers 
reduced breast cancer progression and mortality [182]. Experimental surgical or 
chemical sympathectomy was also able to inhibit prostate cancer xenograft growth 
[183].   
 Norepinephrine (NE), is a sympathetic neurotransmitter that has been shown to 
increase the invasiveness of MiaPaca2 pancreatic cancer cell lines and increase the 
levels of MMP-2, MMP-9 and VEGF, all of which could be inhibited by the β-
adrenergic blocker Propranolol [184]. Guo et al also found that NE increases 
perineural invasive ability of PDAC cells lines through β-adrenergic/PKA/STAT3 
signalling pathway in both in vitro and in vivo models of PNI [185]. Another recent 
study confirmed the expression of β-adrenoreceoptors in cancer cells in pancreatic 
cancer tissues whilst β2-receptor blockade in Panc1 pancreatic cancer cell line 
resulted in G1/S phase arrest and cell death [186]. Similarly, NE increased lymph 
node metastasis from PC-3 prostate cancer in vivo model and this was, again, 
blocked with propranolol [187]. 
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Substance P (SP) is a neuropeptide released from sensory nerves and signals 
through its receptor NK-1R. SP has been shown to increase PDAC cells proliferation 
and invasion in addition to increasing neurite growth from DRGs in co-culture with 
PDAC cells [188]. These effects were blocked by NK-1R antagonists [188]. 
Altogether, evidence suggests a crucial role of several neurotrasmitters in 
modulating cancer cell biology into a more aggressive phenotype. The final 
influence could be dependent on the ability of cancer cells to respond to these cues 
and the degree of cancer innervation and neoneurogenesis, a phenomenon that is 
receiving more interest recently.   
 
Other molecules 
Using rat vagal nerve explants to establish highly neuroinvasive subclones of PDAC 
cell lines followed by gene expression profiling, Abiatari et al produced a catalogue 
of 680 transcripts that were differentially regulated between the less and the highly 
neuroinvasive clones [189]. Amongst these, they identified the kinesin-like protein 
KIF14 as an invasion-suppressing gene that was down-regulated in highly invasive 
clones in vitro as well as in perineurally invasive cancer cells compared to non-
invasive cells in human PDAC tissues. Silencing of KIF-14 in T3M4 PDAC cell line 
resulted in increased invasiveness of these cells using both Transwell and vagus 
nerve invasion assays. In addition, the authors reported that the Rho-GDP 
dissociation inhibitor β (ARHGDIβ) was up-regulated in both highly neuroinvasive 
clones and perineurally invasive cancer cells in PDAC tissues. Silencing of 
ARHGDIβ did not affect transwell invasion but decreased invasion in vagus nerve 
neural invasion assays [189]. In a subsequent report, the same group suggested a 
role of the microtubule-associated protein MAPRE2, another protein that was up-
regulated in the highly invasive clones, in PNI. However, there was no association 
between MAPRE2 expression and PNI in human tissue samples and apart from the 
over-expression in neuroinvasive cell lines, there was no evidence for its 
involvement [190]. 
MUC1 has also been suggested to contribute to PNI by enhancing adhesion to the 
nerves through interaction with the myelin-associated protein (MAG) on Schwann 
cells [191]. Others proposed that the basement membrane proteins laminin, 
fibronectin (FN) and collagen type IV, which are abundantly expressed in the 
basement membrane of perineurium may increase the migration of PDAC cell lines 
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(most notably undifferentiated ones) and contribute to PNI [192]. Specifically, the 
interaction between neuronal laminin and integrin α6β1 on malignant cells has been 
suggested to contribute to the neurotropism of prostate cancer [193]. Similarly, 
laminin γ2 (LAMC2) has been shown to increase the nerve invasion distance of 
PDAC cell lines in an in vivo sciatic nerve model of PNI possibly by enhancing the 
attachment of cancer cells to the neural tissue and/or increasing migration through 
interaction with integrin α6β4 on cancer cell surface [194].  
Several other proteins have also been reported to be involved in PNI. Using a 
subcutaneous mouse model of pancreatic cancer, Koide et al reported that CD74 
was up-regulated in PDAC cell lines with high propensity for PNI and its expression 
correlated with the degree of PNI in human PDAC samples [75]. In a subsequent 
study using the same model, they also found that synuclein-γ (SNGG) was over-
expressed in neuroinvasive cell lines and its expression correlated with PNI, poor 
survival as well as other invasive parameters such as stage, LN metastases and 
tumour size, suggesting that SNGG over-expression results in a more aggressive 
and invasive malignancy and is not specifically related to PNI [76]. In another study, 
SNGG was found to be over-expressed in pancreatic cancer and significantly 
associated with LN metastases but correlation with PNI was not significant [61]. In 
addition, SNGG was not predictive of survival in this study although this could be 
related to the selection of patients as all of them were stage I and II  [61]. In another 
study, Nestin (NES), an intermediate filament protein, has also been shown to 
correlate with PNI in pancreatic cancer using IHC [195]. 
In a genome-wide expression analysis of microRNA and mRNA of prostate cancers 
with and without PNI, Prueitti et al found 19 microRNAs that were over-expressed 
and 34 mRNA transcripts that were down-regulated in cases with PNI including 
genes involved in metabolism, negative regulation of cell death and interestingly 
neurogenesis [196]. 
Lastly, hyperglycemia has been reported to enhance neural alterations and increase 
PNI in pancreatic cancer. Patients with hyperglycemia showed increased neuronal 
density and hypertrophy as well as more frequent PNI [63]. Diabetic patients have 
also been shown to have more PNI and both diabetes and PNI predicted poor 
prognosis [197]. It has been hypothesized that hyperglycemia promotes PNI through 
both increasing proliferation of cancer cells as well inducing nerve damage as seen 
in diabetic neuropathy [198].  
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1.2.8. Neuronal plasticity in cancer 
The presence and implication of alterations in the neuronal structure and/or function, 
neuronal plasticity, in the context of cancer is becoming increasingly recognised. 
Ceyhan et al showed that pancreatic cancer patients have increased neural density 
and hypertrophy and pancreatic neuritis that exceeded the one present in chronic 
pancreatitis, and neural density and hypertrophy significantly correlated with the 
degree of PNI [81]. In a separate study, the same group confirmed the neurotrophic 
effect of pancreatic cancer microenvironment by demonstrating increased neurite 
density in myenteric plexus cells treated with protein extract from pancreatic cancer 
tissues [199]. This effect was partially reversed by depletion of NGF and ARTN from 
the extract suggesting a role for those two proteins in addition to other unknown 
factors. In another report, protein extracts from PDAC and CP tissues increased 
neurite growth, branching complexity and neuronal cell size of both myenteric plexus 
and DRG neurons in vitro [200]. Similar results were obtained by treatment with 
conditioned media from several PDAC cell lines [200].  As pointed out earlier, 
alteration in the nature of autonomic and sensory pancreatic innervations has been 
observed both in human PDAC and in a transgenic mouse model of pancreatic 
cancer [101, 104]. 
In prostate cancer, Ayala et al presented the first evidence for active neurogenesis 
and axonogenesis in cancer [142]. They demonstrated increased neural density as 
well as number and size of neurons in prostate cancer samples compared to normal 
prostate, which was also evident in preneoplastic lesions.  In another study, Magnon 
et al found higher autonomic neural density in high-risk compared to low-risk 
prostate cancer patients which was associated with poor clinical outcome [183].  
In colorectal cancer, Albo et al showed that 66% of patients displayed some degree 
of neurogenesis which was an independent prognostic factor for overall and disease 
free 5-year survival [141]. In their study, colorectal cancer cells were also able to 
induce neurite growth in DRG neurons in vitro.  
There is ample evidence to suggest that neuronal plasticity is a key feature of neuro-
epithelial interactions, particularly in neurotropic cancers. The biological results of 
this in terms of influence on symptoms, aggressiveness of cancer cells and patients’ 
survival are just starting to emerge. 
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1.2.9. Experimental models of PNI  
In vitro models 
In vitro models used primarily two types of neuronal cells or tissue explants co-
cultured with cancer cells. DRG based models are the most widely used to 
investigate PNI. Initial models used DRGs excised from mice, and grown in a drop 
of extracellular matrix (ECM) next to another drop containing cancer cells [147]. 
Subsequent modifications used two drops of ECM on either side of cancer cells, 
only one containing DRG. ECM bridges were used to connect the cancer cells to the 
other two drops, thus the model provided the opportunity to measure unidirectional 
migration of cancer cells towards DRGs ([149]. 
Because DRGs are sensory nerve structures and the innervation of the pancreas is 
largely autonomic, a second model utilizing rat myenteric plexus cells from the 
enteric neuronal system was established, the results using these cells were largely 
consistent with those using DRGs [149]. 
An alternative in vitro model based on passaging cancer cells through a rat vagus 
nerve conduit has been used to establish progressively more neuroinvasive clones 
of PDAC cells [189]. The gene expression profiles of these cells were then 
compared to identify genes that are deregulated during this process. A potential 
disadvantage of this model is the lack of neuronal cells within the conduit as the 
neuronal cell bodies lie within the nucleus ambiguous in the brain and the conduit is 
mainly formed of nerve layers and degenerating axons. 
In vivo models  
In vivo models of PNI have only recently been described but remain limited in scope 
and technically demanding. In a subcutaneous mouse model of PNI, human PDAC 
cells that were injected subcutaneously formed tumours some of which, particularly 
the well differentiated ones showed high prevalence of subcutaneous nerves 
invasion [75]. More recently, an interesting in vivo model has been established by 
injecting cancer cells in the sciatic nerves of mice [194]. The animals are then 
followed up using various imaging and behavioural techniques to monitor tumour 
growth as well as sciatic nerve function. Tissues were also collected for downstream 
analysis. One caveat of this model is that the injection of cancer cells within the 
nerve bypasses the initial steps of the nerve invasion process. A recent modification 
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of the technique involved injecting cancer cells between the perineurium of the 
nerve and the adjacent muscle [201].  
 On the other hand, commonly used orthotopic pancreatic cancer mice models using 
nude mice do not show perineural invasion [202]. This could be, at least in part, due 
to the limited desmoplastic reaction in these models as the severity of dysmoplasia 
correlated with PNI in human PDAC tissues [81].  In a modification of such models, 
fragments of subcutaneously growing human PDAC cell lines in mice were 
transplanted into the pancreata of nude mice. Tumours were then resected at 
specific time points and animals were followed up.  Although  the authors did not 
report PNI in the resected primary pancreatic  tumours, when animals were followed 
up and, subsequently killed, the recurrent tumours demonstrated invasion of 
peripancreatic tissue and nerves [203]. Despite the lack of PNI in the primary 
tumour, the pattern of recurrence following an apparently curative resection did 
resemble the human disease. One of the commonly used transgenic mouse models 
of pancreatic cancer, based on expression of oncogenic KRASG12D has reportedly 
demonstrated PNI [204]. Intriguingly, we could not identify any PNI literature using 
this model.  
In all these models, the neuronal part contains a mixture of neuronal cells, glia and 
other supporting cells, which reflects the structure of peripheral nerves including 
those of the pancreas. While this is more physiological, this makes understanding 
the roles that each of nerve component plays in the neuro-epithelial interaction 
difficult.  Furthermore, the process of harvesting DRGs or myenteric plexus cells is 
laborious and requires the use of large numbers of animals. 
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1.3.  Aim of the project 
PDAC has a grave prognosis, largely due to the aggressive biological behaviour of 
this cancer, of which PNI is a cardinal feature.  Whilst the involvement of nerves, 
along with other adverse biological features, appear to reflect the extremely 
malignant behaviour of this cancer, it also seems to provide further survival 
advantage to malignant cells and a potential nidus for recurrence following surgery. 
It is therefore imperative to understand the biology of PNI and the changes that 
occur to cancer cells and nerves during this process so that more effective 
therapeutic strategies can be designed. 
Despite the increasing scientific interest, our knowledge of the neuro-epithelial 
interactions in cancer remains both limited and fragmented. We identified two key 
areas of deficiency that we could contribute to, namely, the lack of global molecular 
data on both cancer and nerves within PNI in human tissues and the need for a 
simple and easy to manipulate in vitro model of PNI.  
Therefore, this project aims to uncover key molecular alterations underlying PNI and 
neuronal plasticity in PDAC, develop a simple in vitro model of PNI, and try to 
identify potential therapeutic targets for effective treatment strategies that could 
improve survival and alleviate pain in pancreatic cancer patients. Firstly, we will 
perform a detailed proteomic analysis of laser microdissected cancer and nerve 
samples from formalin-fixed, paraffin-embedded (FFPE) PDAC tissues followed by 
IHC validation of selected differentially expressed proteins. We will compare the 
expression profiles of matched perineurally invasive (PNI-cancer) and non-PNI 
cancer as well as invaded and non-invaded nerves. Secondly, we will develop an in 
vitro co-culture model of PNI based on PC12 rat pheochromocytoma cell line as the 
neuronal element. We will use this model to validate and further investigate the 
role(s) and regulation of putative candidates from our proteomic analysis.  
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2. Materials and methods 
2.1. Tissues and cell lines 
Human pancreas tissues (normal, CP and PDAC) were obtained from the Pathology 
departments of the Royal London hospital (London, UK), KBC Regional hospital 
(Osijek, Croatia) and the Department of Surgery, Technische Universität München 
(Munich, Germany). All tissues were obtained after full ethical approval and used in 
accordance with the Human Tissue Act 2004.  
PDAC cell lines (MiaPaca2, BxPC3, Capan1 and Panc1) were obtained from 
Cancer Research UK Tissue Culture Service and routinely cultured in DMEM 
supplemented with 10% heat-inactivated fetal calf serum (FCS) and penicillin 
(100units/ml) /streptomycin (0.1mg/ml) at 37°C in an atmosphere of 5% CO2. Cells 
were routinely passaged using Trypsin-EDTA solution when ~80% confluent. All cell 
lines used were verified by STR profiling. 
PC12 cells, a rat pheochromocytoma cell line, were a kind gift from Dr Lesley 
Robson (Blizard Institute, London), and were routinely grown in poly lysine D coated 
plastic tissue culture flasks  in RPMI media supplemented with 10% heat-inactivated 
donor horse serum, 5% heat-inactivated FCS and penicillin/streptomycin 
(concentrations as above) at 37°C in an atmosphere of 5% CO2.  Media was 
changed every 48 hours and cells were passaged when ~80% confluent.  
 
2.2. Materials 
All reagents were purchased from Sigma (Sigma Aldrich, UK) unless otherwise 
indicated. Acetonitrile (ACN), xylene and ethanol were purchased from Fischer 
Scientific (Fisher Scientific, UK). Hematoxylin and eosin (H&E) from Merck (Merck, 
Germany), MassPREP Enolase digest standard from Waters (Waters Corporation, 
USA), sequencing grade Trypsin from Promega (Promega, USA).  Tissue culture 
media and reagents were from PAA (PAA, Austria) and plasticware and disposables 
from Corning (Corning Incorporated, NY, USA) unless otherwise specified. 
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2.3. Methods 
2.3.1. Tissue section preparation and laser microdissection 
Tissues resected at pancreatectomy were routinely fixed in formalin and embedded 
in paraffin. 5µm sections were cut and routinely stained with H&E. Details of five 
PDAC cases that contained significant PNI and were selected for subsequent laser 
microdissection are summarised below  (Table 2). In addition, one case of normal 
pancreas was also used for preliminary optimisation of the proteomics workflow. 
 
Table 2. Clinical details of PDAC cases used for laser microdissection and proteomic 
analysis. PD: pancreaticoduodenectomy; DP: distal pancreatectomy. TNM: tumour size, 
lymph node, distant metastases 
 Sex Surgery/year TNM (stage) Grade 
PDAC1 F PD/2006 T3N1M0 (IIB) Moderate 
PDAC2 M PD/2009 T3N1M0 (IIB) Poor 
PDAC3 F PD/2006 T2N1M0 (IIB) Moderate 
PDAC4 M DP/2006 T4N1M0 (III) Moderate 
PDAC5 M PD/2007 T3N1M0 (IIB) Moderate 
 
A special LMD slides comprising a glass slide covered with a PEN membrane 
(polyethylene naphthalate) (Zeiss, Germany) were used. PEN slides were baked in 
a UV box for 30min to enhance the adhesion of tissue sections to the membrane. 
10µm sections were cut from PDAC blocks and mounted on the PEN membrane 
slides. For each case, approximately 60-80 sections were cut, stored at 4°C and 
used within two weeks. Every fifth section was cut at 5µm and mounted on standard 
glass slide for routine H&E staining and reviewed to determine areas for laser 
microdissection and estimate the number of cells that can be obtained. PEN slides 
with the mounted sections were then baked in an oven at 55°C for 45min. Sections 
were deparaffinised using xylene and rehydrated in graded ethanol (100%, 90%, 
70%) followed by hematoxylin staining, dehydration through graded ethanol (70%, 
90%, 100%) followed by five dips in xylene and air-drying for 5min. The staining 
procedure was completed in 15min.  
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Laser microdissection was performed using the PALM instrument (Zeiss, Germany). 
10x and 20x objectives were used and energy and focus of laser were adjusted for 
each section to achieve narrowest possible cut. Areas of interest were dissected 
and catapulted into PCR tubes’ caps containing double distilled water within two 
hours of staining. PNI cancer, non-PNI cancer, invaded nerves and non-invaded 
nerves were separately dissected from each of the five pancreatic cancer cases and 
stored at      -20°C. 
For initial evaluation of the proteomics approach, 10µm sections of normal pancreas 
FFPE block were also cut and mounted on glass slides. Slides were then prepared 
similar to PEN slides but without final dehydration step. Approximately 10mm2 of 
sections were scrapped off the slides using the tip of 22G needle and placed in 20µl  
Liquid Tissue (LT) buffer (Expressionpathology, USA) for protein extraction. 
 
2.3.2. Protein extraction for proteomics analysis 
Bovine serum albumin (BSA) peptide digest as well as peptides extracted from 
MiaPaca2 cell line and normal pancreas FFPE tissue were used for the evaluation 
of HPLC fractionation.  
150µg of BSA was suspended in 2% Rapigest (Waters Corporation, USA) in 50mM 
ammonium bicarbonate. Dithiothreitol (DTT) was added to  a  final concentration of 
10mM and sample incubated at 60°C for 30min. Iodoacetamide (IAA) was then 
added to 15mM final concentration and sample incubated in the dark at room 
temperature for 30min. Sequencing grade trypsin was added at a ratio of 1:40 (w/w) 
and samples incubated at 37°C overnight. Formic acid (FA) was then added to a 
final concentration of 2% and samples incubated at 37°C for 30min followed by 
centrifugation at 16,000g for 10min. Supernatant was collected and divided into 
portions equivalent to 30µg BSA each, dried in SpeedVac and stored at -20°C until 
analysis. 
MiaPaca2 cell pellets were resuspended in lysis buffer (8M urea in 20mM HEPES, 
pH 8.0). After sonication, samples were centrifuged at 16,000g for 10min at 5°C. 
Supernatant was transferred to fresh 1.5ml LoBind eppendorf tubes (Eppendorf, 
Hamburg, Germany) and protein concentration was measured using Bio-Rad assay 
(Bio-Rad, UK) according to manufacturer’s protocol. DTT was added to 10mM final 
concentration and samples were incubated at room temperature for 15min, followed 
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by addition of IAA (15mM final concentration) and incubation at room temperature 
for 15min in the dark. Samples were diluted 1:4 with 20mM HEPES buffer, and 
sequencing grade trypsin was added at a ratio of 1:40 (w/w) followed by an 
overnight incubation in a water bath at 37°C . Next day, samples were acidified with 
trifluoroacetic acid (TFA) to a final concentration of 1%, centrifuged and supernatant 
transferred to a fresh eppendorf tube. Subsequently, samples were desalted using 
OASIS C18 cartridges (Waters Corporation, USA). After conditioning of the 
cartridges, samples were added followed by a wash with 2%ACN/0.1%TFA. 
Peptides were eluted with 70%ACN/0.1%TFA. The eluted samples were divided into 
aliquots equivalent to 100µg of protein each, dried in SpeedVac and stored at -20°C 
until used analysis. 
Laser microdissected material from FFPE tissues was pooled according to the cell 
type for each case resulting in four samples per case (PNI and non-PNI cancer, 
invaded and non-invaded nerves) per case. Each sample was dried in SpeedVac, 
resuspended in LT buffer (approximately 20µl/30,000 cells) and protein extraction 
and digestion proceeded according to manufacturer’s instructions. Briefly, samples 
were boiled for 90min at 95°C. After cooling on ice, sequencing grade trypsin was 
added (1µg/20µl buffer) for overnight digestion in a water bath at 37°C. Peptide 
concentration was measured with Micro BCA kit (Thermo Fisher Scientific, USA) 
according to manufacturer’s instructions using 2µl of each sample and BSA 
standard in duplicates. 100mM DTT was added to each peptide sample to a final 
concentration of 10mM DTT and samples were boiled at 95°C for 5min before 
storing at -20°C until further analysis. 
 
2.3.3. Capillary HPLC fractionation 
Fractionation was performed on Agilent 1200 HPLC platform (Agilent Technologies, 
Berkshire, UK) after conversion to a capillary system as described previously [205]. 
Briefly, the conversion was accomplished using a flow splitting T-piece (Upchurch 
Scientific, USA) and restriction capillary. Following preliminary optimisation, the final 
flow from the pump was 380µl/min and flow through column was 5µl/min. Samples 
were injected manually using a Rheodyne manual injection valve (model 7125, 
Perkinelmer, USA) fitted with 20µl sample loop. Samples were injected with a 20µl 
HPLC syringe (Hamilton, USA) using under-fill technique. Samples were loaded on 
a NanoEase Xbridge BEH300 C18 capillary column (300µm ID x 100mm L, 3.5µm 
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particle size) (Waters Corporation, USA). Gradient was developed using buffer A: 
10mM ammonium formate in water and buffer B: 10mM ammonium formate in 80% 
ACN, pH of both buffers was adjusted to 10 using 25% ammonium hydroxide. 
Separation was performed at ambient temperature and chromatograms were 
monitored at 214nm. 
5µg of BSA digest resuspended in buffer A was manually loaded over 20min and 
peptides were then separated using a 2-42% B gradient over 40min. For MiaPaca2 
and normal pancreas FFPE digests, 10µg samples suspended in buffer A were 
loaded over 20min and fractionated using a 2-50% B gradient over 60min followed 
by a final 10min isocratic step at 100%B. Flowthrough was collected followed by 12 
fractions (one fraction every 5min) and a final fraction of the 100%B step (total 14 
fractions). For PNI analysis, 7µg of peptides from each PNI cancer sample from 
three cases were pooled. A matching sample of non-PNI cancer was similarly 
pooled from the same cases. Pooled samples were dried in SpeedVac. Each pooled 
sample was resuspended in buffer A and fractionated in duplicate (10µg each 
replicate) as above. Fractions were collected every 5min (total 12 fractions). The 
flowthrough was added to the first fraction and the 100% B step fraction was added 
to the preceding one. Fractions were dried in SpeedVac and stored at -20°C until 
LC-MS analysis. 
 
2.3.4. LC-MS analysis and data processing 
LC-MS experiments for method validation were performed in the MS facility in 
Centre for Cell Signalling (Barts Cancer Institute) on a Nanoacuity LC system 
(Waters Corporation, USA) coupled to LTQ Orbitrap XL platform (Thermofisher, 
USA). Unfractionated (1µg) or dried fractions of peptide digests from MiaPaca2 cells 
and normal pancreas FFPE samples were suspended in 10µl 0.1% TFA containing 
20 fmole/µl enolase standard digest. Buffer A was 0.1% FA in water, and buffer B 
was 0.1% FA in ACN. 4µl aliquots of the samples were first loaded on a Symmetry 
C18 trap column (180µm ID x 20mm L, 5µm particle size) (Waters Corporation, 
USA). Peptides were then eluted from Nanoacuity BEH130 C18  column (100µm ID 
x 100mm L, 1.7µm particle size) using 0-35% B gradient over 100min at 400nl/min 
flow rate. Total run time was 2 hours/sample. Data was acquired over mass range of 
350-1800 in a data-dependent manner with 90s dynamic exclusion. Each full MS 
scan was followed by MS/MS of the five most abundant ions.  
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Peaks were searched using Mascot v2.2.2 (Matrixscience, USA) against the human 
SwissProt database (20100303, 20,326 entries) with the following critieria: fully 
tryptic peptides with maximum two missed cleavages allowed, 
carbamidomethylation of cysteine and oxidation of methionine as fixed and variable 
modifications respectively and a tolerance of 7ppm for parent ions and 0.6Da for 
fragments. Mascot data files were then analysed in Scaffold v 3-00-08 (Proteome 
Software, USA) to generate nonredundant protein identifications with ≥2 
peptides/protein and minimum 90% and 95% confidence at peptide and protein 
level, respectively. 
PNI proteomic profiling experiments were performed by Richard Jones 
(MSBioworks, USA) on a Nanoacuity LC system coupled to LTQ Orbitrap Velos 
platform (Thermofisher, USA). Unfractionated samples (1µg) or dried fractions were 
suspended in 0.1%FA. Buffer A was 0.1% FA in water, and buffer B was 0.1% FA in 
acetonitrile. 30µl samples were first loaded on an IntegraFrit trap column (75um x 
30mm) packed with Jupiter Proteo C12 material with 5µm particle size 
(Thermofisher Scientfic, USA). Peptides were then eluted from  a 75µm x 250mm, 
4µm particle Jupiter Proteo C12 analytical column (Phenomex, CA, USA) at 
350nl/min using 5-22%B over 70min then to 35%B over 20min and to 85%B over 
15min. Total run time was 2 hours/sample. Data was acquired over mass range 
300-1600 in a data-dependent manner. Each full MS scan was followed by MS/MS 
of the 15 most abundant ions, dynamic exclusion and repeat settings ensured each 
ion was selected only once and excluded for 30s thereafter.  
The MS data were analyzed using MaxQuant version 1.4.0.1 [206]. The proteins 
were identified by searching MS and MS/MS data of peptides against the Swissprot 
human canonical database (20,556 entries) appended with common contaminants 
using the Andromeda search engine. Oxidation of methionine and protein N-terminal 
acetylation were chosen as variable modifications. The minimum peptide length was 
specified to be seven amino acids. The initial maximal mass tolerance in MS mode 
was set to 7 ppm, whereas fragment mass tolerance was set to 0.5 Da for 
fragmentation data. The maximum false protein and peptide discovery rate (FDR) 
was specified as 0.01 and determined using a decoy database. Proteins were 
identified with ≥2 peptides/protein.   
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2.3.5. Immunohistochemistry (IHC) 
IHC validation was performed on 4µm sections cut from FFPE tissue blocks. For 
OLFM4, staining was performed in the Barts Cancer Institute core Pathology service 
using the automated Ventana Discovery System (Illkirch, France). Rabbit anti-
OLFM4 primary antibody (Abcam) was used at 1/400 dilution. Staining intensity was 
semi-quantitatively  assessed at 200x magnification as absent (0), background (1), 
weak (2), moderate (3) or strong (4) and the extent (percentage of cells displaying 
the maximum intensity) was assessed as 0-5% (0), 6-25% (1), 26-50% (2), 51-75% 
(3) or >75% (4). The final IHC score was calculated by adding the intensity and 
extent of immunoreactivity. Of note, all PNI lesions were assessed in each section. 
For non-PNI cancer, at least 10 HPF (high power fields, at 200x) were assessed for 
each section.    
VGF IHC staining was performed manually in the following way: 4µm FFPE tissue 
sections were deparaffinized in xylene and rehydrated in graded ethanol as 
described before, followed by endogenous peroxidase block in 1.5%H2O2 in 
methanol.  Following heat-induced antigen retrieval in citrate buffer (pH 6.0) and 
avidin and biotin block (Vector Labs, CA, USA), staining proceeded using Vectastain 
ABC kit (Vector Labs) according to the manufacturer’s instructions. Protein blocking 
was followed by incubation with rabbit anti-VGF primary antibody (Abcam) at 1/400 
dilution for 1 hour at room temperature. Sections were then washed three times with 
TBS-T 0.05% (Tris buffered saline, 0.05% Tween 20) and incubated with the 
biotinylated secondary antibody for 30min. Following another wash step, the 
sections were incubated with the ABC reagent for 30min, washed twice and 3-3’ 
diaminobenzidine (DAB) kit (Vector Labs) was used for colour development. Slides 
were then counterstained with hematoxylin, dehydrated in graded ethanol and 
mounted. Staining intensity was semi-quantitatively assessed at 200x magnification 
as absent (0), weak (1), moderate (2) or strong (3). Assessment of immunoreactivity 
was done in a blinded manner to clinical details. 
 
2.3.6. Grading of pain 
For correlation of VGF protein expression and pain, tissue sections from clinically 
annotated CP and PDAC cases were provided by our collaborators at the 
Department of Surgery, Technische Universität München (Munich, Germany). Pain 
51 
 
data was collected prospectively from CP and PDAC patients as described 
previously [81]. Briefly, pain intensity was graded as no pain (0), mild pain (1), 
moderate pain (2) or severe pain (3). The frequency of pain was graded as daily (3), 
weekly (2) or monthly (1). The final pain severity score for each patient was 
calculated by multiplying pain intensity and frequency. Patients were then divided 
into three groups according to their pain severity score: No pain (0), mild pain (1-3) 
and moderate to severe pain (4-9). 
 
2.3.7. PC12 co-culture experiments  
Transwell (TW) co-culture: 
1.5x105 PC12 cells were seeded in complete RPMI media in 6-well plates pre-
coated with poly D lysine (PDL). 1.5x105 PDAC cells lines or PC12 cells were also 
seeded in their respective media in 6-well plate inserts (1µm pore size, BD 
Biosciences, CA, USA) in separate plates. Next day, media was removed and cells 
in inserts and wells were washed three times with serum-free RPMI. Subsequently, 
inserts with PC12 or PDAC cells were combined with wells containing PC12 cells 
and serum-free RPMI was then added to wells (2ml) and inserts (1ml). 24 hours 
later, inserts were removed and phase-contrast photographs of PC12 cells in the 
wells were taken using an inverted Olympus CKX41 microscope (Olympus) at 200x 
magnification. PC12 cells were then harvested for RNA, protein extraction and flow-
cytometry. 
 
Contact co-culture:  
1.2x106 PC12 cells were seeded in their complete RPMI media in T75 flasks pre-
coated with PDL. Next day, media was removed and fresh media containing 2.5µM 
CellTracker Green CMFDA (Invitrogen) was added and cells incubated at 37˚ for 
30min. Cells were then washed twice with serum-free RPMI media and 1.2x106 
PDAC or PC12 cells in complete RPMI media were added to the flasks. The added 
cells were then allowed to attach for 2 hours following which media was removed 
and the co-cultures were washed three times with serum-free RPMI. 24ml of fresh 
serum-free RPMI was then added. Co-culture was continued for further 22 hours, 
after which cells were harvested, and CMFDA positive cells (PC12 cells) were 
isolated for protein and RNA extraction using Fluorescence Activated Cell Sorting 
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(FACS). Sorted cells were always re-checked for purity using the same FACS 
settings. In addition, small aliquots of sorted cells were seeded on coverslips for 
subsequent immunocytochemical validation of their purity. 
As noted, for both types of co-cultures, seeding density (~15,000 cells/1cm2), ratio of 
PDAC to PC12 cells (1:1) and ratio of media to cells (1ml/1.0x105) were kept 
constant and both co-cultures were performed and analysed in parallel. 
 
2.3.8. Immunocytochemistry (ICC) 
ICC validation of the purity of the FACS sorted PC12 was performed using antibody 
against the epithelial-specific protein cytokeratin 19 (CK19).  PC12 cells isolated 
from the contact co-culture were cultured in 12-well plates on PLD coated sterile 
coverslips in complete RPMI media. Separately, PDAC cells and PC12 cells alone 
were also similarly cultured and used as positive and negative controls for ICC 
staining, respectively. 24 hours later, media was removed and cells were washed 
with cold PBS and subsequently fixed in 4% paraformaldehyde (PFA) for 10min 
followed by three washes with cold PBS. All subsequent steps were performed at 
room temperature. Cells were permeabilised with 0.2% saponin in PBS followed by 
three washes with PBS and  protein blocking using 6% BSA in PBS. Cells were then 
incubated with mouse ani-CK19 primary antibody (Dako, Cambridgeshire, UK) at 
1/50 dilution in 6% BSA for 45min.  Following 3 washes with PBS, the Alexa Fluor 
568 cunjugated secondary antibody (Invitrogen, 1/1000 dilution) was added for 
30min prior to further three washes with PBS. Coverslips were then mounted on 
glass slides using ProLong Gold mounting media (containing DAPI) (Invitrogen) and 
allowed to dry overnight in the dark. Imaging was performed using LSM 710 Zeiss 
confocal laser scanning system. For each post sort coverslip, a tiled 3x2 image was 
acquired using 40x objective and the number of cytokeratin positive cells were 
counted relative to the total number of cells. 
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2.3.9. Preparation of conditioned media 
PDAC and PC12 cells (4x106) were seeded in T175 flasks in their respective 
complete media. Next day, cells were washed three times with serum-free RPMI, 
and fresh serum-free media was added for conditioning. 24 hours later, media was 
collected, centrifuged at 4,000g for 5min to remove cells and debris, filtered using 
0.22µm filters (Millipore, Cork, Ireland) and immediately used to treat PC12 cells.    
 
2.3.10. K252a treatment 
K252a is a potent and selective inhibitor of Trk tyrosine protein kinases including A, 
B and C and has been shown to block the effects of NGF on PC12 cells [207]. 
K252a (Sigma Aldrich, UK) was dissolved in dimethyl sulfoxide (DMSO) to prepare a 
100µM stock solution. Working solutions were prepared by diluting stock in serum-
free RPMI just before use. PC12 cells were seeded in pre-coated 6-well plates as 
described previously. Next day, media was removed and cells washed three times 
with serum-free RPMI. 1ml serum-free media containing 10, 30 or 100nM K252a or 
DMSO was then added and cells incubated at 37˚C for 1 hour. Media was then 
removed and 2ml of serum-free media containing K252a or DMSO (at the same 
concentration as above) with recombinant human βNGF (R&D systems, Abingdon, 
UK) at 50ng/ml final concentration was added. In other experiments, 2ml of 
conditioned media containing K252a or DMSO was added. 24 hours later, 
photographs for neurite growth quantification were taken, as described previously, 
and cells were harvested for RNA, protein extraction and flow-cytometry. 
 
2.3.11. SiRNA knock-down of VGF 
1.5x105 PC12 cells were seeded in their complete RPMI media in 6-well plates pre-
coated with PDL. Next day, media was removed and 1.5ml of fresh media was 
added. SiRNA knock-down was performed using Lipofectamine RNAiMAX 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions. Following 
preliminary optimization, siRNA was used at 1nM final concentration. For each well, 
siRNA targeting VGF (On target plus pool) or non-targeting siRNA (Dharmacon, 
Fisher Scientific, UK) was mixed with 5µl of Lipofectamine RNAiMAX in 500µl 
Optimem media (Life Technologies, Paisley, UK). The mix was incubated at room 
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temperature for 15min before adding to the wells. Media was removed six hours 
later, cells were washed three times with serum-free RPMI media and PDAC or 
PC12 cells conditioned media was added for 24 hours. 
 
2.3.12. Quantitation of PC12 neurite growth 
Randomly selected HPF (three per well, at 200x magnification) of PC12 TW co-
cultures or conditioned media treatment were analyzed for neurite growth in Image J 
(National Health Institute, http://rsb.info.nih.gov/ij/). The degree of neurite growth 
was estimated by counting the number of cells bearing neurites longer than the 
maximum diameter of the cell body [208]. At least 200 cells were counted in each 
well and results were expressed as percentage of total number of cells. Each 
condition was performed in duplicate in three independent experiments unless 
stated otherwise.   
 
2.3.13. Annexin V/DAPI flow-cytometry assay 
Both floating and attached PC12 cells from co-cultures and conditioned media 
treatment were harvested, centrifuged and washed once with ice cold PBS. Cells 
were pelleted and resuspended in 100µl Annexin binding buffer (10 mM HEPES, 
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) containing 5µl of Annexin V Alexa Fluro 647 
(Invitrogen, Paisley, UK). Following 15min incubation at room temperature in the 
dark, 400µl of the binding buffer containing 1µg/ml 4',6-diamidino-2-phenylindole 
(DAPI) was added to each sample. Cell suspensions were kept on ice and flow-
cytometry was immediately performed using BD Fortessa cell analyzer (BD 
Biosciences, CA, USA). After doublets exclusion, initial gating was performed 
according to unstained samples. PC12 cells growing in their complete media or 
serum-free RPMI were included as negative and positive controls for apoptosis, 
respectively and used for fine-tuning of the gating. Cells that were negative for both 
Annexin V and DAPI were quantified as the surviving fraction and results were 
expressed relative to PC12 survival in complete growth media. Duplicate wells were 
analyzed within each experiment and experiments were repeated three times unless 
otherwise specified. 
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2.3.14. RNA extraction and cDNA synthesis 
Total RNA was extracted using RNAqueous kit (Ambion, CA, USA) according to 
manufacturer’s instructions. Briefly, tissue culture media was removed from the 
tissue culture wells and following a wash with ice cold PBS, 200µl lysis buffer was 
used to lyse cells. Lysate was collected and an equal volume of 64% ethanol was 
added and samples loaded onto the spin columns. Three washes and centrifugation 
steps were performed before eluting RNA in 40µl of elution buffer.  
Quantitative and qualitative assessment of RNA was performed using NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, USA) and gel 
electrophoresis using 1% agarose gel. 
 1µg of total RNA was used for reverse transcription using Quantitech reverse 
transcription kit (Qiagen, West Sussex, UK) according to the manufacturer’s 
instructions. Briefly, RNase-free water was added to RNA to a total volume of 12µl. 
2µl genomic DNA wipeout buffer was then added and samples were incubated at 
42˚C for 9min. Following brief cooling on ice, 6µl mastermix solution containing 4µl 
RT buffer, 1µl Quantitech Reverse Transcriptase and 1µl of RT primers mix (both 
oligo-dT and random primers) was added to each sample and the RT reaction 
proceeded for 15min at 42˚C and terminated by incubation at 95˚C for 3min.  
 
2.3.15. Quantitative real time PCR (qRT-PCR) 
qRT-PCR reaction 
qRT-PCR was performed using the SYBR green method. All primers were obtained 
from PrimerDesign (Southampton, UK). The VGF primers’ sequences were (forward 
5’-TGAGACTTTGACACCCTTATCC and reverse 5’-GGAACCGCCCAGGAATGA). 
Primerdesign, however, does not provide the sequences for their pre-validated 
housekeeping genes. Standard curves using serially diluted cDNA from PC12 cells 
was used to validate the specificity and linear amplification of each pair of primers. 
All primers had a standard curve with R2 ≥0.99 and amplification efficiency of 90-
110%. 
 Several genes were tested for their suitability as housekeeping genes. For this 
analysis, qRT-PCR reactions were run for five genes (GAPDH, B2M, RPL13, CANX, 
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UBC) using PC12 samples from seven experimental conditions (co-culture and NGF 
treatment). Results were analyzed using the geNorm algorithm [209] within qBase 
software  (Biogazelle, Belgium) to determine genes with the most stable expression 
under our experimental conditions. B2M and RPL13 were the most stable and the 
geometric mean of their expression was used for normalization (data not shown).  
 qRT-PCR reactions were set up in 96-well optical reaction plates (Thermofisher 
Scientfic, USA). cDNA was diluted 10 times with RNase-free water,  in each well, 
5µl cDNA was added to 10µl SYBR green reagent (Qiagen, west Sussex, UK) and 
2-3µl of specific primer pair for each gene (for an optimized final concentration of 
600-900nM). Water was added to a total volume of 20µl. For each primer pair, wells 
without cDNA (water only) were included as a control for contamination. Following 
brief centrifugation (1000g x 30sec), the PCR reaction was performed on an 
ABI7500 cycler (Applied Biosystems, CA, USA). Run conditions were as follow: 
50˚C for 2min, 95˚C for 15min followed by 40 cycles of 95˚C for 15sec, 60˚C for30 
sec and 72˚C for 1min. A dissociation step was always performed to check the 
specificity of the amplification and the presence of contaminants or primer dimers. 
Duplicate wells were used for each sample and three independent experiments 
were performed.  
Calculation of CT values and quantitative analysis: 
Data was analyzed using AB17500 software (Applied Biosystems). Threshold was 
set in the exponential phase of the amplification. The cycle number at the point 
where each of the amplification curves crossed the threshold is the Ct value which 
was subsequently used for further analysis.  
Data was analysed with the comparative quantification algorithm using the equation: 
                                                Fold difference = 2-ΔΔCt 
For all primers the Ct value was calculated by subtracting the geometric mean of the 
Ct values of the reference genes from the Ct value of the gene of interest in both the 
control and test samples. The ΔΔCt value was then calculated by subtracting the 
ΔCt value of the control samples from the ΔCt value of the test samples. Results are 
presented as fold change relative to control.  
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2.3.16. Protein extraction, measurement and gel electrophoresis 
Cells lysates were prepared in NP40 lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 
1% NP40 and complete protease inhibitor tablets). Following 15min incubation on 
ice, samples were centrifuged at 16,000g for 15min and supernatant collected for 
analysis. Protein concentration was determined with BioRad assay (BioRad, 
Hertfordshire, UK) at 595nm using BSA standard curve. 15-30µg of protein was 
mixed with 5x Laemmli buffer ( 0.225M Tris pH6.8, 10% SDS, 50% glycerol, 0.25M 
DTT and 0.05% Bromophenol blue) and heated to 70˚C for 10min. Samples were 
then loaded onto 4-12% Bis-Tris NuPage gels (Invitrogen, Paisley, UK). SDS 
electrophoresis was performed at 130V for 90min. Rainbow marker (Amersham 
Biosciences, Sweden) was used for the estimation of molecular weight. Proteins 
were transferred onto PVFD Immobilin-P membranes (Millipore, Watford, UK) using 
a Trans Blot semi-dry transfer cell (BioRad, Hertfordshire, UK) at 20V for 50min. 
 
2.3.17. Western blot 
Following transfer, membranes were blocked in 5% milk in 0.05% TBS-T for 30min 
and then incubated with the primary antibody (Table 3) in blocking buffer at 4˚C 
overnight. Unbound antibody was then washed with TBS-T before incubating the 
membranes with the appropriate HRP conjugated secondary antibody (Santa Cruz 
Biotechnology) at 1/2,000 dilution in blocking buffer for 30min at room temperature. 
Membranes were then washed with TBS-T and signal from bound antibodies was 
visualised using ECL reagents (GE Healthcare, Buckinghamshire, UK) onto 
Hyperfilms (Amersham Biosciences, Sweden). The intensities of the obtained bands 
were quantified in Image J, and the intensity of each target protein band was divided 
by the intensity of the GAPDH in the same sample. Densitometry results of three 
independent experiments were then expressed as a fold change relative to the 
control samples. 
Table 3. Details of the primary antibodies used for Western blot in this project.  
 Antibody Source Host species Dilution 
Anti-VGF Santa Cruz Goat 1/800 
Anti-GAPDH Santa Cruz Mouse 1/20,000 
Anti-GAP43 Abcam Rabbit 1/20,000 
Anti-Nestin Abcam Mouse 1/200 
Anti-Caspase 3 Cell Signalling Rabbit 1/400 
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2.3.18. Statistical analysis 
Statistical analysis for differential expression of proteins was performed in Microsoft 
Excel.  Student’s t-test was performed using peak intensity values for label-free 
relative quantitative analysis of the 1D LC-MS data. For the 2D LC-MS dataset, 
spectral counting was used for relative label-free quantitative analysis. Spectral 
counts refer to the number of times spectra assigned to a particular protein have 
been observed [210]. This has been shown to correlate well with the relative 
abundance of proteins between samples [211, 212].  
Because we had a limited number of replicates, we used the G test of likelihood 
ratio to assess differential expression [212, 213] according to the following equation: 
                                   G = 2[Asc ln(Asc/Esc) + Bsc ln(Bsc/Esc)] 
Where for each protein that has a spectral count A1 and B1 in samples A and B 
respectively, and the total spectral counts for all proteins in each sample is tA and 
tB, Asc is A1+1, Bsc is  (B1+1)(tA/tB) and Esc is (Asc+Bsc)/2. Asc and Bsc  are spectral 
counts normalised to the total number of spectra in the respective sample and to 
which (1) was added to avoid (0) spectral counts. Subsequently, p values were 
calculated from G values based on Chi square probability using one degree of 
freedom. Proteins with p<0.05 (equates to G value of 3.81 at one degree of 
freedom) were deemed significantly differentially expressed. 
For all other statistical analysis, GraphPad Prism 5.03 software was used. For 
continuous data, student’s t-test was used to compare means of data and ANOVA 
with post-hoc correction for multiple comparisons was used when three or more 
samples were compared. For semiquantitative IHC data, Mann Whitney test was 
used to compare the means whereas Kruskal Wallis test with post-hoc correction for 
multiple comparisons was used when comparing more than two groups. Two-tailed 
p values were always calculated and results were plotted as mean ± standard error 
of mean. The significance level was set at p<0.05. 
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Chapter Three: Results 
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3. Results 
3.1. Laser microdissection and protein extraction 
Five cases of PDAC that had significant PNI were used for laser microdissection. On 
average, 60-80 sections were used from each case to dissect PNI cancer, non-PNI 
cancer, invaded and non-invaded nerves (Figure 8). 
                        
     
 
 
 
 
 
 
 
Figure 8. Samples collected by laser microdissection. Matched PNI cancer cells, non-PNI 
cancer cells, invaded nerves and non-invaded nerves were laser microdissected from each 
of five PDAC FFPE tissues. Top panel: before dissection, lower panel: verification of 
dissected material. 
 
Protein extraction using Liquid Tissue buffer yielded satisfactory amounts of peptide 
digests for downstream analysis as shown in Table 4 below. An average of 14.7µg, 
15.6µg, 10.5µg and 12.8µg was extracted from 10mm2 area of non-PNI cancer, PNI 
cancer, invaded nerves and non-invaded nerves, respectively. Approximately 
25,000-55,000 cells were dissected from each of PNI or non-PNI cancer. Due to the 
nature of nerve structure, we did not estimate cell numbers and relied on dissected 
area. 
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Table 4. Area dissected and amount of peptide digest extracted from each sample. 
  Amount of peptide digest extracted in µg (area dissected in mm
2
) 
  Non-PNI cancer PNI Cancer Invaded  nerves Non-invaded nerves 
PDAC1 26.5 (17.0) 26.5 (16.5) 12.2 (13.8) 11.3 (9.7) 
PDAC2 10.6 (10.8) 14.0 (13.3) 11.1 (10.3) 13.6 (9.0) 
PDAC3 17.3 (9.1) 14.3 (8.6) 10.8 (11.4) 11.7 (10.3) 
PDAC4 12.9 (10.2) 13.9 (8.1) 9.8 (9.3) 10.9 (9.5) 
PDAC5 9.9 (6.0) 9.9 (5.6) 8.1 (6.4) 9.1 (6.2) 
 
 
3.2. HPLC conversion 
3.2.1. HPLC conversion set up 
The fractionation of the limited amounts of peptides typically extracted from laser 
microdissected lesions required the use of capillary columns and therefore low flow 
rates. Because the Agilent 1200 LC platform available to us is a standard analytical 
platform, we had to convert this to a capillary HPLC system using previously 
described method [205]. To achieve this, we used a restriction capillary and T-piece 
to split the flow from the pump. The conversion was completed by the exclusion of 
the autosampler, addition of a manual injection valve after the T-piece and replacing 
the standard UV cell within the detector with a nanoflow (80nl) cell. For tubing, small 
internal diameter (ID) capillaries with minimal length were used to minimise dead 
volume (Figure 8). The automated fraction collector was also excluded and fractions 
were collected manually. 
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Figure 9. Schematic representation of the conversion of standard HPLC to capillary HPLC 
system. By using a flow splitting tee and a restriction capillary, most of the buffers (A,B) 
delivered by the pump were diverted to waste. 
 
The minimum flow rate of our standard HPLC pump was 200µl/min, significantly 
larger than the flow rate appropriate for the capillary column we used (3-10µl/min). 
Preliminary tests were done to determine the appropriate length and diameter of the 
restriction capillary and the pump flow rate that will deliver the desired flow rate.  
Using the configuration in Figure 9 we were able to achieve, throughout the gradient 
phase, a stable 5 µl/min flow rate through the column at 380 µl/min pre-split flow 
rate (Figure 10). 
 
 
 
 
 
 
 
 
                    
Figure 10. Post-split flow rate through the capillary column and the HPLC system pressure 
during three blank runs. Using buffers A & B, the run gradient was 2% B for 5min, 2-50% B 
over 50min, 100% B for 10min and then 2% B for 10min. Flow rate was measured by 
collecting flowthrough every 5min. Stable flow of 5µl/min is observed throughout the gradient 
(2-50%B). 
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To estimate the dead volume and determine the start time for the collection of the 
first fraction, we calculated the chromatographic gradient delay of the system. This 
is the time it takes the buffer to move between the pump and the detector and was 
calculated by running a 0-100%B over 20min followed by a hold at 100%B for 
another 20min. (A: 10mM ammonium formate, B: 0.5% acetone in 10mM 
ammonium formate) (Figure 11). The gradient delay (6.2min) was equivalent to 31µl 
dead volume within the system. In addition, the linear increase in absorbance 
indicated the absence of dead volume mixing. 
 
 
 
 
 
 
      
 
   
 
 
 
 
 
Figure 11. Chromatographic delay of the capillary HPLC system using 0.5% acetone as a 
UV marker. Absorbance was measured at 254nm. Gt: gradient time (20min). t50: the time 
corresponding to 50% of the maximum absorbance. 
 
Therefore, the converted system demonstrated stable flow rates and minimal dead 
volume making it a suitable capillary system for further evaluation as the first 
dimension in the two dimensional LC-MS (2D LC-MS). 
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3.2.2. Validation of reproducibility of high pH RP HPLC 
fractionation 
To assess the reproducibility of high pH fractionation using the converted HPLC 
system, we first used BSA as a simple peptide mixture. Intra-day variability was 
quantified using five consecutive replicate analyses of BSA digest on the same day 
(Figure 12A) and inter-day variability was assessed using three consecutive 
replicate analyses of BSA digest on each of three different days (Figure 12B). 
 
(A)  
   
 
 
 
 
(B) 
   
 
 
 
 
 
Figure 12. Chromatographic reproducibility of high pH fractionation of BSA tryptic digest. 
Intra-day variability using five consecutive runs (A) and inter-day variability using three 
consecutive runs on each of three different days (B). 
 
Retention times, peak intensities and peak areas were quantified for selected peaks 
(Figure 13A). The chromatograms as well as CV values of retention times, intensity 
and peak area for the selected peaks demonstrated good reproducibility (Figure 
13B and C). 
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(C) 
 
 
 
 
  
 
 
Figure 13. Quantitative analysis of selected peaks from BSA digest separation 
chromatogram (A) showing CV values of retention time, peak intensity and peak area of the 
selected peaks for evaluation of both  intra-day (B) and inter-day (C) variability. 
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Next, we used MiaPaca2 peptide digest, a complex cellular proteome, to evaluate 
the reproducibility and the depth of proteomic coverage that can be achieved 
through high pH RP fractionation using the converted HPLC system. 10µg of 
MiaPaca2 peptide digest was fractionated, in duplicate, into 14 fractions that were 
subsequently analysed using LC-MS. Additionally, 1µg of unfractionated digest was 
also subjected to LC-MS analysis in duplicate. Visual inspection of the 
chromatograms of the two fractionated samples confirmed excellent reproducibility 
(Figure 14). 
     
 
 
 
 
 
 
 
              
Figure 14. Chromatograms of duplicate runs of MiaPaca2 peptide digest fractionation using 
high pH RP HPLC showing excellent reproducibility. In each run, 10µg of peptide digest was 
fractionated over 70min. 14 fractions were manually collected. 
 
The number of proteins identified from the two fractionated samples was 1602 
compared to 340 from the two unfractionated samples representing approximately 
five-fold increase in the number of identified proteins (Figure 15A). All proteins that 
were identified in the unfractionated samples were also identified in the fractionated 
samples. The reproducibility of protein IDs between the two fractionated samples 
was 76%, which was only 7% lower than the technical reproducibility of the LC-MS 
itself for the technical replicates of unfractionated samples (83%). Furthermore, the 
abundance of proteins as determined by spectral counts was similar between the 
two fractionated replicates indicating good quantitative agreement (Figure 15B). 
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(A)     
 
 
 
 
 
 
(B)   
 
 
 
 
 
 
 
 
 
Figure 15. Qualitative analysis of the number of proteins identified by LC-MS using 
fractionated and unfractionated MiaPaca2 peptide digest. Proteins were identified with ≥two 
peptides with 90% and 95% confidence at peptide and protein level respectively and an FDR 
of 0% (A). Quantitative analysis of the two replicates of fractionation. Spectral counts of 
proteins identified in the two replicates are plotted on the x and y axes. The solid line 
represents optimal correlation while the dashed lines represent ±2 SD (B). 
 
We then assessed the performance of our proteomics approach using normal 
pancreas FFPE and the same protein extraction protocol as will be used in the PNI 
proteomic profiling experiment (Liquid Tissue buffer). 10µg of normal pancreas 
FFPE peptide digest were fractionated and analysed in the same way as MiaPaca2 
digest. The fractionation was similarly reproducible chromatographically (Figure 16) 
and the two fractionated samples yielded 1057 protein IDs compared to 187 from 
the two unfractionated samples, demonstrating again a five-fold increase. The 
reproducibility of protein IDs between the two fractionated samples was also similar 
to MiaPaca2 digest (74%), only 8% lower than the technical reproducibility of the 
LC-MS itself for the technical replicates of unfractionated samples (82%) (Figure 
17A). Quantitatively, the two duplicates of normal pancreas FFPE fractionated 
digests also showed good correlation (Figure 17B). 
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Figure 16. Chromatograms of duplicate runs of normal pancreas FFPE tissue digest 
fractionation showing good reproducibility. 
 
(A)   
 
 
 
 
 
   
(B)                
 
 
 
 
 
 
 
 
Figure 17. Qualitative analysis of the number of proteins identified by LC-MS/MS using 
fractionated and unfractionated normal pancreas FFPE tissue digest. Proteins were 
identified with ≥two peptides with 90% and 95% confidence at peptide and protein level, 
respectively and an FDR of 0.2% (A). Quantitative analysis of the two replicates of 
fractionation. Spectral counts of proteins are plotted on the x and y axes. The solid line 
represents optimal correlation while the dashed lines represent ±2 SD (B). 
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Of note, the number of peptides and proteins identified from FFPE tissues was less 
than those from cell lines. However, whilst the number of peptides identified in the 
MiaPaca2 samples was twice as those identified in the FFPE normal pancreas, the 
number of proteins was only a third higher. This discrepancy can be explained by 
the higher average sequence coverage (representing the part of the protein 
sequence that was identified in LC-MS relative to the full sequence of that protein) of 
proteins in the MiaPaca2 samples (~25%) compared to FFPE normal pancreas 
(~16%) which suggests that proteins in the cell line were identified with more 
peptides than was the case in the pancreas samples. Furthermore, only one third of 
the acquired MS spectra were identified in the FFPE samples compared to 50% in 
the cell line samples, probably reflecting formalin-induced modifications and/or the 
presence of non-tryptic peptides in the FFPE samples. These factors combined, in 
addition to the differences in the sample preparation method and biological 
differences between the samples would account for the observed difference in the 
number of protein identifications. Nonetheless, these results demonstrate excellent 
qualitative and quantitative reproducibility of the high pH RP fractionation using the 
converted HPLC platform as well as significantly wider proteome coverage in the 
two dimensional (2D) LC-MS approach compared to the 1D analysis. 
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3.3. Proteomic analysis of cancer cells and nerves in PNI 
3.3.1. Analysis of PNI and non-PNI cancer 
1D LC-MS analysis  
 
1µg of peptide digest of each of five matched PNI and non-PNI cancer samples was 
subjected to LC-MS analysis in duplicate. We identified 1,432 proteins in the PNI 
samples (1,083-1,266 per sample) and 1,542 proteins in the non-PNI samples 
(1,092-1,258 per sample). A total of 1,610 proteins were identified from all samples 
with at least two unique peptides/protein (the complete list will be deposited in the 
Pancreatic Expression Database, www.pancreasexpression.org).1,346 proteins 
were common to both types of samples, whereas 86 and 196 proteins were unique 
to PNI and non-PNI, respectively. Only 31 proteins (1.9%) were differentially 
regulated (p≤0.05) (Table 5 and 6). Applying a fold change of ≥1.5 in addition to the 
p value resulted in only eight up-regulated and 11 down-regulated proteins. 
 
Table 5. Up-regulated proteins in PNI compared to non-PNI cancer samples analysed using 
1D LC-MS (p≤0.05). Mean values are the average intensity of five FFPE samples. FC: fold 
change. 
Protein 
ID 
Gene  
Name 
Protein name PNI 
Non-
PNI 
p 
value 
FC  
Q15582 TGFBI 
Transforming growth factor-beta-
induced protein ig-h3 
4E+07 2E+07 0.0000 2.29 
P07942 LAMB1 Laminin subunit beta-1 3E+07 7E+06 0.0150 4.01 
Q16363 LAMA4 Laminin subunit alpha-4 1E+07 2E+06 0.0179 7.32 
P26368 U2AF2 Splicing factor U2AF  1E+07 1E+07 0.0195 1.26 
P14543 NID1 Nidogen-1 1E+07 3E+06 0.0231 4.47 
P62269 RPS18 40S ribosomal protein S18 8E+07 6E+07 0.0292 1.33 
O94973 AP2A2 AP-2 complex subunit alpha-2 2E+06 6E+05 0.0334 3.21 
P62899 RPL31 60S ribosomal protein L31 3E+07 2E+07 0.0353 1.35 
P11047 LAMC1 Laminin subunit gamma-1 4E+07 1E+07 0.0360 3.20 
Q6PCB0 VWA1 
von Willebrand factor A domain-
containing protein 1 
4E+06 0 0.0448    - 
P40222 TXLNA Alpha-taxilin 2E+06 3E+05 0.0448 5.65 
Q13509 TUBB3 Tubulin beta-3 chain 8E+07 5E+07 0.0466 1.53 
P49721 PSMB2 Proteasome subunit beta type-2 3E+07 2E+07 0.0487 1.30 
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Table 6. Down regulated proteins in PNI compared to non-PNI cancer samples analysed 
using 1D LC-MS (p≤0.05). Mean values are the average intensity of five FFPE samples. FC: 
fold change. 
Protein 
ID 
Gene 
name 
Protein name PNI 
Non-
PNI 
p 
value 
FC  
P35749 MYH11 Myosin-11 2E+07 1E+08 0.0054 0.16 
P60660 MYL6 Myosin light polypeptide 6 2E+08 2E+08 0.0057 0.77 
P56537 EIF6 Eukaryotic translation initiation factor 6 1E+06 6E+06 0.0067 0.22 
P09525 ANXA4 Annexin A4 7E+08 1E+09 0.0069 0.64 
O15144 ARPC2 
Actin-related protein 2/3 complex 
subunit 2 
5E+07 6E+07 0.0080 0.80 
P45880 VDAC2 
Voltage-dependent anion-selective 
channel protein 2 
2E+07 3E+07 0.0083 0.68 
O15143 ARPC1B 
Actin-related protein 2/3 complex 
subunit 1B 
7E+06 1E+07 0.0092 0.61 
O43396 TXNL1 Thioredoxin-like protein 1 2E+06 4E+06 0.0116 0.45 
P21291 CSRP1 Cysteine and glycine-rich protein 1 2E+07 2E+07 0.0129 0.69 
Q13232 NME3 Nucleoside diphosphate kinase 3 3E+06 6E+06 0.0143 0.55 
O75436 VPS26A 
Vacuolar protein sorting-associated 
protein 26A 
6E+06 1E+07 0.0226 0.54 
Q9H0E2 TOLLIP Toll-interacting protein 6E+06 8E+06 0.0253 0.74 
P21333 FLNA Filamin-A 3E+08 5E+08 0.0277 0.73 
O14880 MGST3 Microsomal glutathione S-transferase 3 6E+06 1E+07 0.0283 0.54 
P09493 TPM1 Tropomyosin alpha-1 chain 8E+06 2E+07 0.0361 0.37 
Q9UJU6 DBNL Drebrin-like protein 1E+07 2E+07 0.0410 0.78 
Q01995 TAGLN Transgelin 9E+07 2E+08 0.0418 0.58 
P23142 FBLN1 Fibulin-1 5E+06 1E+07 0.0486 0.39 
 
 
 
ArrayTrackTM software was used to perform unsupervised hierarchical cluster 
analysis of these samples based on all identified proteins. PNI and non-PNI samples 
from each case clustered together, further supporting the largely similar nature of 
those samples (Figure 18).  
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Figure 18. Hierarchal clustering of PNI and non-PNI cancer samples according to their 
protein expression profile. Each PNI sample clustered with its matching non-PNI sample. 
Clustering was performed using ArrayTrack
TM 
software.  
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2D LC-MS analysis 
 
As the 1D LC-MS analysis of PNI and non-PNI cancer revealed limited number of 
differentially regulated proteins, and in order to achieve in depth proteomic analysis 
of these samples, we performed 2D LC-MS using pooled material from three of the 
five cases that had sufficient peptide digest. For this, we pooled equal amount of 
peptides from PNI cancer from those three cases into one sample and similarly 
pooled non-PNI cancer from the same cases. The two pooled samples were then 
fractionated in duplicate into 12 fractions using high pH RP HPLC (Figure 19). Each 
fraction was subsequently submitted to LC-MS analysis in the same way as the 1D 
analysis.   
 
 
(A)  
        
 
 
 
 
 
 
 
 
(B) 
  
 
 
 
 
 
 
        
Figure 19. Chromatograms of high pH RP HPLC of pooled PNI cancer (A) and non-PNI 
cancer (B) samples. Fractions were collected every 5min (12 fractions per sample). 
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This in-depth profiling resulted in the identification of 3,229 proteins (3,160 in the 
PNI and 3,136 in the non-PNI samples) with an FDR of 1% (the complete list will be 
deposited in the Pancreatic Expression Database, www.pancreasexpressio.org).  
97% of the proteins identified in 1D LC-MS were also identified in 2D LC-MS, only 
39 proteins (1.2%) were found to be differentially expressed (p≤0.05) (Table 7 and 
8). Using a fold change of ≥1.5 as an additional filter, we identified 18 up-regulated 
and 15 down-regulated proteins in PNI compared to non-PNI cancer samples. 
Table 7. Up-regulated proteins in PNI compared to non-PNI cancer samples analysed using 
2D LC-MS (p≤0.05). Mean values are the average spectral counts of the two technical 
replicates. FC: fold change. 
Protein 
ID 
Gene 
name 
Protein name PNI 
Non-
PNI 
p 
value 
F/C 
P41219 PRPH Peripherin 37 1.5 0.0000 24.67 
P24043 LAMA2 Laminin subunit alpha-2 12.5 0 0.0003    - 
Q6UX06 OLFM4 Olfactomedin-4 76 39.5 0.0006 1.92 
P02511 CRYAB Alpha-crystallin B chain 11 0 0.0009    - 
P24821 TNC Tenascin 12 0.5 0.0012 24.00 
P48681 NES Nestin 19.5 4.5 0.0024 4.33 
P09622 DLD 
Dihydrolipoyl dehydrogenase, 
mitochondrial 
25.5 8 0.0026 3.19 
P55011 SLC12A2 Solute carrier family 12 member 2 21 5.5 0.0028 3.82 
Q2UY09 COL28A1 Collagen alpha-1(XXVIII) chain 9 0 0.0035     - 
P07942 LAMB1 Laminin subunit beta-1 23.5 7.5 0.0043 3.13 
Q14112 NID2 Nidogen-2 15.5 3.5 0.0068 4.43 
P12111 COL6A3 Collagen alpha-3(VI) chain 134 94.5 0.0082 1.42 
P14543 NID1 Nidogen-1 12 2 0.0093 6.00 
P68133 ACTA1 Actin, alpha skeletal muscle 115 80.5 0.0127 1.43 
P12036 NEFH Neurofilament heavy polypeptide 7 0 0.0128     - 
P46821 MAP1B Microtubule-associated protein 1B 7.5 0.5 0.0200 15.00 
P12110 COL6A2 Collagen alpha-2(VI) chain 41 22.5 0.0205 1.82 
P07196 NEFL Neurofilament light polypeptide 6 0 0.0245     -   
Q05707 COL14A1 Collagen alpha-1(XIV) chain 16.5 6 0.0305 2.75 
Q16363 LAMA4 Laminin subunit alpha-4 10.5 2.5 0.0336 4.20 
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Table 8. Down-regulated proteins in PNI compared to non-PNI cancer samples analysed 
using 2D LC-MS (p≤0.05). Mean values are the average spectral counts of the tow technical 
replicates. FC: fold change. 
Protein 
ID 
Gene 
name 
Protein name PNI 
Non-
PNI 
p 
value 
F/C 
P01275 GCG Glucagon 5 46 0.0000 0.11 
P35749 MYH11 Myosin-11 16.5 69.5 0.0000 0.24 
Q01995 TAGLN Transgelin 50 91 0.0006 0.55 
O60218 AKR1B10 
Aldo-keto reductase family 1 member 
B10 
6 23.5 0.0014 0.26 
P67936 TPM4 Tropomyosin alpha-4 chain 44 78 0.0023 0.56 
P15924 DSP Desmoplakin 102.5 151 0.0027 0.68 
P58107 EPPK1 Epiplakin 20.5 44 0.0038 0.47 
O00338 SULT1C2 Sulfotransferase 1C2 0 8 0.0068 0.00 
P21333 FLNA Filamin-A 104.5 148 0.0071 0.71 
Q12929 EPS8 
Epidermal growth factor receptor kinase 
substrate 8 
29 53.5 0.0078 0.54 
Q9UHG2 PCSK1N ProSAAS 0 7.5 0.0095 0.00 
Q7Z406 MYH14 Myosin-14 248.5 309.5 0.0118 0.80 
P00488 F13A1 Coagulation factor XIII A chain 2 10.5 0.0217 0.19 
P23141 CES1 Liver carboxylesterase 1 1.5 9.5 0.0220 0.16 
Q15149 PLEC Plectin 619.5 706 0.0225 0.88 
P21397 MAOA Amine oxidase [flavin-containing] A 7.5 19.5 0.0246 0.38 
O95833 CLIC3 Chloride intracellular channel protein 3 1.5 9 0.0289 0.17 
P12814 ACTN1 Alpha-actinin-1 62.5 89.5 0.0317 0.70 
P05408 SCG5 Neuroendocrine protein 7B2 0 5 0.0473 0.00 
 
 
 
GO analysis (geneontology.org) of the PNI, non-PNI and the differentially expressed 
proteins (Figure 20) revealed that our LC-MS analysis detected less membranous 
and more cytoplasmic proteins compared to all GO annotated proteins. The 
distribution of subcellular localisation of the detected proteins is broadly consistent 
with published literature [214-216] and reflects the difficulty of extracting 
hydrophobic membranous proteins. The GO annotations for both PNI and non-PNI 
samples were similar, however the differentially expressed proteins included a 
significantly higher percentage of the extracellular proteins compared to the whole 
cohort of identified proteins. 
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Figure 20. Cell component GO annotations comparing all GO annotated proteins detected in 
PNI cancer and non-PNI cancer as well as differentially regulated proteins. 
 
To further explore this and look into the overall functional roles of the differentially 
expressed proteins, we performed GO enrichment analysis of the differentially 
expressed proteins against the background of all identified proteins using Gene 
Enrichment Analysis and Visualization (GOrilla) tool (http://cbl-
gorilla.cs.technion.ac.il). This analysis confirmed the significant enrichment of 
extracellular proteins and to a lesser degree basement membrane and intermediate 
filaments proteins in addition to others (Figure 21).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. GO cellular component enrichment analysis of the differentially regulated 
proteins. Red line represents the –log10 of 0.05. 
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Ingenuity Pathway Analysis (IPA) was also used to explore the Molecular and 
Cellular functions and Disease processes attributed to the differentially regulated 
proteins. The top enriched functions included ‘Cellular Assembly and Organisation’ 
and ‘Cellular Function and Maintenance’ (such as cytoskeleton organisation, 
microtubule formation and axonogenesis). Enrichment in proteins related to ‘Cellular 
Movement’ included migration, chemotaxis and invasion, whereas ‘Cell Death and 
Survival’ enrichment included functions related to tumour and neuronal cell survival 
(Figure 22). 
 
 
 
 
 
 
 
 
 
Figure 22. IPA analysis of GO Molecular and Cellular function enrichment of the differentially 
expressed proteins in PNI and non-PNI cancer samples. The threshold line represents                                                                             
-log (0.05). 
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3.3.2. 1D LC-MS analysis of invaded and non-invaded nerves 
1µg of peptide digest of each of matched invaded and non-invaded nerve samples 
from five cases was subjected to LC-MS analysis in duplicate. A total of 925 unique 
proteins were identified from all samples with at least two unique peptides/protein. In 
the invaded nerves, we identified 847 proteins (681-729 proteins per sample) 
whereas in the non-invaded nerves 833 proteins (578-729 proteins per sample) 
were detected. 167 proteins (18%) were differentially expressed (p≤0.05) 
(Appendix table 1 and 2), 99 of which had a fold change of ≥1.5. Selected up-
regulated and down-regulated proteins are shown in Tables 7 and 8, respectively. 
 
Table 9. Selected up-regulated proteins in invaded compared to non-invaded nerves 
analysed using 1D LC-MS (p≤0.05 and fold change ≥1.5). Mean values are the average 
intensity from five FFPE samples. FC: fold change, IN: Invaded nerves, NIN: non-invaded 
nerves 
Protein 
ID 
Gene name Protein name Mean IN 
Mean 
NIN 
p value FC 
P07942 LAMB1 Laminin subunit beta-1 7E+08 4.1E+08 0.0031 1.60 
P54577 YARS Tyrosine--tRNA ligase, cytoplasmic 2E+06 258950 0.0040 7.57 
P48681 NES Nestin 4E+08 1.1E+08 0.0048 3.35 
P24043 LAMA2 Laminin subunit alpha-2 5E+08 2.7E+08 0.0072 1.69 
P21796 VDAC1 
Voltage-dependent anion-selective channel 
protein 1 
1E+07 5364680 0.0080 2.40 
O15240 VGF Neurosecretory protein VGF 1E+08 2.7E+07 0.0086 5.15 
P24821 TNC Tenascin 5E+07 2E+07 0.0088 2.57 
P45880 VDAC2 
Voltage-dependent anion-selective channel 
protein 2 
1E+07 6897500 0.0118 2.04 
Q9UHG2 PCSK1N ProSAAS 3E+07 6256750 0.0123 4.69 
P54920 NAPA Alpha-soluble NSF attachment protein 5E+06 2404260 0.0123 2.16 
O15075 DCLK1 Serine/threonine-protein kinase DCLK1 4E+06 886260 0.0142 4.26 
O00429 DNM1L Dynamin-1-like protein 1E+07 5517700 0.0174 1.76 
P61803 DAD1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit DAD1 
4E+06 1026970 0.0190 3.76 
Q15063 POSTN Periostin 1E+08 4.1E+07 0.0201 3.54 
P61981 YWHAG 14-3-3 protein gamma 9E+07 5.4E+07 0.0209 1.60 
P78559 MAP1A Microtubule-associated protein 1A 9E+06 4469180 0.0213 1.93 
P17677 GAP43 Neuromodulin 2E+08 8.9E+07 0.0311 2.14 
Q9NRW1 RAB6B Ras-related protein Rab-6B 4E+07 2E+07 0.0365 1.84 
Q05193 DNM1 Dynamin-1 3E+07 1.7E+07 0.0368 1.70 
O60716 CTNND1 Catenin delta-1 3E+06 476250 0.0374 6.31 
P18509 ADCYAP1 
Pituitary adenylate cyclase-activating 
polypeptide 
7E+06 0 0.0499  - 
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Table 10. Selected down-regulated proteins in invaded compared to non-invaded nerves 
analysed using 1D LC-MS (p≤0.05 and fold change ≥1.5). Mean values are the average 
intensity from five FFPE samples. FC: fold change. IN: Invaded nerves, NIN: Non-invaded 
nerves 
Protein 
ID 
Gene 
name 
Protein name Mean IN 
Mean 
NIN 
p value FC 
P32119 PRDX2 Peroxiredoxin-2 2.1E+08 6E+08 0.0010 0.37 
P11532 DMD Dystrophin 2.6E+07 6E+07 0.0012 0.42 
P13591 NCAM1 Neural cell adhesion molecule 1 1.3E+08 3E+08 0.0079 0.44 
P12429 ANXA3 Annexin A3 2.2E+07 4E+07 0.0118 0.62 
P04271 S100B Protein S100-B 7.9E+08 4E+09 0.0179 0.19 
Q01118 SCN7A Sodium channel protein type 7 subunit alpha 6975530 5E+07 0.0347 0.14 
P69905 HBA1 Hemoglobin subunit alpha 7363660 2E+07 0.0357 0.36 
P68871 HBB Hemoglobin subunit beta 6752000 1E+07 0.0357 0.65 
P08294 SOD3 Extracellular superoxide dismutase [Cu-Zn] 1084070 7E+06 0.0368 0.16 
P00915 CA1 Carbonic anhydrase 1 1.9E+07 4E+07 0.0400 0.51 
P11166 SLC2A1 
Solute carrier family 2, facilitated glucose 
transporter member 1 
4366370 2E+07 0.0408 0.23 
Q9NZN4 EHD2 EH domain-containing protein 2 1.4E+07 2E+07 0.0480 0.62 
P11277 SPTB Spectrin beta chain, erythrocyte 3.7E+07 6E+07 0.0482 0.63 
P00918 CA2 Carbonic anhydrase 2 5196460 1E+07 0.0492 0.54 
 
 
Unsupervised hierarchal cluster analysis was performed as described for cancer 
samples. Interestingly, all invaded nerves clustered together, separate from the four 
out of five non-invaded nerves (Figure 23). The clustering of NIN-1 with IN samples 
could be due to microdissection of some nerves that were in fact invaded at a 
different depth in the tissue. Nonetheless, the clustering pattern strongly suggested 
common features of molecular changes upon neural invasion that surpasses the 
biological matching of samples.  
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Figure 23. Hierarchal clustering of invaded and non-invaded nerve samples according to 
their protein expression profile. Clustering was performed using ArrayTrack
TM 
software.   
 
IPA analysis was also performed to identify enriched cellular functions and disease 
processes. Not surprisingly, ‘Neurological Diseases’ was the most enriched disease 
category. In addition, other interesting disease processes included ‘Immunological 
Diseases’ and ‘Inflammatory Response’ (Figure 24). 
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Figure 24. IPA analysis of diseases and disorders enrichment of the differentially expressed 
proteins in invaded and non-invaded nerves. Top 10 disease processes are shown. 
 
Analysis of molecular and cellular function revealed enrichment in ‘Cell Death and 
Survival’ function including neuronal cell survival as well as ‘Cell Morphology’ 
(mostly relating to axonogenesis and neurite formation). Other enriched functions 
included ‘Cellular Growth and Proliferation’ and ‘Cellular Movement’ (such as 
migration and invasion) (Figure 25). 
 
 
 
 
 
 
 
Figure 25. IPA analysis of molecular and cellular enrichment of the differentially expressed 
proteins in invaded and non-invaded nerves. Top 10 function categories are shown. 
 
Overall, the proteomics data from the nerve samples reveal extensive molecular and 
thus biological alterations that are closely related to the neuroplasticity phenotype 
that has been described in PNI by several studies. 
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3.3.3. Assessment of the purity of LCM samples 
One of the important factors to consider in LMD is the degree of cross contamination 
between closely related samples such as in our case PNI cancer and invaded 
nerves. We therefore attempted to estimate the degree of contamination based on 
the assumption that for a neuronal protein, for example, the level of expression in 
the PNI cancer relative to the invaded nerves is indicative of the degree of 
contamination of cancer sample by the adjacent nerve. We identified four known 
neuronal markers in the nerves dataset: Glial fibrillary acidic protein (GFAP), S100B, 
neurofilament heavy polypeptide (NEFH) and neurosecretory protein VGF. We first 
calculated the abundance of each protein relative to the sample in which it was 
identified. The obtained value for each protein in the PNI cancer sample was then 
expressed as a percentage of its abundance in the matching invaded nerve sample 
(Figure 26). Whilst most of these proteins were not detected in most PNI cancer 
samples, the relative abundance varied between proteins in the same sample pair 
(PNI cancer and invaded nerve) as well as for the same protein in different sample 
pairs particularly for GFAP. 
 
 
 
 
 
 
 
 
 
Figure 26. Abundance of selected neuronal proteins in PNI cancer samples relative to 
invaded nerves. The relative abundance for each protein was calculated by dividing the 
expression level in PNI cancer by the level in invaded nerves in the same PDAC case.  
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We then used the relative abundance of the other four proteins in each sample pair 
to estimate the degree of contamination of the PNI-cancer sample by the matching 
invaded nerves’ sample. The estimated purity of the microdissected PNI cancer 
samples based on the average relative abundance of the four proteins was 98 and 
96% for PNI-1 and PNI2, respectively, and ≥99% for the last three samples (Figure 
27). Although the average clearly does not reflect the fact that most of these 
proteins were not detected, it still indicates high degree of purity of the PNI cancer 
samples at this depth of proteomic analysis. In fact, except for sample PNI cancer 
sample two (PNI-1) in which two of the four proteins were detected, not more than 
one protein was detected in three samples whilst none of the four proteins was 
identified in PNI-4 (Figure 26). 
 
 
 
 
 
 
 
 
Figure 27. Estimation of contamination of PNI cancer samples by invaded nerves. The 
abundance of four proteins (NEFH, GFAP, S100B and VGF) in the PNI cancer samples 
relative to the matching invaded nerves samples was used to estimate the degree of 
contamination for each PNI cancer sample. 
 
We were not able to identify any epithelial specific protein in the invaded nerves 
samples, which would suggest even higher degree of purity of those samples. A 
similar analysis of contamination in the 2D dataset was not possible, as we did not 
perform 2D LC-MS analysis of the nerves. However, the peptide digest that was 
used for this analysis was pooled from PNI-1, PNI-3 and PNI-4 cancer samples, 
which demonstrated high degree of purity in the above analysis.  
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3.4. IHC validation:  
3.4.1. Expression of OLFM4 in PNI 
Olfactomedin 4 (OLFM4) was one of the most significantly up-regulated proteins in 
the PNI compared to non-PNI cancer samples in the 2D analysis (Table 7). It was 
selected for validation using immunohistochemistry as it has been reported to have 
antiapoptotic properties [217] as well as conferring poor prognosis in PDAC [218]. 
IHC was performed on 30 PDAC cases. All PDAC cases displayed OLFM4 
expression to varying degree and OLFM4 immunoreactivity varied also within the 
same section. However, cancer cells in PNI lesions usually displayed strong 
immunoreactivity (Figure 28). This was significantly higher than in non-PNI cancer 
(p=0.028) (Figure 29). 
 
     
 
 
 
 
 
 
 
 
Figure 28. Immunohistochemsitry analysis of OLFM4 expression in PNI and non-PNI 
cancer. Representative images of two different PDAC cases (100x magnification) illustrate 
that OLFM4 showed variable expression in non-PNI cancer (left panel) while PNI cancer was 
usually strongly positive (right panels). 
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Figure 29. Semiquantitative analysis of OLFM4 in PNI and non-PNI cancer using 
immunohistochemistry.  OLFM4 was significantly over-expressed in PNI compared to non-
PNI cancer. Each data point represents the average score of all PNI cancer or at least 10 
HPFs of non-PNI cancer for one patient. *p=0.028 
 
 
3.4.2. Expression of VGF in the nerves 
Neurosecretory protein VGF (non-acronymous) was one of the top up-regulated 
proteins in the invaded compared to non-invaded nerves (Table 9). VGF has been 
implicated in the generation of neuropathic pain [219] as well as in cell survival 
[220], both of which are closely linked to PNI, and was therefore selected for further 
validation and analysis. 
VGF expression was evaluated in normal pancreas, CP and PDAC cases. In normal 
pancreas, VGF expression was limited to the islets which served as the internal 
positive control. VGF expression in normal pancreas nerves was occasionally weak 
but predominantly absent as shown on the left panel (Figure 30A). 
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Figure 30. VGF expression in normal pancreata (n=14), CP (n=36) and PDAC (n=45). 
Representative images (200x magnification) showing that VGF is significantly over-
expressed in both CP and PDAC nerves (N) compared to normal pancreas (A). No 
significant difference in the levels of VGF expression between CP and PDAC was detected 
(B). Arrow head pointing towards an islet which expresses VGF. Each data point represents 
one patient (the average score of all nerves in the indicated category). **p≤0.01, ***p≤0.001 
 
In addition to the islets, nerves in the setting of CP and PDAC showed diverse 
immunoreactivity that ranged from weak to strong. Quantitation of VGF expression 
revealed a significant difference between both CP and PDAC and normal pancreas, 
however, the difference between CP and PDAC did not reach statistical significance 
(Figure 30). 
In PDAC, nerves displayed a spectrum of immunoreactivity from absent to strong. 
Nerves invaded with cancer displayed, in the majority of cases, moderate to strong 
expression that was significantly higher than non-invaded nerves (Figure 31A and 
B). However, we noticed an interesting pattern of VGF expression in the non-
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invaded nerves where nerves outside the tumour/stroma mass did not usually 
express VGF whereas nerves within the tumour showed weak to moderate 
expression (Figure 31A). Based on this observed pattern, we classified nerves into 
invaded nerves, intra-tumoural non-invaded nerves and extra-tumoural non-invaded 
nerves. VGF expression was significantly different between these three groups of 
nerves (Figure 31C). 
 
(A) 
 
 
 
 
(B)                                                                  (C)   
 
 
 
 
 
  
 
Figure 31. Analysis of VGF expression in PDAC cases using IHC. Representative images 
(200x magnification) of PDAC nerves (N) showed a range of immunoreactivity. 
Extratumoural nerves (left) were usually negative, whereas intratumoural non-invaded 
nerves were weakly to moderately positive (middle) and invaded nerves strongly positive 
(right, Ca is invading cancer) (A). VGF expression was significantly higher in invaded 
compared to non-invaded nerves (B). VGF expression was also significantly different 
between the three groups of nerves in PDAC (C). Each data point represents one patient 
(the average score of all nerves in the indicated category). ***p<0.001 
 
88 
 
N
or
m
al
 n
er
ve
s
N
o 
P
ai
n
G
1&
2 
P
ai
n
0
1
2
3 **
***
V
G
F
 I
H
C
 s
c
o
re
N
o 
Pa
in
G
1 
pa
in
 
G
2 
pa
in
0
1
2
3
***
V
G
F
 I
H
C
 s
c
o
re
3.4.3. Correlation of pain and VGF expression 
Because VGF has been linked to neuropathic pain, we further investigated whether 
VGF expression in CP and PDAC patients is related to pain. The severity and 
frequency of pain was used to classify CP and PDAC patients into three groups as 
described in the Methods section: no pain, mild pain (G1 pain) or moderate-severe 
pain (G2 pain). VGF was significantly over-expressed in CP patients with pain 
compared to those who did not have pain (p<0.01) (Figure 32A & B). There was 
also a trend of increased VGF expression with increasing degree of pain but this 
was not statistically significant (Figure 32C).  
 
(A) 
 
 
 
 
(B)                                                               (C) 
  
 
 
 
 
 
 
Figure 32. Correlation between VGF expression and pain in CP patients.  Representative 
images (200x magnification) of three different CP cases with increasing pain and levels of 
VGF expression are shown (A). VGF expression was significantly higher in patients with pain 
compared to those without pain (B). There was a trend of increasing VGF expression with 
the increasing degree of pain but this was statistically significant only for G2 pain (C). 
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This is likely due to the small number of cases in the subgroups as Spearman’s 
correlation analysis revealed a strong correlation between VGF expression and the 
degree of pain (correlation coefficient 0.7, p<0.0001).  Noticeably, pancreatic nerves 
from CP patients with no pain displayed weak or absent VGF expression similar to 
what was observed in normal pancreata.  
Furthermore, nerves were classified according to their VGF expression into low 
expression (absent or weak) and high expression (moderate to strong) groups and 
expressed as percentage of the total number of nerves in each tissue section. This 
analysis reveals that as pain increases, the percentage of nerves with high VGF 
expression also increases (Figure 33), (Pearson’s correlation coefficient 0.66, 
p<0.0001). 
 
 
 
 
 
 
 
 
                               
Figure 33. Correlation between VGF expression and degree of pain in CP patients. Nerves 
were divided into low expression or high expression groups. As the degree of pain increases, 
the percentage of nerves with high VGF expression increases. *p<0.05, **p<0.01 
 
Unfortunately, up till now, we had only limited number of clinically annotated PDAC 
cases to complete the critical investigation of the relationship between VGF 
expression in nerves in PDAC. Disappointingly, this analysis is thus still pending and 
due to time constraints will have to be performed as soon as we receive the 
outstanding tissue sections.   
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3.5. In vitro modelling of neuro-epithelial interactions 
We established an in vitro co-culture model in order to further validate molecular 
changes observed in our proteomic analysis and characterise the molecular 
mechanisms underlying them focusing, initially, on neuronal alterations.  
For this model, we used PC12 cells as the neuronal element. PC12 cells are rat 
pheochromocytoma cell line that was established by Greene [221]. Upon exposure 
to NGF, PC12 cells differentiate into sympathetic like neurons, exit the cell cycle, 
extend neurites and become electrically excitable [221]. Due to their molecular and 
phenotypic response to neurotrophins, PC12 cells have been extensively used to 
study neuronal plasticity, neuronal differentiation, toxicity and response to injury 
[222-224]. We therefore hypothesized that PC12 cells could represent a useful 
model to study neuro-epithelial interactions. 
 
3.5.1. Transwell co-culture system 
Using Transwell inserts, PC12 cells were co-cultured with several PDAC cell lines in 
serum-free media for 24 hours. As a control, PC12 cells were cultured on their own 
and their number was adjusted to match the total number of cells in the co-culture 
system with cancer cells. In addition, PC12 cells were grown in serum free media 
with or without NGF as additional controls. Co-culture with MiaPaca2, Capan1 and 
BxPc3 induced neurite extension in PC12 cells similar to that induced by NGF. 
Panc1 cells, however, failed to induce neurite extension (Figure 34 and 35).  
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Figure 34. Representative images of PC12 neurite growth in co-culture with PDAC cell lines 
(200x magnification).  NGF was used as positive control. 
 
 
 
 
 
 
 
 
   
                      
Figure 35. Neurite growth in Transwell co-culture of PC12 cells with several PDAC cell lines. 
PC12 co-cultured on their own were used as controls. NGF (50ng/ml) treatment was used as 
a positive control.  Cells extending neurites longer than the maximum diameter of the cell 
body were counted and represented as a percentage of total number of cells. Data 
represents three independent experiments.***p<0.001. SF: serum free media. 
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PC12 cells are known to undergo apoptotic cell death in serum-free media whilst 
NGF promotes their survival under these conditions [225]. We wanted to explore 
whether PDAC cell lines could also provide protection against apoptosis in PC12 
cells.  
Following 24 hours co-culture, floating and attached PC12 cells were harvested for 
survival analysis using Annexin V and DAPI as described in the Methods section. 
Co-culture with MiaPaca2, Capan1 and BxPc3 protected PC12 cells from serum 
starvation induced apoptosis similar to complete media and NGF. Again, Panc1 
cells did not provide significant protection (Figures 36 and 37).  
In agreement with this, we observed an abrogation in the levels of cleaved Caspase-
3 (CASP3) in PC12 cells when co-cultured with MiaPaca2, Capan1 and BxPc3, 
which was comparable to the effect of NGF (Figure 36B).  
This data shows that three out of four PDAC cells lines were able to induce neuronal 
plasticity in PC12 cells similar to the effects of NGF and consistent with the features 
of neuronal plasticity in human PDAC tissues and in other in vitro models of PNI [81, 
149]. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
Figure 36. PC12 survival in transwell co-cultures using Annexin V/DAPI flow-cytometry 
assay. SF (serum-free) conditions were used as positive control for apoptosis whereas CM 
(complete media) and NGF (50ng/ml) were negative controls. Following 24 hours co-culture 
in serum-free-media, floating and attached PC12 cells were harvested, stained with Annexin 
and DAPI and analyzed as detailed in Methods section (A). Western  blot showing decrease 
in CASP3 (p17) levels in PC12 cell co-cultured with three PDAC cell lines indicating reduced 
apoptosis comparable to the  effect of NGF. GAPDH was used as a loading control (B).        
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Figure 37. Annexin V/DAPI flow-cytometry apoptosis assay of PC12 cells co-cultured with 
PDAC cells lines or NGF (50ng/ml). The percentage of live cells (negative for both Annexin V 
and DAPI) in each condition was expressed relative to live cells in complete media. 
***p<0.001 
 
In addition to the phenotypic changes, PC12 cells exposure to NGF induces the 
expression of a variety of genes including VGF [226]. Therefore, we investigated 
whether PDAC cell lines can also induce molecular alterations in PC12 cells similar 
to what we have observed in the proteomic analysis of cancer-invaded nerves.  
QRT-PCR analysis revealed significant induction of VGF gene expression in PC12 
cells co-cultured with MiaPaca2, Capan1 and BxPC3 cells but not with Panc1 cells 
(Figure 38). 
 
 
 
 
 
 
 
Figure 38.  VGF gene expression in PC12 cells co-cultured with several PDAC cell lines. 
Values are relative to PC12 only co-culture. *p<0.05, **p<0.01 
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Next, we determined the level of VGF protein expression under these conditions 
using Western blot. Similar to gene expression, VGF protein was up-regulated by 
two fold in PC12 cells co-cultured with the same cell lines (Figure 39). Hence, 
MiaPaca2, Capan1 and BxPc3 cells are able to, induce VGF expression in PC12 
cells in the Transwell co-culture system at both mRNA and protein levels. 
 
(A) 
 
 
 
 
 
(B) 
 
 
 
 
 
 
Figure 39. VGF protein expression in PC12 cells in Transwell co-culture with PDAC cell 
lines or with PC12 as control.  A representative Western blot is shown.  VGF appear as a 
doublet at ~80 and ~90kDa, the lower band is thought to be a limited proteolytic product of 
the upper one [227] (A). Densitometry analysis of three independent experiments. Bands are 
normalized to GAPDH as a loading control and the results are expressed as fold change 
relative to control (B). SF: serum free media. *p<0.05, **p<0.01 
 
 
 
96 
 
P
C
12
/P
C
12
P
C
12
/M
ia
P
ac
a2
P
C
12
/C
ap
an
1
P
C
12
/B
xP
c3
P
C
12
/P
an
c1 SF
N
G
F
0
1
2
3
4
*
*
R
e
la
ti
v
e
 N
e
s
ti
n
 p
ro
te
in
 e
xp
re
s
s
io
n
PC
12
/P
C
12
PC
12
/M
ia
Pa
ca
2
PC
12
/C
ap
an
1
PC
12
/B
xP
c3
PC
12
/P
an
c1 SF
N
G
F
0.0
0.5
1.0
1.5
2.0
2.5
**
**
***
R
e
la
ti
v
e
 G
A
P
4
3
 p
ro
te
in
 e
xp
re
s
s
io
n
As PDAC cell lines were able to induce plasticity in PC12 cells along with up-
regulation of VGF, we investigated whether PDAC cell lines are also able to induce 
the expression of other proteins that we have observed as up-regulated in invaded 
nerves in our proteomic analysis. We selected two of these proteins, Nestin (NES) 
and Neuromodulin (GAP43) as they have been linked with neuronal plasticity in 
PDAC and CP. NES has been reported to be associated with PNI and expressed at 
a higher level in invaded nerves [195, 228]. Similarly, Neuromodulin (GAP43) is a 
neuroplasticity marker that has been shown to be up-regulated in PDAC and CP 
related pancreatic neuropathy and neuroplasticity [81]. Indeed, the expression of 
both proteins was significantly increased in PC12 cells co-cultured with Capan1 or 
BxPc3 cells (Figure 40). Interestingly, VGF and GAP43 but not NES were induced 
in PC12 upon NGF treatment.  
 
(A) 
 
 
 
 
 
(B)                                                          (C)                   
 
 
 
 
 
 
Figure 40. Western blot analysis of PC12 cells in Transwell co-culture.  Representative 
Western blot of the expression of Nestin, Gap43 and cleaved caspase-3 (A). Densitometry 
quantitation of Nestin (B) and GAP43 (C). GAPDH was used as a loading control.*p<0.05, 
**P<0.01, ***p<0.001 
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3.5.2. Contact co-culture system 
The Transwell co-culture model allows free exchange of media and soluble factors 
between the two cell types in a similar manner to PNI. Our data indicate that PDAC 
cell lines are able to induce phenotypic and molecular plasticity in PC12 cells similar 
to published observations and our proteomic data. However, because we observed 
even stronger VGF immunoreactivity in the nerves as they come in close contact 
with cancer cells, we used a contact co-culture to further test whether our co-culture 
system could recapitulate this pattern of VGF expression in human PDAC tissues. In 
this system, PC12 cells were seeded, stained with CellTracker fluorescent dye and 
PDAC cell lines were subsequently added to achieve a direct contact with PC12 
cells as detailed in the Methods section. 
24 hours later, the co-cultured cells were separated based on the CellTracker using 
FACS sorting, and PC12 cells were collected and used for downstream analysis. 
For Annexin V/DAPI assay, both floating and attached cells in the co-culture were 
collected and following Annexin V and DAPI staining, survival was measured in 
PC12 cells (positive population for the CellTracker). 
PC12 isolated using FACS sorting were re-checked for purity using the same FACS 
setting. Purity of the samples was 97% ±1.6 (mean ± SD). In addition, aliquots of the 
post-sorting PC12 cells were seeded on coverslips and immunocytochemistry 
staining with anti-CK19 antibody was performed to assess epithelial contamination. 
The purity of PC12 cells was >99% based on CK19 staining (Figure 41). 
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Figure 41. Immunocytochemistry staining of post-sorting PC12 using anti-CK19 antibody. 
Representative images (x400 magnification) of post-sorting PC12 cells (right panel), the lack 
of CK staining indicates high degree of purity. PC12 cells and PDAC cells on their own were 
used as negative and positive controls, respectively (left panel). DAPI was used to stain 
nuclei. 
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Similar to what was seen in the Transwell co-cultures, PDAC cell lines in the contact 
co-culture protected PC12 cells from serum-starvation induced apoptosis (Figure 
42A). Furthermore, PC12 cells co-cultured with Capan1 cells appear to survive even 
better in the contact compared to the Transwell co-culture (Figure 42B). 
 
(A) 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
      
Figure 42. PC12 cell survival measured using Annexin V /DAPI flow-cytometry assay in 
contact co-culture (A) and both Transwell and contact co-cultures depicted on the same 
graph (B). Capan1 cells further increased the survival of PC12 cells when in direct contact 
compared to Transwell co-culture. *p<0.05, **p<0.01 
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Furthermore, VGF induction in PC12 cells was stronger in contact compared to 
Transwell co-culture. This, approximately two-fold, increase in VGF protein 
expression was observed for all PDAC cell lines including Panc1, which did not 
induce strong expression of VGF in the Transwell co-cultures (Figure 43).  This is 
therefore reminiscent of what we have observed in pancreatic nerves in the context 
of PDAC. 
 
(A) 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
Figure 43. Induction of VGF protein expression in PC12 cells in Transwell and contact co-
culture systems. Representative Western blot showing the higher increase in VGF protein 
expression in the contact co-culture for all four PDAC cell lines tested (A). Densitometry of 
three independent experiments illustrates the statistically significant increase in VGF 
expression (B). GAPDH was used as a loading control and data expressed as fold change 
relative to control. *p<0.05  
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3.5.3. Role of NGF in PC12 plasticity induced by PDAC cells 
NGF has been suggested to be an important factor in PNI as well as in generation of 
pain in pancreatic cancer, CP and other non-pancreatic diseases [71, 106, 107]. 
Clinical trials are ongoing to evaluate targeting of NGF-Trk signalling pathway as a 
potential pain modulation strategy [107]. NGF is also a well-known inducer of 
neuroplasticity and differentiation in PC12 cells as mentioned previously and as our 
data show.  
Because several of the effects of PDAC cell lines on PC12 cells mimic those of 
NGF, we sought to investigate whether the observed effects are mediated via NGF. 
In the first instance, we tried to determine whether the three PDAC cell lines that 
induced PC12 plasticity (MiaPaca2, Capan1 and BxPc3) express and secret NGF. It 
has been previously reported, using ELISA, that whilst MiaPaca2 and Panc1 and to 
a lesser extent Capan1 cells express NGF, only MiaPaca2 and Panc1 secreted 
NGF in their conditioned media [160]. Of note, Panc1 cells were not able to induce 
PC12 plasticity in our co-culture system. We used the same ELISA to measure NGF 
in the lysates and conditioned media from MiaPaca2, Capan1 and BxPc3. However, 
the ELISA did not work in our hands, including with the positive control (rat brain 
lysate). Using Western blot, we observed, inconsistently, bands corresponding to 
NGF in the lysates and sometimes in BxPc3 conditioned media (data not shown). 
The authenticity of our cell lines have been confirmed using STR profiling. 
Nonetheless, we determined that functional testing for potential effects of NGF 
would answer whether NGF is contributing to the PC12 plasticity phenotype we 
observed in the co-culture system. To achieve this, we treated PC12 cells with 
conditioned media from MiaPaca2, Capan1 and BxPc3 cells with or without K252a, 
a known inhibitor of TrK receptor (NGF receptor) that blocks the phosphorylation of 
the Trk receptors (A, B and C) and thus blocks the effects of NGF as well as other 
neurotrophins that act through the same receptor such as BDNF and NT3 [207].  
We initially optimised the dose of K252a required to neutralise NGF effect on PC12 
cells. Based on literature reports, we tested three different concentrations of K252a 
and found that at 30nM, K252a blocked the survival (Figure 44), neurite extension 
(Figur45A) as well as VGF expression induced by NGF (Figure 45B and C).  
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Figure 44. Optimisation of the K252a concentration required to block NGF effects on PC12 
cells. PC12 cells were treated with 50ng/ml NGF with either K252a in various concentrations 
or vehicle only (DMSO) in serum-free (SF) conditions.  Serum-free alone and NGF alone 
were used as positive and negative control, respectively. Flow cytometry analysis using 
Annexin V/DAPOI (A). Quantitation of flow-cytometry data from two independent 
experiments. Live cells are expressed as a percentage relative to live PC12 cells growing in 
complete media (B). ** p<0.01 
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Figure 45. Optimisation of K252a concentration required to block NGF-induced neurite 
extension and VGF induction.  PC12 cells were treated with 50ng/ml NGF with either K252a 
in the stated concentrations or vehicle only (DMSO) in serum-free conditions.  Serum-free 
alone and NGF were used as positive and negative controls respectively. Number of PC12 
cells extending neurites was expressed as a percentage of total cells (A).  A representative 
Western blots showing VGF protein expression (B), and Densitometry quantitation of VGF 
protein expression (n=2). *p<0.05 *** p<0.001  
 
Next, PC12 cells were treated with PDAC cell lines conditioned media in addition to 
either 30nM K252a or DMSO and  PC12 cells survival, neurite extension as well as 
induction of VGF expression were determined. K252a failed to abrogate PC12 cells 
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neurite extension and VGF expression induced by PDAC cells conditioned media 
suggesting that these effects are not mediated via NGF (Figure 46). It was 
somewhat surprising that the neuritogenic effect of MiaPaca2 conditioned media 
was in fact augmented by K252a. Similar trend was noted for BxPc3 conditioned 
media although this did not reach statistical significance. 
 
 
 
 
 
 
 
Figure 46. PC12 neurite extension following treatment with PDAC cell lines conditioned 
media (CnM) with 30nM K252a or DMSO. NGF was used as a positive control. *p<0.05 
 
Treatment with K252a also could not reverse PC12 survival induced by PDAC cells 
conditioned media (Figure 47). 
 
 
 
 
 
 
 
Figure 47. PC12 cells survival as determined by Annexin V/DAPI flow-cytometry assay  
following treatment with PDAC cell lines conditioned media (CnM) with  30nM K252a or 
DMSO. NGF was used as a positive control. **p<0.01 
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Finally, K252a was also not able to block the PDAC cells mediated up-regulation of 
VGF protein in PC12 cells (Figure 48). 
 
(A) 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
Figure 48. VGF protein expression in PC12 cells following treatment with PDAC cell lines 
conditioned media (CnM) with 30nM K252a or DMSO. NGF was used as a positive control. 
A representative Western blot (A) and densitometry quantification of VGF protein expression 
relative to control (PC12 CnM treatment) (B). GAPDH was used as a loading control. 
 
These experiments indicated that while NGF is capable of inducing PC12 cell 
plasticity, its presence in the PDAC cells conditioned media is not necessary for the 
plasticity induced by PDAC cells. 
106 
 
3.5.4. Role of VGF in PC12 cells plasticity induced by PDAC cells 
VGF has been recently suggested to play a role in cell survival [220] and neuronal 
plasticity [229]. Due to the observed pattern of induction of VGF that mirrors the 
PC12 survival and neurite extension, we tested whether VGF could mediate some of 
these changes. In order to investigate that, we used VGF-specific siRNA to block 
the induction of VGF expression by PDAC cell lines conditioned media. The siRNA 
successfully prevented the up-regulation of VGF as shown in Figure 49. Of note, we 
optimised the siRNA experiment to block the induced VGF expression but to 
maintain the basal levels of VGF at our time point of interest (24 hours). 
 
 
 
 
 
 
 
 
Figure 49. SiRNA mediated block of VGF induction by PDAC cells conditioned media 
(CnM). Following  gene silencing using VGF-specific siRNA or a non-targeting siRNA, PC12 
cells were then treated with PDAC cells as detailed in the Methods section. Cells were 
harvested following 24 hours treatment with CnM. Representative Western blot showing that 
the VGF siRNA maintained the baseline level of VGF preventing its up-regulation. 
 
24 hours after treatment with conditioned media, we measured neurite extension as 
well as cell survival. Using Annexin/DAPI flow-cytometry assay we could not detect 
any significant difference in survival after blocking VGF induction (Figure 50).  
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Figure 50.  PC12 cell survival analysis following VGF siRNA or non-targeting siRNA using 
Annexin v/DAPI flow-cytometry assay. Survival was expressed relative to live cells in 
complete growth media.  
 
PC12 neurite extension, on the other hand, was reduced with all PDAC cell lines’ 
conditioned media treatment when blocking VGF induction. This was statistically 
significant for both MiaPaca2 and BxPc3 conditioned media but did not reach 
statistical significance for Capan1 conditioned media (p=0.09) (Figure 40). Hence, 
VGF appears to contribute significantly to the neuroplasticity response of PC12 cells 
to PDAC cells. It is clear however, that VGF is only part of the molecular machinery 
driving this response.   
 
 
 
 
 
 
 
Figure 51. PC12 cells neurite extension induced by PDAC cells CnM with or without 
blocking VGF induction by siRNA pre-treatment. Blocking VGF induction significantly 
reduced the neurite extension in PC12 cells mediated by both MiaPaca2 and BxPc3 
conditioned media.*p<0.05 
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Chapter Four: Discussion 
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4. Discussion 
4.1. 1D and 2D Proteomics of FFPE tissues 
In this project, we set out to investigate the molecular alterations in nerves and 
cancer cells involved in PNI in PDAC and develop an in vitro model that would 
recapitulate these changes. Firstly, we performed proteomic analysis of PNI lesions 
to identify differentially regulated proteins and pathways between PNI and non-PNI 
cancer as well as between invaded and non-invaded nerves. The limited availability 
of fresh frozen tissues and the infrequent occurrence of PNI lesions within 
histological sections of small fresh frozen material necessitated the use of FFPE 
PDAC tissues. Until recently, protein expression profiling of FFPE tissue samples 
has been met with very limited success due to formalin-induced modifications 
resulting in difficulties in extracting good quality soluble proteins from such samples 
[230, 231]. Proteomic analysis using FFPE tissues has, therefore, been largely 
limited to immunohistochemistry, a technique that can only target previously known 
single proteins in order to assess their expression in a particular tissue types. 
However, recent advances in protein extraction and MS techniques allowed an 
unprecedented ability to compare global protein expression in the large archives of 
FFPE samples enabling the discovery of potential novel disease biomarkers in 
several tissue types [232, 233]. Plethora of studies have demonstrated the 
equivalence of proteomic profiles of FFPE tissues to those obtained from fresh 
frozen samples  using a variety of tissue types and proteomic analysis platforms 
including gel-based methods [234, 235], MS [214, 215, 236, 237] and protein arrays 
[230, 238]. Furthermore, proteins extracted from FFPE tissues also retain protein 
expression data related to subproteomes such as phosphoproteins and 
glycoproteins [239]. In pancreatic cancer, a recent study has demonstrated, using 
gel-based techniques, comparable protein pattern between FFPE and frozen PDAC 
tissues but a lower concentration of proteins was obtained from the FFPE samples 
[235]. In addition, comparison of the proteomic profiles of fresh frozen and FFPE 
normal pancreas using LC-MS revealed similar protein identifications and 
subcellular localisation [231]. This success is mainly attributed to the newly 
developed protein extraction methods that rely principally on heat-induced antigen 
retrieval methods as well as detergents [215, 216, 236]. In this project, we used 
Liquid Tissue (LT) buffer, a proprietary reagent that was specifically designed to 
extract proteins from FFPE tissues and particularly tailored to minute amounts of 
samples such as those procured by laser microdissection [240]. Using LC-MS, this 
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buffer enabled the acquisition of equivalent proteomic data from fresh frozen and 
FFPE liver and kidney tissues [214, 233]. Several other studies have also 
successfully reported the usage of this buffer for large scale MS based proteomic 
profiling of FFPE tissues resulting in identification of hundreds of proteins from 
several tissue types including prostate, lung and brain tissues [214, 241-243]. This 
method allowed us to extract ~15µg of peptide digest/10mm2 tissue area, which is in 
line with published literature using LT [237] as well as other protein extraction 
protocols [238]. Using 1µg of normal pancreas digest we were able to confidently 
identify 1,000 peptides and 187 proteins with ≥ 2 peptides/proteins and an FDR of 
0% from two replicate LC-MS analyses. It is difficult to compare this head to head 
with other studies due to differences in sample processing, LC-MS protocols and 
platforms and data analysis methods. In a review of FFPE proteomics studies, 
Reimel et al reported the identification of 1,168 peptides and 370 proteins from 
normal pancreas FFPE tissue and 990 peptides and 340 proteins from frozen 
samples [231]. Our results are comparable in terms of peptide identifications; 
however, the minimum number of peptides used for protein identification in the 
mentioned study was not specified.  Also consistent with our findings, a recent study 
using LC-MS/MS and mice pancreas tissue reported the identification of 237 and 
271 proteins from 8 biological replicates of FFPE and fresh frozen samples 
respectively with 80% overlap and similar molecular function and subcellular 
localization [244]. Cheung et al also reported proteomic profiling of pancreatic 
intraductal papillary mucinous neoplasm (IPMN) from FFPE tissues using LT and 
LC-MS. They identified 1,534 peptides corresponding to 523 proteins, 95 of which 
were identified with ≥2 peptides [241]. Our results are also consistent with studies 
using other tissues such as colon and kidney [214, 233, 243]. 
Proteomic analysis using 1D LC-MS provides proteomic coverage limited to the 
highly abundant proteins and multidimensional fractionation is necessary to achieve 
adequate depth of complex proteome analysis [245]. To perform 2D LC-MS using 
our samples, several challenges had to be resolved. Firstly, the amounts of proteins 
obtained from laser microdissected samples, particularly for PNI, are typically 
minute necessitating some degree of pooling to allow downstream fractionation. 
Secondly, our protein extraction protocol allows only for fractionation at the peptide 
level, as the final product is a mixture of peptides rather than full-length proteins. 
Lastly, HPLC fractionation of such minute amounts of peptides requires a 
capillary/nano HPLC platform whereas the system available to us was a standard 
analytical HPLC.    
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The most commonly used technique of peptide fractionation is strong cation 
exchange (SCX) in different formats including off-line, on-line and MudPIT [246]. In 
this method, peptides are first fractionated primarily based on their charge using 
SCX stationary phase; each fraction is then submitted to RP LC-MS analysis in the 
second dimension. Because SCX and RP utilize two different properties of peptides 
for separation, charge and hydrophobicity, respectively, a good orthogonality is 
achieved [247, 248]. Recently, high pH RP fractionation in the first dimension has 
been introduced and is being increasingly used. In this workflow, peptides are 
separated based on hydrophobicity using RP stationary phase in both dimensions 
with a high pH mobile phase in the first dimension and low pH in the second [249]. 
This change in pH results in modification of the charges of some amino acids and 
therefore peptide hydrophobicity resulting in different selectivities in the two 
dimensions [250]. Several studies have evaluated this method in comparison to 
other techniques particularly SCX [250, 251]. High pH separation in the first 
dimension has an orthogonality that is comparable to SCX, however, because of the 
high resolving power of RP, the practical peak capacity of RP-RP workflow is much 
higher than SCX-RP resulting in superior separation efficiency and therefore higher 
number of peptide and protein identifications [247, 249, 252] In addition, RP 
separation results in lesser sample loss often associated with SCX, especially the 
off-line variety and avoids the need for sample preparation, particularly desalting 
prior to fractionation [252, 253]. 
With these considerations in mind, our proteomic analysis workflow involved 1D LC-
MS analysis of all samples, individually, and 2D LC-MS analysis of pooled and 
matched samples of PNI cancer and non-PNI cancer. To perform the latter, we, 
firstly, converted our standard analytical HPLC into a capillary system using T-piece 
and restriction capillary to split the flow and validated the reproducibility and 
enhancement of protein coverage achieved by high pH fractionation using the 
converted system. At 380µl pump flow rate and using a 50cm restriction capillary 
with 50µm internal diameter, we were able to achieve a stable and reproducible 
column flow of 5µl/min throughout the separation gradient. The chromatographic 
reproducibility of BSA digests fractionation and inter- and intra-day reproducibility 
further demonstrated the robustness of the system. To further assess the degree of 
reproducibility and the improvement in the depth of proteomic analysis following high 
pH RP fractionation, we first fractionated 10µg of MiaPaca2 cell line digest into 14 
fractions, in duplicate, and submitted each fraction as well as unfractionated 
samples to LC-MS analysis. This demonstrated high qualitative and quantitative 
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reproducibility of proteomic data obtained from 2D LC-MS analysis approaching the 
analytical reproducibility of the LC-MS itself. Equally important, the fractionation 
process resulted in a 5-fold increase in the number of proteins identified (340 vs 
1602 proteins). In an on-line version of 2D LC-MS using high pH fractionation in the 
first dimension, Siu et al identified ~12,000 peptides and ~2,500 proteins 
(≥1peptides/protein) from 13 fractions of mouse fibroblast peptide digest over 52 
hours of MS time [254]. Another study also obtained protein identifications 
comparable to ours (1,338 proteins from 12 fractions of frozen mouse cardiac tissue 
digest, 100µg fractionated) [251]. The number of proteins identified from normal 
pancreas FFPE tissue digest (~1,000) was smaller but the improvement in the depth 
of analysis as well as reproducibility was similar to that of the cell lines. In 
agreement with our results, a recent study using FFPE renal tissues identified ~ 250 
and ~500 proteins (≥1peptide/protein) from 1D and five fractions 2D LC-MS, 
respectively, using high pH RP fractionation [216]. Of note, collecting only 14 
fractions largely reduces the resolving power of the first dimension and therefore the 
power of the 2D LC-MS method; however, larger number of fractions would have 
large impact on LC-MS time and therefore the throughput and the overall cost of the 
whole method. 
The largest FFPE proteome coverage using MS was achieved in the laboratory of 
M. Mann [255, 256]. In their latest report, extensive proteomic analysis of 
microdissected FFPE tissue from colon adenoma was performed using a 
combination of heat and detergent based protein extraction, multi-enzyme digestion, 
strong anion exchange fractionation and the latest MS platform resulting in the 
identification of ~8500 proteins per sample [257]. This not only illustrates the 
importance of incorporating multiple strategies in order to increase the proteome 
coverage but also the rapid progress in the field of proteomics and particularly FFPE 
proteomics.    
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4.2. Laser microdissection 
In the last decade, Laser Microdissection (LMD) has emerged as an effective and 
elegant way of collecting homogeneous cell populations whilst avoiding many of the 
pitfalls of manual microdissection. Several recent reports have emphasized the role 
of LMD in revealing tumour cell specific molecular alterations that could not be 
detected using bulk tissue analysis [258, 259].  Furthermore, the authenticity of the 
dissected material can be directly verified and documented by microscopic 
visualisation. LMD can be used to dissect groups of cells, individual cells or even 
subcellular organelles for a variety of downstream molecular analyses including 
genomic, RNA and protein analysis using various platforms [260]. The process of 
LMD itself appears to have minimal impact on downstream molecular analysis [261-
263]. Most of the biological material in the path of the narrow cutting laser is 
completely destroyed and does not take part in subsequent analysis and heat 
conduction to the dissected material is limited to <1µm for few microseconds [264] . 
On the other hand, optimal microscopic visualisation requires preparation and 
staining of tissue sections that could interfere with downstream analysis and add to 
the experimental variables. For example, whilst both toluidine blue and hematoxylin 
have been shown to be compatible with proteomics analysis using both gel-based 
and MS-based methods, toluidine blue should be removed prior to analysis [262, 
265]. Eosin, on the other hand, may affect protein focusing in 2 dimensional 
electrophoresis (2DE) [266]. We used a short (15min) preparation protocol for tissue 
sections that involved rapid deparafinization, rehydration and hematoxylin-only 
staining as this is compatible with our protein extraction protocol and downstream 
LC-MS analysis. The sections were then dehydrated, stored at 4°C and used within 
two weeks. Of note, the samples that were microdissected were completely 
matched, not only biologically but also technically, as they were microdissected from 
the same tissue sections. Therefore, PNI and non-PNI cancer samples as well as 
nerve samples have undergone the same tissue fixation and processing as well as 
tissue section preparation, staining and storage. From the point of microdissection, 
downstream experiments were performed in parallel.  
Samples collected using LMD are typically limited and require optimised protocols 
for extraction and subsequent analysis of biological molecules. The number of cells 
required depends on the desired molecular analysis. While mutation analysis can be 
performed on single cells, gene expression profiling often requires 100s-1000s of 
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cells while proteomics often require thousands of cells depending on the analytical 
platform [260]. Recently, several approaches have been developed for proteomic 
analysis of laser microdissected specimens [262, 267]. As previously mentioned, in 
this project we used a commercially available kit, Liquid Tissue (LT) (Expression 
Pathology) that has been specifically designed for protein extraction from small 
FFPE samples for subsequent MS-based proteomic analysis [237].    
Despite the advantages of LMD, it remains true, that procurement of samples using 
this technique is time consuming. The obtainment of our specimens involved more 
than 600 hours of laser microdissection time. However, the high homogeneity of the 
specimens was necessary in order to generate high quality data in downstream 
profiling experiments. In addition, the nature of PNI lesions requires high degree of 
precision to isolate cells from such specific tissue compartments. The collection of 
both the nerves and cancer specimens would not have been possible without the 
LMD technique. 
 
Purity of samples collected by LMD 
Because the aim of LMD is to procure highly homogenous and pure samples, one of 
the key issues is the degree of purity of the collected material and its potential 
contribution to aberrant differential expression. This was particularly important in this 
study as cancer and nerves are in a close proximity within the PNI lesions. Several 
studies assessed the relative purity of collected material within the context of gene 
expression profiling [268, 269]. This is relatively straightforward task, as global gene 
expression studies involve hybridization of all samples to a known set of probes and 
therefore the signal attributed to a particular gene relies primarily on its absolute 
expression level, the levels of cell-specific genes can subsequently be used to 
assess the cross contamination. In global proteomic analysis using  MS, on the 
other hand, peptides (and hence proteins) compete for identification and the 
detection of  a particular protein in two different samples relies primarily on its 
abundance in the sample relative to the other proteins as well as the depth of 
proteomic coverage (assuming similar protein modifications, equal digestion and 
MS/MS fragmentation efficiency). This is particularly true for low abundance proteins 
such as cross-contaminants. Although qualitative assessment of the purity of LCM 
samples have been attempted in the context of proteomic analysis [270], we are not 
aware of any proteomic studies that tried to evaluate that quantitatively. Here we 
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used an approach that, similar to ones used in gene expression studies, relies on 
the expression of known tissue-specific markers to gain insight into the relative 
enrichment or depletion of that particular tissue type. Because this requires the 
analysis of both tissue types in a similar way, our 1D analysis of cancer and nerve 
samples allows us to perform this type of analysis. Using this approach, we looked 
at the expression levels of several neuronal makers in the PNI cancer samples and 
compared their relative abundance to that in invaded nerves. This revealed variation 
in the estimated contamination depending on the protein evaluated. Using the 
relative abundance values for four neuronal proteins (NEFH, GFAP, S100B and 
VGF), the estimated purity of three of the five PNI cancer samples was ≥99%, whilst 
the other two samples showed 96% and 98% enrichment. Whilst this represents 
high degree of purity, several factors could have contributed to the low level of 
contamination observed. In addition to the close proximity of PNI cancer and 
invaded nerves, inadvertent catapulting of loose non-target tissue could have 
contributed. Furthermore, as the tissue section thickness is 10µm, the demarcation 
between neuronal and epithelial components is not necessarily similar on the top of 
the section compared to the bottom [270]. This, however, is unavoidable except by 
using thinner sections, which would, in turn, reduce protein yield and significantly 
increase the total dissection time.  
Using the same approach, we were not able to identify any epithelial specific 
proteins in the invaded nerves’ samples, which would suggest high purity of those 
samples. We also could not perform a similar contamination assessment for the 2D 
data because only cancer samples were analyzed using this approach. Finally, 
whilst the main concern in this work would be cross contamination between cancer 
and nerves within PNI lesions, other potential sources of contamination, including 
adjacent stroma could not be assessed, as we did not perform the same proteomic 
analysis for those compartments.  
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4.3. Proteomic analysis of PNI and non-PNI cancer 
1D LC-MS analysis of PNI and non-PNI cancer identified ~1600 proteins, 
surprisingly, only a few were differentially regulated as further illustrated by 
hierarchal clustering. Using 2D LC-MS to achieve wider coverage of the proteome, 
we identified ~3,200 proteins, which represent the largest proteomic profile in 
pancreatic cancer to date. In comparison, a previous study from our laboratory 
comparing the proteomes of PDAC cells from matched primary and lymph node 
metastasis identified ~1500 proteins using 10-fractions MudPIT approach [271], 
highlighting the advantages of high pH RP fractionation. Nonetheless, even using 
2D analysis, only 39 proteins were differentially expressed, indicating relatively high 
degree of similarity between the two samples.  
In the only study that investigated laser microdissected PNI and non-PNI cancer 
using human tissues, Chen et al performed gene expression profiling of these cells 
from fresh frozen salivary adenoid cystic carcinoma [74]. The authors described 54 
deregulated genes (out of 18,716 genes) and validated the up-regulation of MCAM 
in PNI cancer compared to non-PNI cancer. We did not see any commonalities 
between their deregulated gene list and the differentially regulated proteins in our 
data set. This is not surprising considering the different tissue types and the different 
technologies used, as proteomics has a limited depth of coverage compared to gene 
expression in addition to the recognized lack of agreement between gene and 
protein expression [272].  
In another study, using bulk prostate cancer tissue from cases with or without PNI, 
Prueitt et al investigated the expression profiles of genes and microRNAs [196]. 
Whilst the clustering pattern of microRNAs could differentiate the two groups of 
samples, the RNA expression failed to do so and only 34 transcripts out of 13,000 
were differentially regulated, none of which again corresponded to our dataset [196]. 
To our knowledge, the  two studies mentioned above are the only studies that used 
human tissues for large scale expression profiling in the context of PNI, and despite 
the different approaches, the largely similar profiles in PNI and non-PNI cancer is  
highly consistent with our findings. 
Although the overall proteomic profiles of PNI and non-PNI cancer were similar, 
there were some interesting differences. IPA analysis of differentially regulated 
proteins in both the 1D and the 2D datasets revealed largely similar enrichment in 
biological functions such as Cell Movement (migration and invasion), Cellular 
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Organization as well as Cell Survival and Proliferation. Furthermore, subcellular 
localization analysis revealed enrichment of extracellular proteins (such as laminins, 
collagens and nidogens) consistent with published literature suggesting a role for 
ECM proteins in pancreatic cancer migration and invasion [273, 274]. For example, 
TGFβ induced protein (TGFBI) is an extracellular protein that was shown to be over-
expressed in several cancers including pancreatic cancer [275] and has been 
suggested to play roles in cellular adhesion and migration [276] as well as 
metastasis of colon cancer cells [277]. TGFBI was one of the top up-regulated 
proteins in PNI cancer samples using 1D LC-MS. Unfortunately, attempts at 
validating its expression using immunohistochemistry were not successful due to the 
low signal to noise ratio.  
Ryschich et al showed that PDAC cell lines migration was significantly increased by 
laminin, fibronectin and collagen IV [192] whilst ECM proteins including laminin 
increased pancreatic cancer cells survival [278]. A study of PNI using an in vivo 
sciatic nerve model found that the level of expression of several laminins, most 
significantly LAMC2 correlated with the distance of PNI [194]. Furthermore, laminins 
as well as several of their receptors, including integrins, are widely expressed in the 
nervous system and play important roles in neurite growth and regeneration [279]. 
Indeed, amongst other ECM proteins, laminins have been shown to induce the 
highest neurite outgrowth in mouse DRG neurons and LAM1-mediated 
neuritogenesis was independent of neurotrophic factors [280]. Similarly, LAMC1 was 
shown to be vital for peripheral nerve regeneration and myelination following injury 
[281]. It has also been suggested that axonal guidance molecules secreted by 
cancer cells could contribute to neurogenesis and axonogenesis [142, 282] which is 
also supported by the unidirectional growth of neurites from DRGs towards cancer 
cell colonies in vitro [140, 149]. The dual effects of ECM proteins on both cancer 
cells and nerves could represent one of the key mechanisms underlying neuro-
epithelial interactions and driving neurotropism. This extends beyond just ECM 
proteins, for example, NES, one of the proteins that were up-regulated in the PNI 
cancer, have been described previously in the context of PNI. Using IHC, Kawamoto 
et al showed that NES was over-expressed in PDAC and its expression correlated 
with PNI [195]. However, NES was also up-regulated in invaded nerves and plays 
an important role in neuronal response to injury as will be discussed later on. 
Several studies have previously shown that interaction of nerves and cancer cells 
induces up-regulation of antiapoptotic pathways resulting in enhanced survival of 
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cancer cells [140, 144, 145]. We identified several apoptosis related proteins as 
differentially regulated in the PNI cancer including Alpha-crystallin B chain (CRYAB), 
monoamine oxidase A (MAOA) and OLFM4. CRYAB is a small heat shock protein 
that has oncogenic properties; it increased the migration and invasion of breast 
cancer cells and predicted poor outcome as well as resistance to chemotherapy in 
this malignancy [283, 284]. Although there is no data describing CRYAB in 
pancreatic cancer, in vitro studies using other cell lines have shown its ability to 
promote cell survival through several mechanisms such as prevention of protein 
aggregation, regulation of caspase-3 activation as well as sequestration of Bax and 
Bcl-X(S) proteins [285, 286]. 
MAOA is a mitochondrial enzyme that is highly expressed in neuroendocrine tissue 
and has been shown to induce oxidative stress and apoptosis of neuronal cells [287, 
288]. The expression of MAOA in pancreas cancer has not been studied in details 
although there was a report suggesting it is expressed in human PDAC tissues 
[289]. In a meta-analysis of gene expression studies in PDAC, MAOA was reported 
to be consistently down-regulated in PDAC [290]. Our proteome data indicates that 
in PNI-cancer, MAOA expression is further down-regulated consistent with reduced 
apoptosis in these cells [140].  
OLFM4 was one of the most significantly up-regulated proteins in PNI compared to 
non-PNI cancer. OLFM4 is a stem cell marker that displays anti-apoptotic properties 
and plays a role in cell-cell adhesion [291]. Induction of OLFM4 in myeloid cells was 
shown to be regulated by NF-κB and mediated through ERK1/2 MAPK pathway 
[292]. OLFM4 also attenuated apoptosis in the presence of cellular stress and 
promoted prostate cancer cell growth in vivo [293]. Similar anti-apoptotic effects of 
OLFM4 regulated via NF-κB were also demonstrated in gastric cancer [217]. In 
Panc1 PDAC cell line, OLFM4 promoted cellular proliferation but its silencing did not 
increase apoptosis [294]. Clinically, OLFM4 was reported to correlate with better 
differentiation in gastric cancer [295], although another study did not find such 
correlation, but revealed the association between OLFM4 expression and lymph 
node metastasis as well as poor prognosis in these patients [296]. In colon cancer, 
OLFM4 expression also correlated with differentiation and its levels were reduced in 
advanced compared to early stage tumours precancerous adenomas [297, 298]. It is 
notable, however, that OLFM4 expression was significantly higher in tumours with 
activated KRAS-NF-κB pathway [297]. In pancreatic cancer, OLFM4 expression did 
not correlate with differentiation but its expression predicted poor outcome [218]. 
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We found that OLFM4 was widely expressed in PDAC but with striking 
heterogeneity within the same tissue section; poorly differentiated areas of the 
tumour tended to secrete OLFM4 into the ECM, whereas the immunoreactivity was 
largely cytoplasmic and membranous in the well-differentiated cancer glands; 
however this was not anlaysed quantitatively. 
Despite this variability, PNI cancer demonstrated higher OLFM4 expression 
compared to non-PNI cancer. Interestingly, we have throughout this project, 
observed that PNI cancer foci were almost always moderately to well-differentiated. 
This has also been previously observed [33], although we are aware of the risk of a 
potential bias due to the ease of detecting well differentiated PNI glands compared 
to poorly differentiated cells. In view of the literature reports of a correlation between 
OLFM4 expression and differentiation, it is conceivable that OLFM4 up-regulation in 
PNI cancer is a marker of differentiation. It will be interesting to quantify the 
differentiation of cancer in PNI foci and investigate further whether this has any 
correlation with OLFM4 expression. On the other hand, over-expression of OLFM4 
in PNI cancer is consistent with the reported reduced apoptosis of cancer cells 
within the perineural environment and with the poor outcome associated with both 
PNI and OLFM4 expression in PDAC.  
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4.4. Proteomic analysis of invaded and non-invaded 
nerves 
The molecular analysis of invaded and non-invaded nerves from human tissues 
including pancreatic cancer has not been performed before. In our analysis, we 
identified 925 proteins in the nerves, which is considerably less than the number of 
proteins detected through the similar analysis of PDAC cancer cells. This is not 
surprising as the nerve is less cellular and largely composed of axons and ECM 
proteins. Almost 20% of the identified proteins were differentially regulated. The 
significant alteration in the molecular profile of the nerves when invaded by cancer 
was further illustrated by the clustering of samples according to invasion status. IPA 
analysis revealed enrichment of several functional groups related, mainly, to ‘Cell 
Survival’, ‘Cellular Organization’, ‘Morphogenesis’ and ‘Cellular Movement’. Sub-
categories related to neuritogenesis and axonal development were also enriched.  A 
core set of differentially regulated proteins including microtubule-associated protein 
1B (MAP1B), doublecortin-like kinase 1 (DLCK1), LAMA1, LAMB1, Tenascin C 
(TNC), defender against cell death 1 (DAD1), VGF, NES as well as GAP43 
contributed to several of these biological functions (Figure 52 and 53). 
For example, MAP1B was shown to play an important role in the nervous system 
development and axonogenesis through cytoskeletal re-organisation that involves 
interactions with actin and microtubules [299, 300]. Equally important, this does not 
only depend on the level of MAP1B but also on alteration in its phosphorylation 
status [301]. Similarly, DLCK1 is a microtubule associated protein that contributes to 
axonogenesis through regulation of F-actin and stabilization of the microtubules in 
the growth cone thus facilitating response to axonal guidance cues [302, 303]. On 
the other hand, DAD1 has a protective role against apoptosis [304]. 
Some of the proteins that were identified as differentially regulated in our study have 
been previously reported in literature using immunohistochemistry, including NES 
and GAP43. GAP43 is a neuronal plasticity marker that has been shown to be up-
regulated in nerves in PDAC as well as CP [81]. NES on the other hand, is an 
intermediate filament and a stem cell marker expressed in neuronal progenitor cells, 
its expression is usually absent in adult post mitotic neuronal cells [305]. NES is up-
regulated in nerves in PDAC with invaded nerves showing higher expression levels 
compared to non-invaded nerves [195]. It is also up-regulated in CP nerves and its 
up-regulation is correlated with pain [104]. 
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Figure 52. IPA functional enrichment showing neuritogenesis-related functions and the 
proteins contributing to those functions. Colours of the nodes reflect the level of 
activation/inhibition according to the colour key. 
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Strikingly, several of the proteins that were up-regulated in our dataset have been 
also shown to be up-regulated in peripheral nerve injury. For example, using gene 
expression profiling, VGF and GAP43 have been shown to increase in rat DRGs 
following spinal nerve ligation [306]. Similarly, Pituitary adenylate cyclase-activating 
polypeptide (ADCYAP1), Laminin A, NES as well as TNC were up-regulated under 
similar conditions [307]. NES has also been shown to be up-regulated in the spinal 
cord of mice following nerve injury [308], in rats major pelvic ganglion following 
cavernous nerve crush injury [309] as well as in the rat nucleus ambiguous following 
vagal nerve transection [310]. These similarities suggest common features of 
neuroplasticity that are independent of the underlying cause. In a recent review of 
neural plasticity in gastrointestinal disease, Demir et al concluded that common 
phenotypic, neurochemical and functional features of neuronal plasticity exist and 
are independent of the underlying aetiology [311]. We would suggest that some of 
these features also extend, beyond the gastrointestinal tract, to other neuropathies 
and neuronal plasticity responses in the peripheral nervous system in general. In the 
only reported expression analysis of nerves  in the context of PNI and using a sciatic 
nerve in vivo model of PNI,  Mitsunaga et al performed gene expression profiling of 
sciatic nerves proximal to either PNI or crush/suture injury to the nerve. Interestingly, 
not only was there no overlap with our findings, but also they could not detect any of 
the proteins commonly identified as up-regulated following peripheral nerve injury 
[194]. As they compared invaded nerves to nerves traumatized otherwise, this 
supports our assertion that many of the molecular changes that we observed are in 
common with changes following nerve injury in general. However, the presence or 
absence of certain molecular features that would represent a neuronal response to 
specific type of neuropathy cannot be ruled out and could depend, in part, on the 
nature of nerves involved. 
As alluded to before, we identified several ECM proteins as up-regulated in invaded 
compared to non-invaded nerves that were similarly deregulated in PNI compared to 
non-PNI cancer including LAMA2, LAMB1, LAMC1, collagen VI A3 (COL6A3), 
nidogen 1 (NID1) and TNC. These would constitute, at least, part of the extracellular 
milieu within which cancer cells and nerves are interacting and many of them have 
dual roles in promoting cancer growth as well as neurogenesis. This provides further 
support to the notion that the PNI environment offers beneficial growth conditions for 
both cancer and nerves [312]. The extracellular nature of the aforementioned 
proteins, however, precludes firm conclusions as to their exact source based on 
proteomic methods and would require in situ hybridization experiments. For 
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example, COL6A3 is highly expressed in the stroma of PDAC, particularly in the 
vicinity of cancer cells [313], and its serum levels were significantly higher in PDAC 
patients compared to normal and benign controls [314]. Furthermore, COL6A3 
provides neuronal protective effect against cellular stress such as UV irradiation 
through activation of PI3K pathway [315].   
TNC, an extracellular glycoprotein, is also another intriguing example. It was shown 
to be up-regulated in both CP and PDAC stroma whilst PDAC cells were devoid of 
TNC expression using IHC [316]. The source of TNC is most likely the stellate cells 
[316]. However, PDAC cell lines do express TNC mRNA which increases their 
proliferation, migration and adhesion [317]. TNC is also expressed in the nervous 
system where it promotes neurite growth and regeneration following injury [318, 
319]. We have previously used IHC to investigate the expression of TNC in PDAC 
(unpublished data) and found a similar stromal expression pattern. Within PNI 
lesions, and consistent with our proteomic data, TNC was seen expressed at the 
interface between cancer and endoneurium explaining its up-regulation in both PNI 
cancer and nerve samples. 
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Figure 53. IPA analysis of differentially regulated proteins in the nerve samples 
demonstrating several proteins contributing to the activation of cell survival and inhibition of 
apoptosis. Colours of the nodes reflect the level of activation/inhibition according to the 
colour key. 
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4.5. Immunohistochemical evaluation of VGF expression 
In our proteomic analysis, VGF was one of the most up-regulated proteins in 
invaded compared to non-invaded nerves. VGF was first described by Levi et al as a 
transcript that was rapidly up-regulated in PC12 cells following NGF treatment [320]. 
VGF is exclusively expressed in the central and peripheral nervous system as well 
as in neuroendocrine cells in the gut [321]. The protein is stored in secretory 
vesicles and released upon various stimuli in a similar manner to neuropeptides and 
neurotransmitters [227]. VGF is cleaved into at least a dozen of proteolytic peptides 
by the actions of peptidases including prohormone convertases 2 and 1/3, several of 
these peptides are biologically active [322, 323]. Several biological activities have 
been attributed to VGF and/or specific peptides including energy and water balance, 
and regulation of body weight, neuropathic pain as well as neuronal plasticity [227, 
322]. 
Using IHC, we were able to confirm the up-regulation of VGF in invaded nerves and, 
interestingly, found that VGF expression is gradually increased as the nerves lie 
closer to cancer. This is consistent with previous observation of increasing 
neuroplasticity the closer the nerves are to cancer [199] . Several inducers of VGF 
that have been reported in the literature, including NGF [324] , BDNF [325] and 
basic fibroblast growth factor (bFGF) [326] are also expressed in pancreatic cancer 
[159, 327] and it is conceivable that one or more of them may contribute to VGF 
induction in PDAC nerves. Furthermore, the induction of VGF in CP suggests that 
the inflammatory stroma can also induce VGF expression in pancreatic nerves. In 
addition, pancreatic stellate cells have been suggested to play an important role in 
PNI as well as neuronal plasticity [200] and their potential ability to induce VGF 
could be related to their expression of neurotrophic factors such as NGF [328]. 
Furthermore, the up-regulation of VGF following nerve injury, as pointed out earlier, 
suggests that intrinsic mechanisms within the nerve components, activated by 
PDAC induced neuropathy may contribute to VGF induction. 
The observed VGF distribution pattern and previous reports that neuroplasticity 
changes become more prominent the closer the nerves are to cancer, suggest that 
the differences we have observed in the proteome are attenuated due to the 
combining of intratumoural and extatumoural non-invaded nerves during 
microdissection. Comparison of normal nerves and invaded nerves would likely 
reveal even more extensive neuroplasticity changes. 
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VGF has been recently linked to neuropathic pain. In a mouse model of 
inflammatory pain using formalin, Rizzi et al showed that TLQP-21, a VGF derived 
peptide mediates inflammatory pain when injected peripherally but has an analgesic 
effect when injected centrally [329]. In a more detailed study of peripheral nerves 
injury, VGF was rapidly up-regulated in rat DRGs within 24 hours following nerve 
ligation or in vitro culture of DRGs. Injection of VGF derived peptides (AQEE-30 and 
LQEQ-19) intrathecally (around the spinal cord) resulted in a dose-dependent 
increase in thermal hyperalgesia [219]. 
We unfortunately obtained only a limited number of clinically annotated PDAC cases 
and were, therefore, not able to make any conclusions regarding association of pain 
and VGF expression in cancer specimens. Additionally, the fact that PNI is 
associated with pain in PDAC and that VGF expression is higher in invaded nerves 
necessitates relatively large number of cases to perform detailed statistics and 
multivariate analysis. We were able, however, to investigate the relationship of VGF 
expression and pain in CP cases. In CP, VGF expression strongly correlated with 
the degree of pain. In fact, pancreatic nerves from patients without pain showed 
either weak or no immunoreactivity, almost similar to VGF expression in nerves from 
normal pancreata. The mechanisms underlying VGF mediation of pain are not clear.  
Riedl et al reported that phosphorylation of p38 MAPK in spinal glial cells was 
necessary for thermal hyperalgesia induction by intrathecal injection of AQEE-30 
and LQEQ-19 peptides [219]. In support of that, MAPK pathway has been 
extensively linked to neuronal plasticity and neuropathic pain development and 
maintenance and several noxious stimuli as well as pain-related neuropeptides such 
as SP can activate this pathway [330]. 
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4.6. In vitro modelling of neuronal plasticity in neuro-
epithelial interactions 
Previous studies to model PNI in vitro relied largely on rodents’ DRGs or their 
dissociated primary sensory neurons [140], whilst others used dissociated myenteric 
plexus cells from rats [149]. These primary cells and tissue explants are not easy to 
handle and require using large number of animals. In addition, while DRGs enable 
the study of the interaction between cancer cells and the whole nerve structure 
including all its components, it does not allow the study of interactions between 
specific nerve component and cancer cells. Finally, as mentioned earlier, harvesting 
DRGs and their dissociated cells itself represents a nerve injury in which several 
neuroplasticity alterations are already activated and continue to evolve over time in 
culture [307]. Immortalized cell lines, on the other hand, represent an infinite source 
of cells that can be manipulated in various ways, which are not always possible 
using DRGs or primary cells. They can also be used to investigate the role(s) of 
specific neuronal components.  
In our experiments, we have used PC12 cells along with several PDAC cell lines to 
establish a co-culture model of neuro-epithelial interactions. As mentioned 
previously, PC12 is a rat pheochromocytoma cell line, which upon exposure to NGF, 
and several other neurotrophic factors, exits cell cycle, extends neurites and 
becomes electrically excitable, leading to a sympathetic-like neuronal phenotype 
[221]. In the field of PNI, PC12 cells have been used in only one study in which they 
were treated with media from DRG or DRG/prostate cancer cells co-culture; PC12 
cells extended neurites under these conditions [142].  
In our co-culture model, three out of four PDAC cell lines were able to recapitulate 
the major phenotypic features of neural plasticity associated with neuro-epithelial 
interactions that have been observed in tissues as well as in vitro model of PNI, 
namely survival and neuritogenesis. These effects were comparable to those 
induced by NGF. In addition, the model recapitulated several of the molecular 
changes that were observed in our proteomic analysis.  PDAC cell lines were able to 
induce VGF expression reprising the VGF induction in human tissues and 
demonstrated the ability of PDAC cancer cell lines to up-regulate VGF 
independently of the stroma. It is important to note that we did not examine the 
expression of specific VGF proteolytic peptides due to lack of commercially available 
antibodies. This would be important because the proteolytic cleavage of VGF into 
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peptides with different biological activities represents an extra layer of its regulation, 
as it has been shown by the differential proteolytic profile that varies between 
tissues [331], which would not be captured by measuring its total levels. In support 
of this, one of the proteins which was up-regulated in invaded nerves in our 
proteomic dataset was PCSK1N, a known modulator of prohormone convertase 1, 
an enzyme responsible for VGF proteolytic cleavage [323].  
Furthermore, PDAC cell lines were able to induce GAP43 as well as NES 
expression in PC12 cells, which was again consistent with our proteomics data. The 
induction of NES is particularly interesting, as NGF treatment could not induce NES 
expression in PC12 cells in the control experiments.  The expression levels of NES 
in PC12 cells following NGF treatment have been reported twice in literature with 
one report showing a reduction in NES expression consistent with differentiation 
[332], and another reporting an increase in NES levels [333]. Both of these reports 
involved longer NGF treatment than the 24 hours point we used. As NES is a 
neuronal progenitors marker and its expression level is reduced in post-mitotic 
neurons, NES up-regulation following nerve injury suggests a possible de-
differentiation in support of repair and regeneration [309, 310].  In view of this, our 
proteomics data and our observation of an increase in both neurite growth 
(differentiation) as well as NES (de-differentiation/regeneration), it is very tempting 
to suggest that cancer cells provide neuronal cues that keeps a delicate balance 
between the two processes resulting in not only growth of axons (axonogenesis) but 
also new neurons (neuronogenesis), the two phenomena which have already been 
described in human tissues in the context of neuro-epithelial interactions [142]. 
In view of the VGF expression pattern in PDAC nerves, we used both a Transwell 
and a contact co-culture to further model the physical proximity of nerves and 
cancer cells. Interestingly, the up-regulation of VGF in PC12 cells was even higher 
when cancer cells were in direct contact with PC12 cells. This could be due to 
exposure of PC12 cells to locally higher concentration of soluble cancer factors, 
direct cell-to-cell communication and/or interaction with ECM deposited by cancer 
cells. We believe, however, that both models represent direct neuro-epithelial 
interactions similar to PNI as there is a free exchange of soluble factors between 
both cell types with the added advantage of possible enhanced cellular 
communication in the contact model.  
In addition to its effects on PC12 cells, NGF is thought to be involved in PNI and 
pancreatic cancer and CP associated neuropathy. We tested whether at least some 
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of the PC12 neuroplasticity changes induced by PDAC cells are mediated through 
NGF. Trk receptor inhibition with K252a failed to block survival, differentiation as 
well as VGF induction of PC12 cells treated with conditioned media from the three 
PDAC cell lines. Interestingly, and rather unexpectedly, K252a significantly 
increased PC12 neurite extension induced by MiaPaca2 conditioned media. 
Although the reason for this is unclear as yet, it has been reported that epidermal 
growth factor (EGF) can induce the extension of short neurites in PC12 cells and 
this effect is augmented by K252a [334]. It is possible that K252a enhanced an 
otherwise small effect of EGF in MiaPaca2 conditioned media. This indicated that in 
our model and using these cell lines, factor(s) other than NGF were responsible for 
the PC12 phenotype although this doesn’t rule out contribution of NGF to PNI in 
human tissues.  
Whilst the induction of VGF expression in nerves in human PDAC and CP tissues, 
and in PC12 cells in the co-culture systems as well as the association of VGF 
expression with pain in CP were clearly demonstrated, further functional relevance 
of VGF up-regulation in the setting of neuronal plasticity were still not obvious.  VGF 
has been implicated in neuronal cell survival and plasticity. Previous studies 
indicated that TLQP-21, a VGF derived peptide protects cerebellar granular cells 
from serum and potassium deprivation induced apoptosis [220]. Furthermore, VGF 
mediated the protection of neuroblastoma cells from endoplasmic reticulum stress 
induced cell death [335]. Induction of VGF by BDNF has also been shown to 
mediate neuronal synaptic plasticity and memory in hippocampal cells [229].  On the 
other hand, PC12 cells undergo apoptosis in serum-free media and several factors 
including NGF, bFGF and cAMP are known to protect them from serum starvation 
mediated apoptosis via multiple initial signaling pathways that converge downstream 
[326]. There is, however, no data on whether VGF is involved in the survival of 
PC12 cells under these conditions. Using siRNA-mediated gene silencing, we 
blocked VGF up-regulation that is induced by PDAC cells conditioned media. This 
did not affect PC12 survival indicating that VGF is not necessary for this process. 
Blocking VGF however, resulted in significant reduction in neurite extension using 
both MiaPaca2 and BxPc3 conditioned media although it did not abrogate it 
completely. This indicated that whilst VGF is induced as part of the neuroplasticity 
response, it is also augmenting this process in an autocrine/paracrine fashion. This 
is likely as VGF is a secreted protein and some of its biological activities such as cell 
survival was reported to occur in this manner [220]. In support of this, VGF up-
regulation in DRGs following peripheral nerve injury is limited to the neurons but not 
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glial cells [336], whilst its effects on pain behavior in the same setting is mediating 
through activation of glial cells [219].  
Finally, we should point out that we have not yet investigated the functional and 
molecular alterations in PDAC cells in the co-culture system. The strong up-
regulation of VGF in both invaded nerves as well as PC12 co-cultures poses an 
important question regarding potential roles of VGF in cancer cell biology. Barring 
the description of its expression in neuro-endocrine tumours [337], there is no data 
in the literature regarding its presence or putative functions in other tumours. 
Additionally, in our immunohistochemistry analysis, cancer cells did not show any 
VGF staining. The presence of reciprocal signaling pathways between cancer cells 
and nerves is widely perceived to underpin the mutual neuro-epithelial interactions; 
however, such a loop of reciprocal signaling has rarely been demonstrated 
experimentally. Due to the ability of VGF to activate, in a paracrine manner, MAPK 
signaling pathway in glial cells [219], and the central role this pathway plays in 
tumorigenesis and cancer progression [338], it is conceivable that VGF secreted by 
the nerves could also activate MAPK cascade in the cancer cells within the 
perineural environment. The ability of the neurotransmitter NE to activate p38 MAPK 
in pancreatic cancer cells enhancing their migration and proliferation is a prototype 
for such interaction [339]. This would potentially be an interesting loop whereby 
PDAC cells induce VGF expression which then activates survival, invasion and 
migration in cancer cells via MAPK and this could possibly further augment VGF 
induction. The presence of such signaling loop is yet to be elucidated and further 
characterization of the molecular alteration using our co-culture model may reveal 
further pathways. The flexibility of the model with regard to gene manipulation and 
obtaining relatively large quantities of condition media from both cancer cells as well 
as PC12 cells will undoubtedly facilitate such investigations and underscores the 
model’s advantages compared to primary neuronal cells and neural tissue explants. 
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4.7. Conclusions 
 
In this work we investigated the alterations in the proteomic profiles of PDAC cells 
and nerves within the PNI environment. Using laser microdissection and MS based 
proteomic analysis we were able to identify more than 3000 proteins from small 
amount of peptide digest derived from FFPE PDAC specimens. Our data revealed 
that despite some differences, of which we validated the up-regulation of OLFM4 in 
PNI compared to non-PNI cancer, these cells are largely similar. Nerves, on the 
other hand, displayed a wide range of molecular alterations driving the major 
phenotypic features of neuroplasticity observed in published literature. Several of 
these changes are similar to those observed in neuropathies associated with other 
clinical conditions such as chronic pancreatitis as well as peripheral nerve injury, 
underscoring the importance of common neuronal response to injury. We validated 
the up-regulation of VGF in invaded nerves as well as in nerves of chronic 
pancreatitis and unveiled a strong association between VGF expression and pain in 
CP. However, the correlation of VGF expression and pain in PDAC cases still 
remains to be established. 
We also developed a model of neuro-epithelial interactions using co-culture of PC12 
cells and PDAC cell lines. Several PDAC cell lines were able to induce neuronal 
plasticity changes in PC12 cells similar to what has been reported in PDAC tissues. 
In addition to neuritogenesis and cell survival, PDAC cell lines induced VGF, NES 
and GAP43 expression in PC12 cells. Interestingly, the induction of VGF was 
stronger when these cells were in direct contact which is consistent with our 
immunohistochemistry findings. Furthermore, we show that the effects of PDAC cell 
lines on PC12 cells are not mediated via NGF, a well-known effector of PC12 
differentiation, and that VGF induction is not necessary for PC12 cell survival. 
However, VGF contributes to the neurite extension, likely in an autocrine/paracrine 
manner.   
While PC12 model clearly recapitulated several phenotypic and molecular features 
of neuroplasticity seen in PDAC, and indeed, in other neuropathic conditions, the 
extent of functional and molecular alteration of cancer cells in this model and their 
resemblance to findings in human tissues remain to be established. 
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5. Future directions 
 
The work that was performed herein represents an important addition to our 
knowledge of the biology of neuro-epithelial interactions. While the proteomic 
analysis contains wealth of information, and the co-culture model adds a unique tool 
to the available armamentarium of PNI models, both present several questions and 
lines of inquiry that could be pursued using immunohistochemical and functional 
validation. 
 
5.1. Correlation between VGF expression and pain in 
PDAC 
We have illustrated a strong relationship between pain and VGF expression in CP 
patients. The clarification of the relationship between VGF expression and pain in 
PDAC patients remains outstanding as we are yet to receive the additional sections 
from our collaborators in order to have an adequate number of cases for robust 
statistical analysis. The experiment will be performed as soon as the sections are 
received. While this would, hopefully, answer the question of clinical correlation, it 
would not explain the underlying mechanisms. A VGF knock-out model has been 
described in the literature and used to investigate the role of VGF in the regulation of 
body weight and energy balance [340]. It would be interesting to investigate 
alterations in pain sensation in response to injury in such a model in comparison to 
VGF competent mice. 
 
5.2. The regulation of VGF induction in PC12 cells by 
PDAC cells  
We have demonstrated that PDAC cell lines as well as their conditioned media are 
able to induce phenotypic and molecular neuronal plasticity in PC12 cells and ruled 
out NGF as a contributing factor under our experimental conditions. However, the 
identification of the factor(s) responsible for this biological activity is crucial to the 
understanding of the mechanisms of these alterations and their relevance to neuro-
epithelial interactions in human tissues. To achieve this, a combination of multi-
dimensional HPLC fractionation (size exclusion, SCX) and mass spectrometry will 
be used to separate and identify proteins in PDAC cells conditioned media. HPLC 
134 
 
fractions will be tested for biological activity using PC12 survival, neurite extension 
and VGF induction as output assays. Biologically active fractions can then be further 
fractionated to narrow down the list of potential candidates. Depending on the 
putative factors and available reagents, we will subsequently use a combination of 
antibody-based neutralization, small molecular inhibitors and/or gene silencing to 
confirm the identity and validate the functions of putative candidates. 
The expression of these proteins in human tissues will then be determined using 
immunohistochemistry prior to detailed investigation of their mechanisms of action, 
particularly in relation to the induction of VGF expression using the PC12 cells 
model. 
 
5.3. The effects of VGF induction on PC12 cells  
VGF gene silencing resulted in a significant attenuation of PC12 neurite extension in 
response to conditioned media from PDAC cells. We would like to further investigate 
how VGF is contributing to neuritogenesis and whether this is mediated through 
specific VGF derived peptides. We will use mass spectrometry to identify VGF 
proteolytic peptides in PC12 secretome to investigate the presence of differential 
proteolytic profile in response to PDAC conditioned media compared to NGF 
treatment. We will also use exogenous VGF derived peptides to establish whether 
VGF alone (or its peptides) are able to induce neurite extension.  
 
5.4. The functional significance of NES up-regulation 
We have observed up-regulation of NES in invaded nerves as well as in PC12 in co-
culture with PDAC cells but not in PC12 treated with NGF. Of note, NES was shown 
to have prosurvival effects on neuronal cells via sequestration of Cdk5 [341], and 
whilst this doesn’t seem to be required in the case of NGF treated PC12 cells, it may 
play a role in the co-culture system. It would be interesting to investigate, using gene 
silencing, whether NES serves similar functions in PC12 co-culture or if it 
contributes to other features of neuronal plasticity such as neurite extension.  
On a similar note, we would like to investigate the expression of NES as well as the 
degree of differentiation of PC12 cells treated with PDAC cells conditioned media at 
further time points to determine whether, contrary to NGF treatment, a significant 
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proportion of these cells remain undifferentiated and expressing NES. 
Immunocytochemistry will also assist in clarifying whether all PC12 cells treated with 
conditioned media up-regulate NES or specific group of cells (differentiated or 
undifferentiated). 
 
5.5. Investigation of the functional and molecular 
alterations in PDAC cells in the co-culture PNI model 
As pointed out earlier, we have not yet investigated the changes in PDAC cells in 
the co-culture model. It will be interesting to investigate whether cancer cells display 
similar changes to what have been described in literature, including increasing 
migration and invasion as well as up-regulation of antiapoptotic pathways. We will 
use the same co-culture system but with larger pore size inserts allowing the 
quantitation of Transwell migration and invasion of PDAC cells in the inserts towards 
PC12 cells co-cultured in the bottom wells. Additionally we will investigate, in PDAC 
cells in co-culture, the expression of some of the proteins that were deregulated in 
our proteomic profiling starting with OLFM4 and further characterize its functional 
relevance. 
 
5.6. Validation of differentially regulated proteins 
Finally, we would also like to validate the differential expression of several other 
interesting proteins from our proteomic datasets. Clear candidates would be ECM 
proteins due to their role in both cancer progression and neuronal plasticity as 
discussed earlier. In the cancer samples, several antiapoptotic proteins that have 
not been studied in pancreatic cancer, such as CRYAB and MAOA, are potential 
candidates. This will rely in part on the availability and performance of reagents that 
are required for validation particularly antibodies. 
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Appendix table 1. List of proteins up-regulated in invaded nerves compared to non-
invaded nerves. The mean of intensity values from five samples is shown.  IN: 
invaded nerves, NIN: non-invaded nerves. FC: fold change 
Protein  
ID 
Gene  
Name 
Protein name IN NIN p value FC 
P51659 HSD17B4 
Peroxisomal multifunctional enzyme 
type 2 
2E+06 0 0.0000 
 
O00231 PSMD11 
26S proteasome non-ATPase regulatory 
subunit 11 
4E+06 0 0.0001 
 
P50440 GATM 
Glycine amidinotransferase, 
mitochondrial 
2E+06 0 0.0005 
 
P37802 TAGLN2 Transgelin-2 2E+08 1E+08 0.0008 1.63 
Q14764 MVP Major vault protein 5E+07 3E+07 0.0010 1.44 
P04075 ALDOA Fructose-bisphosphate aldolase A 2E+08 1E+08 0.0011 1.52 
O95782 AP2A1 AP-2 complex subunit alpha-1 1E+07 9E+06 0.0016 1.34 
P59768 GNG2 
Guanine nucleotide-binding protein G 
subunit gamma-2 
2E+07 7E+06 0.0017 2.27 
P38646 HSPA9 Stress-70 protein, mitochondrial 4E+07 3E+07 0.0017 1.53 
Q96FW1 OTUB1 Ubiquitin thioesterase OTUB1 1E+07 1E+07 0.0017 1.37 
P26641 EEF1G Elongation factor 1-gamma 2E+07 2E+07 0.0022 1.26 
P19367 HK1 Hexokinase-1 5E+07 3E+07 0.0022 1.74 
Q99798 ACO2 Aconitate hydratase, mitochondrial 5E+07 4E+07 0.0027 1.38 
P07942 LAMB1 Laminin subunit beta-1 7E+08 4E+08 0.0031 1.60 
P07339 CTSD Cathepsin D 6E+07 3E+07 0.0037 2.03 
Q9UHQ9 CYB5R1 NADH-cytochrome b5 reductase 1 2E+07 1E+07 0.0039 1.96 
P14618 PKM2 Pyruvate kinase isozymes M1/M2 6E+08 4E+08 0.0040 1.44 
Q8TAT6 NPLOC4 
Nuclear protein localization protein 4 
homolog 
2E+07 2E+06 0.0040 8.12 
P54577 YARS Tyrosine--tRNA ligase, cytoplasmic 2E+06 3E+05 0.0040 7.57 
P61158 ACTR3 Actin-related protein 3 3E+07 2E+07 0.0041 1.25 
Q15233 NONO 
Non-POU domain-containing octamer-
binding protein 
3E+07 2E+07 0.0044 1.27 
P48681 NES Nestin 4E+08 1E+08 0.0048 3.35 
Q00839 HNRNPU 
Heterogeneous nuclear 
ribonucleoprotein U 
3E+07 3E+07 0.0050 1.20 
P50479 PDLIM4 PDZ and LIM domain protein 4 4E+07 3E+07 0.0052 1.50 
Q13200 PSMD2 
26S proteasome non-ATPase regulatory 
subunit 2 
8E+06 5E+06 0.0054 1.51 
P51149 RAB7A Ras-related protein Rab-7a 5E+07 4E+07 0.0056 1.23 
P19971 TYMP Thymidine phosphorylase 6E+07 2E+07 0.0064 2.42 
P13521 SCG2 Secretogranin-2 3E+07 3E+06 0.0064 9.61 
P24043 LAMA2 Laminin subunit alpha-2 5E+08 3E+08 0.0072 1.69 
Q00325 SLC25A3 Phosphate carrier protein, mitochondrial 8E+06 2E+06 0.0072 3.36 
Q96TA1 FAM129B Niban-like protein 1 3E+07 1E+07 0.0074 1.81 
P00403 MT-CO2 Cytochrome c oxidase subunit 2 3E+07 2E+07 0.0074 1.38 
P49368 CCT3 T-complex protein 1 subunit gamma 3E+07 3E+07 0.0075 1.22 
P63104 YWHAZ 14-3-3 protein zeta/delta 3E+08 2E+08 0.0077 1.44 
P21796 VDAC1 
Voltage-dependent anion-selective 
channel protein 1 
1E+07 5E+06 0.0080 2.40 
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O15240 VGF Neurosecretory protein VGF 1E+08 3E+07 0.0086 5.15 
P24821 TNC Tenascin 5E+07 2E+07 0.0088 2.57 
P18085 ARF4 ADP-ribosylation factor 4 2E+07 1E+07 0.0091 1.31 
Q01105 SET Protein SET 2E+07 2E+07 0.0096 1.19 
O75390 CS Citrate synthase, mitochondrial 1E+07 1E+07 0.0102 1.32 
P12111 COL6A3 Collagen alpha-3(VI) chain 4E+09 3E+09 0.0107 1.35 
Q9HCJ6 VAT1L 
Synaptic vesicle membrane protein 
VAT-1 homolog-like 
2E+07 5E+06 0.0111 2.80 
Q14204 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 3E+08 2E+08 0.0111 1.32 
P31949 S100A11 Protein S100-A11 1E+07 7E+06 0.0112 1.94 
O60831 PRAF2 PRA1 family protein 2 5E+06 3E+06 0.0114 1.88 
P45880 VDAC2 
Voltage-dependent anion-selective 
channel protein 2 
1E+07 7E+06 0.0118 2.04 
P52272 HNRNPM 
Heterogeneous nuclear 
ribonucleoprotein M 
3E+07 3E+07 0.0122 1.19 
Q9UHG2 PCSK1N ProSAAS;KEP 3E+07 6E+06 0.0123 4.69 
P54920 NAPA Alpha-soluble NSF attachment protein 5E+06 2E+06 0.0123 2.16 
P11142 HSPA8 Heat shock cognate 71 kDa protein 3E+08 2E+08 0.0123 1.31 
O60506 SYNCRIP 
Heterogeneous nuclear 
ribonucleoprotein Q 
2E+07 2E+07 0.0125 1.25 
P40926 MDH2 Malate dehydrogenase, mitochondrial 4E+07 3E+07 0.0126 1.47 
Q01484 ANK2 Ankyrin-2 5E+07 2E+07 0.0126 2.06 
P02794 FTH1 Ferritin heavy chain 3E+07 2E+07 0.0131 1.60 
P36543 ATP6V1E1 V-type proton ATPase subunit E 1 9E+06 4E+06 0.0133 2.27 
P63010 AP2B1 AP-2 complex subunit beta 1E+07 9E+06 0.0141 1.39 
O15075 DCLK1 Serine/threonine-protein kinase DCLK1 4E+06 9E+05 0.0142 4.26 
Q9UI12 ATP6V1H V-type proton ATPase subunit H 6E+06 3E+06 0.0154 2.24 
P00338 LDHA L-lactate dehydrogenase A chain 2E+08 2E+08 0.0158 1.24 
P09104 ENO2 Gamma-enolase 2E+08 8E+07 0.0167 1.84 
Q00610 CLTC Clathrin heavy chain 1 2E+08 2E+08 0.0168 1.23 
Q9NTK5 OLA1 Obg-like ATPase 1 3E+06 7E+05 0.0169 3.53 
P49721 PSMB2 Proteasome subunit beta type-2 9E+06 5E+06 0.0171 1.60 
O00429 DNM1L Dynamin-1-like protein 1E+07 6E+06 0.0174 1.76 
P19338 NCL Nucleolin 4E+07 4E+07 0.0178 1.18 
P43121 MCAM Cell surface glycoprotein MUC18 9E+07 7E+07 0.0189 1.35 
P61803 DAD1 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
DAD1 
4E+06 1E+06 0.0190 3.76 
Q15063 POSTN Periostin 1E+08 4E+07 0.0201 3.54 
P61981 YWHAG 14-3-3 protein gamma; 9E+07 5E+07 0.0209 1.60 
P78559 MAP1A Microtubule-associated protein 1A 9E+06 4E+06 0.0213 1.93 
P61978 HNRNPK 
Heterogeneous nuclear 
ribonucleoprotein K 
1E+08 1E+08 0.0216 1.17 
Q96QK1 VPS35 
Vacuolar protein sorting-associated 
protein 35 
2E+07 1E+07 0.0222 1.19 
P17174 GOT1 
Aspartate aminotransferase, 
cytoplasmic 
2E+07 7E+06 0.0223 2.40 
Q15121 PEA15 Astrocytic phosphoprotein PEA-15 2E+07 1E+07 0.0235 1.40 
P27348 YWHAQ 14-3-3 protein theta 5E+07 3E+07 0.0239 1.37 
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P61160 ACTR2 Actin-related protein 2 2E+07 2E+07 0.0262 1.19 
P12109 COL6A1 Collagen alpha-1(VI) chain 1E+09 8E+08 0.0268 1.26 
P17096 HMGA1 
High mobility group protein HMG-
I/HMG-Y 
3E+07 6E+06 0.0271 5.15 
P13473 LAMP2 
Lysosome-associated membrane 
glycoprotein 2 
2E+07 1E+07 0.0275 1.58 
P48163 ME1 NADP-dependent malic enzyme 2E+06 5E+05 0.0289 3.58 
Q9BW30 TPPP3 
Tubulin polymerization-promoting 
protein family member 3 
5E+07 3E+07 0.0295 1.45 
Q6PCE3 PGM2L1 Glucose 1,6-bisphosphate synthase 1E+07 8E+06 0.0299 1.85 
P06753 TPM3 Tropomyosin alpha-3 chain 8E+07 6E+07 0.0302 1.30 
P55072 VCP 
Transitional endoplasmic reticulum 
ATPase 
1E+08 9E+07 0.0302 1.28 
P21281 ATP6V1B2 
V-type proton ATPase subunit B, brain 
isoform 
4E+07 2E+07 0.0306 1.61 
Q16799 RTN1 Reticulon-1 1E+07 5E+06 0.0307 2.51 
P62857 RPS28 40S ribosomal protein S28 1E+07 1E+07 0.0310 1.21 
P17677 GAP43 Neuromodulin 2E+08 9E+07 0.0311 2.14 
O75348 ATP6V1G1 V-type proton ATPase subunit G 1 9E+06 4E+06 0.0340 2.09 
O00154 ACOT7 
Cytosolic acyl coenzyme A thioester 
hydrolase 
1E+07 4E+06 0.0342 2.75 
Q99623 PHB2 Prohibitin-2 4E+07 3E+07 0.0350 1.27 
Q9UJ70 NAGK N-acetyl-D-glucosamine kinase 1E+07 9E+06 0.0355 1.23 
P11047 LAMC1 Laminin subunit gamma-1 9E+08 7E+08 0.0356 1.32 
P62318 SNRPD3 Small nuclear ribonucleoprotein Sm D3 1E+07 8E+06 0.0363 1.38 
Q9NRW1 RAB6B Ras-related protein Rab-6B 4E+07 2E+07 0.0365 1.84 
P46821 MAP1B Microtubule-associated protein 1B 4E+08 3E+08 0.0365 1.48 
Q05193 DNM1 Dynamin-1 3E+07 2E+07 0.0368 1.70 
Q15084 PDIA6 Protein disulfide-isomerase A6 4E+07 3E+07 0.0372 1.29 
O60716 CTNND1 Catenin delta-1 3E+06 5E+05 0.0374 6.31 
P12110 COL6A2 Collagen alpha-2(VI) chain 6E+08 5E+08 0.0374 1.30 
Q1KMD3 HNRNPUL2 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
2E+06 4E+05 0.0377 4.18 
P31948 STIP1 Stress-induced-phosphoprotein 1 1E+07 9E+06 0.0378 1.44 
P49748 ACADVL 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
3E+07 2E+07 0.0379 1.25 
P20591 MX1 
Interferon-induced GTP-binding protein 
Mx1 
8E+06 2E+06 0.0389 4.07 
P38606 ATP6V1A 
V-type proton ATPase catalytic subunit 
A 
6E+07 3E+07 0.0390 1.59 
P25789 PSMA4 Proteasome subunit alpha type-4 5E+06 4E+06 0.0397 1.51 
Q14194 CRMP1 Dihydropyrimidinase-related protein 1 7E+06 4E+06 0.0400 1.88 
P40121 CAPG Macrophage-capping protein 1E+07 2E+06 0.0401 5.18 
P50395 GDI2 Rab GDP dissociation inhibitor beta 1E+08 1E+08 0.0409 1.17 
P14543 NID1 Nidogen-1 5E+08 3E+08 0.0410 1.44 
Q86Y82 STX12 Syntaxin-12 1E+06 0 0.0420 
 
P62249 RPS16 40S ribosomal protein S16 8E+06 6E+06 0.0426 1.36 
Q9P0J7 KCMF1 E3 ubiquitin-protein ligase KCMF1 335538 0 0.0426 
 
P59998 ARPC4 
Actin-related protein 2/3 complex 
subunit 4 
3E+07 2E+07 0.0427 1.17 
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Q02218 OGDH 
2-oxoglutarate dehydrogenase, 
mitochondrial 
7E+06 6E+06 0.0428 1.31 
Q13509 TUBB3 Tubulin beta-3 chain 3E+09 2E+09 0.0444 1.31 
P10809 HSPD1 
60 kDa heat shock protein, 
mitochondrial 
1E+08 8E+07 0.0445 1.21 
Q08211 DHX9 ATP-dependent RNA helicase A 1E+07 9E+06 0.0449 1.27 
P26373 RPL13 60S ribosomal protein L13 1E+07 1E+07 0.0452 1.34 
P46940 IQGAP1 
Ras GTPase-activating-like protein 
IQGAP1 
7E+07 6E+07 0.0463 1.24 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 3E+08 3E+08 0.0483 1.13 
P07437 TUBB Tubulin beta chain 4E+08 3E+08 0.0485 1.22 
P10599 TXN Thioredoxin 4E+07 4E+07 0.0489 1.14 
P14314 PRKCSH Glucosidase 2 subunit beta 3E+07 2E+07 0.0491 1.18 
P18509 ADCYAP1 
Pituitary adenylate cyclase-activating 
polypeptide 
7E+06 0 0.0499 
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Appendix table 2. List of proteins down-regulated in invaded nerves compared to 
non-invaded nerves. The mean of intensity values from five samples is shown.  IN: 
invaded nerves, NIN: non-invaded nerves. FC: fold change 
Protein 
ID 
Gene  
name 
Protein name IN NIN p value FC 
P02647 APOA1 Apolipoprotein A-I 2E+08 6E+08 0.0010 0.37 
P04040 CAT Catalase 3E+07 6E+07 0.0012 0.42 
P11166 SLC2A1 Solute carrier family 2 7E+06 5E+07 0.0036 0.16 
P08294 SOD3 
Extracellular superoxide dismutase [Cu-
Zn] 
3E+06 1E+07 0.0069 0.18 
P30041 PRDX6 Peroxiredoxin-6 7E+07 9E+07 0.0074 0.81 
P68871 HBB 
Hemoglobin subunit beta;LVV-
hemorphin-7 
1E+09 8E+09 0.0078 0.19 
P01857 IGHG1 Ig gamma-1 chain C region 1E+08 3E+08 0.0079 0.44 
P02730 SLC4A1 Band 3 anion transport protein 6E+05 1E+07 0.0083 0.04 
P11277 SPTB Spectrin beta chain, erythrocyte 2E+05 2E+06 0.0098 0.08 
O95865 DDAH2 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 
2E+07 3E+07 0.0105 0.64 
P30043 BLVRB Flavin reductase (NADPH) 2E+07 4E+07 0.0118 0.62 
P23229 ITGA6 Integrin alpha-6 9E+07 1E+08 0.0130 0.79 
O00159 MYO1C Unconventional myosin-Ic 4E+07 6E+07 0.0142 0.60 
P06727 APOA4 Apolipoprotein A-IV 3E+07 7E+07 0.0150 0.47 
P00918 CA2 Carbonic anhydrase 2 5E+05 7E+06 0.0155 0.07 
P02042 HBD Hemoglobin subunit delta 1E+07 1E+08 0.0155 0.10 
O00339 MATN2 Matrilin-2 4E+07 5E+07 0.0157 0.76 
P69905 HBA1 Hemoglobin subunit alpha 8E+08 4E+09 0.0179 0.19 
P32119 PRDX2 Peroxiredoxin-2 5E+07 7E+07 0.0190 0.71 
P01834 IGKC Ig kappa chain C region 7E+07 2E+08 0.0202 0.38 
P12429 ANXA3 Annexin A3 8E+06 1E+07 0.0231 0.56 
P00915 CA1 Carbonic anhydrase 1 7E+06 4E+07 0.0232 0.17 
P00450 CP Ceruloplasmin 2E+07 5E+07 0.0240 0.44 
P02790 HPX Hemopexin 5E+07 9E+07 0.0266 0.50 
Q15631 TSN Translin 3E+06 7E+06 0.0287 0.45 
Q9BZQ8 FAM129A Protein Niban 4E+06 7E+06 0.0287 0.66 
P02787 TF Serotransferrin 1E+08 2E+08 0.0293 0.52 
P08107 HSPA1A Heat shock 70 kDa protein 1A/1B 1E+08 1E+08 0.0318 0.76 
Q96AC1 FERMT2 Fermitin family homolog 2 1E+07 2E+07 0.0321 0.53 
Q9NZN4 EHD2 EH domain-containing protein 2 7E+06 5E+07 0.0347 0.14 
P00747 PLG Plasminogen 7E+06 2E+07 0.0357 0.36 
O43175 PHGDH D-3-phosphoglycerate dehydrogenase 7E+06 1E+07 0.0357 0.65 
P05156 CFI Complement factor I 1E+06 7E+06 0.0368 0.16 
Q14624 ITIH4 
Inter-alpha-trypsin inhibitor heavy chain 
H4 
2E+07 4E+07 0.0400 0.51 
Q01118 SCN7A 
Sodium channel protein type 7 subunit 
alpha 
4E+06 2E+07 0.0408 0.23 
P16144 ITGB4 Integrin beta-4 1E+08 1E+08 0.0422 0.76 
P04271 S100B Protein S100-B 1E+08 2E+08 0.0457 0.51 
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P01008 SERPINC1 Antithrombin-III 1E+07 2E+07 0.0480 0.62 
P11532 DMD Dystrophin 4E+07 6E+07 0.0482 0.68 
P13591 NCAM1 Neural cell adhesion molecule 1 4E+07 6E+07 0.0482 0.63 
P01019 AGT Angiotensinogen 5E+06 1E+07 0.0492 0.54 
P05546 SERPIND1 Heparin cofactor 2 2E+06 7E+06 0.0493 0.30 
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